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A RETROSPECTIVE COHORT STUDY TO DETERMINE THE ASSOCIATION 
OF MMR VACCINATION COVERAGE AND INCIDENCE OF MEASLES IN 
THE UNITED STATES BETWEEN 1996 AND 2012 
EMILY ANNE SKELTON 
ABSTRACT 
Purpose: The purpose of this study was to investigate the potential relationship between 
MMR vaccination coverage and measles incidence in the US, as well as to examine the 
demographic characteristics and socio-economic status of unvaccinated individuals to 
determine if there are certain sub-populations who are routinely not receiving the MMR 
vaccine.  
Methods/Procedures: This retrospective cohort study determined the MMR vaccination 
coverage per year and compared it to the measles incidence for the same year. 
Results: Results from this study suggest that regional differences in MMR vaccination 
rates spanning across multiple sub-populations are associated with the increasing measles 
incidence in the US.  
Conclusions: The correlations between MMR vaccination coverage and measles 
incidence in the US should be investigated further to determine what specific programs 
can be put in place to increase MMR vaccination rates state-wide and among vulnerable 
sub-populations. 
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INTRODUCTION 
Measles Virus 
The measles virus is a single stranded ribonucleic acid (RNA) microbe which 
belongs to the Paramyxoviridae family. This family of viruses contains respiratory 
syncytial virus, mumps, and measles, among others. The specific genus that includes 
measles is Morbillivirus.
1
 The measles virus is a spherical, enveloped particle with a 
central helical nucleocapsid containing a negative sense RNA genome. This specific 
structure allows the virus to enter host cells located in the lymphatic, respiratory, 
intestinal, and urinary systems therefore inducing viral transcription and replication.
1
  
The virus enters the body through the transmission of bodily fluids. These include 
saliva and/or mucous from coughing or sneezing or tears from the eye. An individual can 
be infected with measles for up to four days before producing symptoms and since 
measles can survive outside the body for as long as 2 hours, many people can 
unsuspectedly become infected.
2
 Measles can affect many different organ systems 
although the main cause of complications from measles is not the virus itself, but from 
secondary infections such as otitis, pneumonia, and encephalitis.
1
 Encephalitis is found in 
approximately 1 in 1,000 individuals who become infected with measles.
1
 The most 
common symptoms  include fever, runny nose, cough, and a rash covering the body.
3
 
Measles is considered the most contagious diseases among vaccine preventable 
diseases. It is estimated that for every 1 person who contracts the measles virus, 12 to 18 
people who were in contact with that individual will be susceptible to the disease.
4
 In 
  
2 
order to protect society from vaccine preventable diseases like measles, healthcare 
workers calculate the percentage of people who should be vaccinated to prevent a 
resurgence of measles. If this percentage is reached, healthcare workers can be confident 
in nationwide protection against measles but if the vaccination coverage drops below this 
level, there is a risk of outbreaks. Given its high rate of transmission, approximately 93% 
of the population needs to be vaccinated to ensure the safety of everyone. Thus, in order 
to eliminate measles permanently, 93% of the population needs to be vaccinated at all 
times.
4
 However, the average MMR immunization coverage in the US currently hovers 
around 90%; close to the ideal of 93% but also demonstrating that while some 
communities might be at 100% vaccination coverage, other communities may have only 
80% vaccination coverage.
5
 This raises a significant issue for the general population’s 
protection against measles. 
History of Measles & MMR Vaccine 
Evidence of the measles virus was found as early as the 7
th
 century A.D. From 
this time until the mid-20
th
 century, when more people were afraid of measles than 
smallpox, measles was just as common as the influenza virus is now. During this period, 
more than half of the population contracted measles by the time they were 6 years old, 
and an astonishing 90% of people contracted measles by the time they were 15.
6
 In the 
decade before the MMR vaccine was introduced in the US, an estimated 3 million people 
were infected with measles,
7
 resulting in approximately 500 deaths annually from the 
virus.
3
 In the late 1950s the first measles vaccine was tested and in 1963 the first measles 
vaccine was licensed and introduced into a regular vaccination schedule. Shortly after 
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this, a combination vaccine for measles, mumps, and rubella, (the MMR vaccine), was 
developed, and in conjunction with pervasive vaccination rates, lead to a dramatic drop in 
the incidence of measles. Ultimately, in 2000 this decrease in diagnosis and increase in 
vaccination rates led to a declaration that measles had been eliminated in the US.
8
  
MMR Vaccine 
 The MMR vaccine is administered in two doses; the first dose administered 
between 12 and 15 months of age, and the second dose administered between 4 and 6 
years of age. While the first dose of the MMR vaccine was shown to be 95% effective on 
its own, the second dose was introduced (in 1989) to enhance protection because 
approximately 2–5% of children did not respond to the initial dose.7 The second dose is 
administered to all children to ensure that everyone who received the two vaccines is 
protected (from measles, mumps and rubella). Furthermore, the MMR vaccine is also 
recommended for anyone over the age of 18 who has not previously received two doses 
of the vaccine, or who has been infected with one of the three viruses.
9
  
Similar to other vaccines, the MMR vaccine comes with risks but medical 
professionals agree that the proven benefits of the MMR vaccine outweigh any potential 
risks. The potential risks associated with the MMR vaccine and their relative incidences
9
 
are summarized in Table 1.  
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TABLE 1: ADVERSE EVENTS ASSOCIATED WITH THE MMR VACCINE 
 Adverse Event Incidence 
Mild Symptoms 
Fever 1 in 6 people 
Mild rash 1 in 20 people 
Swelling of glands in 
cheeks or neck 
1 in 75 people 
Moderate Symptoms 
Seizure caused by fever 1 in 3,000 doses 
Temporary pain and 
stiffness in the joints 
1 in 4 mostly teenage or 
adult women 
Temporary low platelet 
count, leading to bleeding 
disorder 
1 in 30,000 doses 
Severe Symptoms (very 
rare) 
Serious allergic reaction < 1 in 1 million doses 
Deafness These events have not 
occurred enough times to 
be measured against the 
population of vaccinated 
children 
Long-term seizures, coma, 
or lowered consciousness 
Permanent brain damage 
 
Resurgence of Measles & Causes 
Since the MMR vaccine was first introduced in 1963, multiple measles outbreaks 
have been recorded. From 1989 through 1991, 55,622 people contracted the measles 
virus with the majority of these cases occurring in children under the age of 5, resulting 
in 123 deaths.
6
  In looking closely at the diagnostic data, it was discovered that 90% of 
the children who died from measles prior to 1991were not vaccinated against the virus. 
This pattern was concerning and underscored the efficacy of the vaccine as this level of 
  
5 
severity caused from the measles virus had not been seen in almost 20 years.
6
 Due to this 
fact, concern about the root cause of repeated outbreaks arose.
6
  
Despite both the efficacy and availability of the vaccine, there has been a 
resurgence of the disease in the last decade, in the US (Figure 1).
5
 While the national 
average MMR vaccination coverage in the US is 90%, fifteen states have fallen below 
this rate.
5
 This lack of universal vaccination coverage and the recent increase in the 
incidence of measles can be attributed to several factors including: vaccine exemptions, 
increased travel into and out of the US, and vaccine-hesitance, a person’s indecision to 
get the vaccine.
5
  
 
FIGURE 1: INCIDENCE OF MEASLES IN THE US, 1994–2014 
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Vaccine Exemptions 
Medical Exemption 
In the last decade, an increase in the number of people who are electing to not 
receive the MMR vaccine has been observed. For example, certain individuals are unable 
to receive the MMR vaccine for medical reasons, including those who are 
immunocompromised; those who are allergic to the vaccine; and those individuals who 
have an underlying moderate or severe illness whereby the vaccine would put their health 
at greater risk than the possibility of contracting measles.
9
 This segment of the population 
is relying on the vaccination of others – also known as herd immunity – to eliminate or 
minimize occurrences thus reducing their exposure and risk of contracting the measles 
virus. This form of herd immunity takes on even greater significance because while these 
individuals are unable to receive the MMR vaccine, due to medical contraindications, 
they are at greater risk of serious complications if they contract measles. 
Religious Exemption 
In addition to medical reasons for non-vaccination, there are also religious groups 
which do not condone the use of vaccinations as prevention for common communicable 
diseases. Not all religions have the same philosophies about vaccinations but the 
overarching attitudes can be summarized into three main categories: vaccinations are a 
violation of prohibitions against taking life, are a violation of dietary laws, and they 
interfere with natural order thereby interfering with the course of life events.
10
 Although 
the US ensures freedom of religion under the 1
st
 Amendment, there is substantial 
evidence that not vaccinating in large groups affects not only individuals in that group but 
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also those outside that group,
10
 raising the question of whether an individual’s right to 
waive vaccination supersedes the general populations’ right to protection from the 
measles virus.  An article published in Vaccine examined different religious beliefs about 
vaccines and the implications of large groups not vaccinating. In this journal, several 
studies were analyzed and found that the risk of contracting the measles virus was 6 to 35 
times higher among people claiming exemption to immunization compared to a similar 
population of vaccinated individuals.
10
  
Philosophical Exemption 
More recently, statistics have shown that people are electing to not vaccinate their 
children for philosophical or personal reasons. They believe that the MMR vaccine is 
unsafe or unnecessary and they do not want to subject their children to a perceived 
danger.
11
 In response to the decreasing rates of vaccination, Daniel A. Salmon and his 
colleagues at the CDC conducted a cohort study to assess the Health Consequences of 
Religious and Philosophical Exemptions from Immunization Laws.
12
 This study found 
that people who did not receive the MMR vaccine were on average 35 times more likely 
to contract measles than people who received the vaccine. Due to the highly contagious 
nature of the measles virus, this increase in diagnosis depicts the escalation of risk and 
ultimately reinforces the need for MMR vaccination in everyone who qualifies. Full 
compliance by all eligible groups would, theoretically, reduce the overall risk of people 
who cannot be vaccinated due to medical reasons from contracting measles. 
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Introduction of Measles into the US 
Another factor contributing to the recent measles outbreaks may be the 
introduction of the virus from individuals traveling into and out of the US. Without 
uniform vaccination laws or uniform vaccination recommendations worldwide, it is 
difficult to prevent viruses from being brought into the US. While almost all countries 
worldwide recommend their children receive at least the monovalent measles vaccine, 
many low or middle income countries have not attained the recommended 90% 
vaccination coverage. These countries have also not implemented routine immunization 
programs to ensure compliance with vaccination recommendations.
13
 Due to this lack of 
vaccination compliance, as people immigrate to or visit the US, the potential to introduce 
measles into the US population is increased. Similarly, if unvaccinated Americans travel 
abroad and contract the measles virus, and re-enter the US, a large portion of the US 
population is placed at risk. 
The scenarios stated above have a cumulative effect in that while the MMR 
vaccination rate in the US continues to decrease resulting in a larger percentage of the 
general population being unprotected, the potential for a wide-spread outbreak increases. 
Similarly, infected persons who enter the US increase the likelihood they could transmit 
the virus to another individual who was not vaccinated and begin an outbreak. The cycle 
continues to escalate as people who are not vaccinated become infected and infect others. 
The serious implications of decreasing vaccination rates continues to plague the US even 
though just one dose of the MMR vaccine is 95% effective at preventing the transmission 
of measles.
7
  
  
9 
Dr. Andrew Wakefield 
The lower vaccination rates observed in those who claim philosophical or 
personal exemptions could be due, in part, to a paper written by Wakefield et al., 
published in the Lancet in 1998. Wakefield et al. conducted a study to determine if there 
was a correlation between “children with chronic enterocolitis and regressive 
developmental disorder”.14  
Study Design 
This study was conducted in 12 children, 11 of whom were boys. Children were 
chosen as study subjects if they were referred to a pediatric gastroenterology unit with 
“previously normal acquired skills but recent loss of these skills along with the 
occurrence of gastrointestinal (GI) discomfort”.14 The children were examined intensely 
to assess the gastroenterological, neurological, and developmental systems in order to 
associate a cause to their recently developed regression. The tests included laboratory, 
endoscopic, and histological analysis to get a full picture of the child’s health.14  
Study Results 
This study concluded that in 8 of the 12 pediatric subjects the onset of behavioral 
symptoms, including the loss of acquired skills such as language, was associated with the 
MMR vaccine.
14
 The association between the onset of developmental symptoms and the 
MMR vaccine was linked by either the child’s physician or their parents for these eight 
children. Five of the eight children experienced adverse reactions to the vaccine itself and 
all eight children developed the loss of acquired skills within approximately two weeks 
(1–14 days) of getting the vaccine.14 
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Bias & Limitations 
The authors describe many sources of bias in the article, the most concerning 
being selection bias of the parents who had already decided that the MMR vaccine had 
caused their child’s autism spectrum disorder.14 Wakefield and his colleagues attempted 
to alleviate this concern by noting that the link between GI symptoms (similar to those 
seen in this population) had already been shown to be associated with autism spectrum 
disorders. The link was first published by Asperger H, et al. in the Annals of Pediatrics in 
1961.
14
 Wakefield et al. cites this paper noting that these children developed GI 
symptoms with associated laboratory and histologically confirmed findings after 
receiving the MMR vaccine and that these GI symptoms had already been shown to be 
associated with autism spectrum disorders.
15
 Another bias that was seen in this study was 
the selection of the study population. The population that was chosen for this study did 
not represent the population as a whole. Autism is 3 times as likely to occur in boys than 
in girls,
16
 and since 11 out of 12 of the subjects were boys, Wakefield’s results were 
biased towards him finding a correlation between the MMR vaccine and autism. 
Discussion 
Since the publication of the Wakefield study in 1998, 11 of the 13 authors have 
retracted their findings and The Lancet retracted the paper from their journal in 2010. 
Andrew Wakefield was investigated by the General Medical Council (GMC) for the 
unethical conduct of his study, as well as the results he found. The council determined 
that his conduct was “irresponsible and dishonest”, citing that his results could not be 
replicated, the equipment he used was not routinely maintained, and the samples were 
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contaminated with the measles virus before they were tested. Lastly, and most 
importantly, the committee determined that Wakefield put the children at higher risk than 
was acceptable by doing hundreds of tests on them including a spinal tap and 
colonoscopy. The enormous risk to the children in the study would have become apparent 
had the study had gone through an ethics committee approval but the study was never 
submitted to London’s Royal Free Hospital’s ethics committee. According to the 
committee, Wakefield acted with “callous disregard to the distress and pain the children 
might suffer”.17 
In May of 2010, after the GMC had ruled against Wakefield on all charges, his 
name was removed from the United Kingdom Medical Registrar. This was the harshest 
punishment ever given by the GMC; they claimed that Wakefield had “brought the 
medical profession into disrepute” and that nothing short of removing his name from the 
register would be appropriate.
17
 
Even with the investigation and invalidation of Wakefield’s work, the public’s 
perception of the safety of the MMR vaccine was irreparably harmed. Since the 
publication of Wakefield’s fraudulent study, many researchers have worked relentlessly 
to prove that the MMR vaccine is safe and efficacious, unfortunately the conclusive data 
has not swayed the opinions of a small percentage of parents who believe any level of 
risk of side effects is unacceptable.
18
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Studies in Response to Wakefield’s Article 
MMR Vaccine – Worries are not justified 
In 2001, Bedford Elliman published an article in The Journal of the Royal College 
of Paediatrics and Child Health, detailing the history of the MMR vaccine and the recent 
events that caused controversy over this vaccine. He specifically mentions Wakefield’s 
study and how even though the author’s stated that they “had not proven a link between 
the vaccine and the disorders”, many people failed to interpret that correctly and the 
media hysteria over the article quickly ensued.
19
 Elliman also mentions that between 
1998 and 2001 many researchers set out to specifically investigate the correlation 
between the MMR vaccine, autism, and bowel disease, resulting in, inconclusive findings 
on the subject. Two studies were conducted investigating the time interval between the 
MMR vaccine and the supposed onset of autism; one was performed with an interval of 1 
year between MMR vaccination and onset of autism, and another executed with a three 
year period between the two events. In both studies, it was found that there was no link 
between MMR vaccination and onset of autism.
19
 There were also two meta-analyses 
performed of both published and unpublished data. The results were presented at the 
American Academy of Pediatric conference where it was reported that “available 
evidence does not support the hypothesis that MMR vaccine causes autism or associated 
disorders, or inflammatory bowel disease.” Ultimately, Elliman concluded that “there is 
no good scientific evidence to support a link between MMR vaccine and autism” and that 
“there is mounting evidence that shows no link”. He goes on to say that the MMR 
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vaccine is both safe and effective and that trying to find a new vaccine for the prevention 
of measles, mumps, and rubella is only taking a step backward.
19
 
No Effect of MMR Withdrawal on the Incidence of Autism: A Total Population Study 
One year later a study was conducted for the same purpose as Elliman’s 
investigation to disprove any correlation between the MMR vaccine and autism. Unlike 
Elliman’s article, this study hoped to disprove Wakefield’s claims with clinical data. This 
study was conducted in central Japan, a country that had similar vaccination laws to the 
US until 1993 when MMR vaccination laws were terminated due to an increase in cases 
of aseptic meningitis, a suspected side effect of the MMR vaccine.
20
 With no vaccination 
laws in place for the MMR vaccine, not a single MMR vaccination was administered in 
central Japan after 1993. Dr. Hideo Honda and his colleagues determined that this 
location would be the most ideal environment to study the effects of the MMR vaccine on 
the incidence of autism. Their hypothesis was that if the rates of autism decreased after 
1993, there was a good chance that the MMR vaccine might have played a role in the 
development of autism. Conversely, if the incidence of autism stayed the same or even 
increased, this would suggest a lack of an association. The study examined the 
cumulative incidence of autism for children born from 1988 until 1996 in Yokohama, 
Japan. The children were followed from birth to the age of 7 to determine incidence of 
autism. The study looked at the incidence of autism in the years before MMR vaccination 
laws were repealed (1988–1992) compared to those seen in the years where not a single 
MMR vaccine was given (1993–1996). Honda et al. found that rates in the incidence of 
autism continued to rise (0.476% in 1988 compared to 1.17% in 1996) while the rates of 
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MMR vaccine use were close to 0%.
20
 Due to the nature of the study, the results do not 
prove a causal relationship but these results add circumstantial data to the mounting 
evidence that there is no link between the MMR vaccine and autism.
20
 Conclusions from 
this study were not surprising to medical professionals but did help ease the mind of 
parents who were trying to decide whether or not to vaccinate their children against the 
measles virus. 
Media Coverage of the Measles-Mumps-Rubella Vaccine and Autism Controversy and 
its Relationship to MMR Immunization Rates in the US 
Even though many researchers had disproved Wakefield’s correlation between the 
MMR vaccine and autism, people remained skeptical as to whether they should vaccinate 
their children. To further investigate the public’s perceived safety of receiving the MMR 
vaccine, Smith et al. conducted a study in 2004 looking at the rate of MMR vaccination 
in relation to media stories using key words such as “measles”, “MMR”, and “autism”. 
The National Immunization Survey (NIS) was used to determine the rate of MMR 
vaccination in the US each year between 1995 and 2004.
21
 Information on media 
coverage was collected through the LexisNexis database; which compiled all news stories 
on a national and local level. The primary objective of the study was to determine if there 
were trends toward selective non-receipt of the MMR vaccine. That is, were parents 
allowing their children to receive every other childhood vaccination except the MMR 
vaccine or were they just not receiving any vaccinations at all? The researchers wanted to 
know the true effect of Wakefield’s article and the media coverage that followed on 
MMR vaccination rates. Surprisingly, the study found that the rate of MMR vaccine use 
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did not have any statistically significant correlation to media coverage in the US.
21
 
Although the vaccination rate did decline, lower vaccination rates were not seen in parts 
of the country with the most media coverage and vice versa as was hypothesized. The 
concern about media coverage and the MMR/autism scandal was and still is an important 
and justifiable issue in the US. Smith et al.’s contribution was important because it 
eliminated one more factor from the debate over MMR vaccination. 
Lack of Association between Measles Virus Vaccine and Autism with Enteropathy: A 
Case-Control Study 
Similar to the articles mentioned previously, a case-control study was conducted 
in 2008 to “determine whether children with GI disturbances and autism were more likely 
than children with GI disturbances alone to have the measles virus and/or inflammation 
present in their bowel tissues and if autism and/or GI episode onset related temporally to 
receipt of MMR”.22 While Wakefield reported that the measles virus was found in the 
bowel tissue of children with autism spectrum disorders and GI disturbances, numerous 
studies have proven no association with the MMR vaccine and autism. Unfortunately, 
there is not conclusive data as not many studies have looked specifically for the presence 
of the measles virus in the bowel of children who suffer from autism and GI 
disturbances.
22
  
This study took samples from children who were already undergoing clinically 
indicated testing for their GI problems. The two groups included 25 children with autism 
and GI disturbances compared to a group of 13 children who had GI disturbances with no 
diagnosis of autism. Blinded tests were performed on samples obtained from all children 
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and the relationship between the onset of GI episodes and autism in relation to the timing 
of MMR vaccination was determined using a real-time reverse transcriptase polymerase 
chain reaction (PCR).   
The study results found that there was no difference between the group of 
children with autism and GI disturbance and those with only GI disturbance in the 
presence of the measles virus in the bowel tissue and that GI symptoms were unrelated to 
MMR timing. The authors report that this study “provides strong evidence against 
association of autism with persistent the measles virus in the GI tract or MMR 
exposure.”22 
Public Health Concern  
Although the studies cited above and many other similar investigations have 
shown a lack of association between MMR vaccination and the onset of autism, a large 
portion of parents do not believe that the vaccine is safe enough to administer to their 
child. Historical data showing an increase in the number of reported cases of measles was 
published in the September 2014 Morbidity and Mortality Weekly Report (MMWR): 
Summary of Notifiable Diseases.
23
 Figure 2 depicts how the incidence of measles went 
from being extremely high in 1978 to almost non-existent in 1998.  It also reflects the 
resurgence of cases beginning in 2008.  
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FIGURE 2: INCIDENCE OF MEASLES IN THE US, 1977–2012 
 
An editorial published in the New England Journal of Medicine in October 2014 
cites that “more measles cases have been reported in the US so far in 2014 – 592 cases 
from January 1 to August 29 – than during any year in the past two decades”.4 The 
article, titled “Mounting a Good Offense against Measles” was in response to the 
astounding number of measles cases seen in the US during this time. Dr. Walter 
Orenstein and his colleague Katherine Seib wrote the article in hopes that it would bring 
into focus the dangers of not receiving the MMR vaccine and how the outbreaks of 
measles could begin to adversely affect the US.
4
 One of the most important aspects of 
this article is how diagnosis of the measles virus can be used as an indicator of the 
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compliance and efficacy of the US’ immunization program as a whole. While there have 
been gaps in the immunization program in the past, the measles virus was always the first 
of the vaccine preventable viruses to present itself as an increasingly common 
occurrence. The measles outbreaks that is currently ongoing is a good indicator that low 
immunization coverage has become a significant public health issue.
4
 
The paper attributes the increase in cases of measles in the US to three factors, 
including a lack of support for global immunization programs, lack of a standardized 
system worldwide for detecting certain strains of measles in the infected population, and 
a hesitancy to vaccinate.
4
  First, they argue that implementing a global vaccination 
strategy would allow for universal vaccination coverage for people traveling into and out 
of different countries, thereby decreasing the potential for cross-continental infections. 
Secondly, if it is known that some strains have been eliminated but certain strains keep 
reappearing, more research can be done to determine how the strain differs from the 
others and how best to prevent it in the future. Lastly, and most importantly, the hesitancy 
to vaccinate against measles in the US is directly undermining the possibility of 
eliminating the virus for good. Determining exactly why parents are hesitant to vaccinate 
and why physicians are willing to allow exemptions, will provide important insight as to 
how to tailor educational and support programs that will lead to increased vaccination 
rates.
4
 Unfortunately, the paper also states that the lack of perceived risk from the 
measles virus is impeding any progress scientists and healthcare workers have made i.e. 
measles only makes news when outbreaks are observed.
4
 Since the US has so many 
residents, a mere 588 cases over an 8 month period seems relatively small. It is only 
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when you consider the alarming trend in comparison  to previous years’ cases that you 
realize the current impact and potential escalation of the measles virus in the US.
4
  
Possible Solutions  
Among the mounting evidence regarding the lack of correlation between the 
MMR vaccine and autism, are articles addressing how to change the public’s perception 
of the safety of the MMR vaccine and vaccines in general. These articles bring attention 
to the harsh reality that the media too often opts sensationalism over accuracy and does 
not always focus on the correct stories. For example, the lay person may not understand 
the results or outcomes of a clinical trial, and that the best way to overcome the 
immunization epidemic in the US is to re-educate parents and healthcare providers on the 
importance of vaccinating against vaccine preventable diseases and the very real risks 
associated with contracting a vaccine preventable disease such as measles.
24
 
Communicating Science to the Public: MMR Vaccine and autism 
 An article published in Vaccine in 2003, which focused on the disconnect 
between scientists and the general public with regards to publishing results from clinical 
trials, explained the importance of disseminating critical information to the public, 
including determining how false reports of the association between the MMR vaccine and 
autism were developed; ways that this association was disproved how the study and 
similar studies have been communicated to the media; and ways to improve 
communication in order to give the public more accurate information. 
24
 
 Details of Wakefield’s hypothesis and the studies performed to disprove it have 
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been discussed at length and do not need repeating but Offit’s perspective on how study 
results are communicated to the media and therefore the general public and ways to 
improve communication are of important public interest.  
There are three characteristics that can have an effect on how the public perceives 
medical information, including the way in which the media catches the public’s attention; 
the confusion between results reported from a clinical trial and what they actually mean; 
and the lack of knowledge surrounding how the scientific process works.
24
  
As seen in most parts of our society, the most interesting things to people are 
uncommon, dramatic, and sensational. The same can be seen with news reports; people 
are more interested in things that are not the status quo, or things that challenge what we 
have always known to be correct. In this sense, news stations, newspapers, and radio 
stations are more likely to report the uncommon statistics rather than more common and 
mundane statistics. These reports, especially when it comes to medical conditions or 
adverse events of any kind, often include emotional and dramatic stories to catch the 
public’s attention.  
 This problem is exacerbated by the fact that not everyone understands how the 
results published in a medical journal correlate to changes they should be making in their 
personal healthcare. It is not well known that cohort studies cannot actually show a causal 
relationship and that this type of relationship can only be proven in a randomized, 
double-blind, placebo-controlled clinical trial. There is a wide belief that when an 
association is reported, it means that something causes something else. What is really 
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being reported is that there is evidence to support that the two events being investigated 
did not just happen by chance and that they might be connected in some way. It is hard to 
relay this information to the public especially when the media does not preface its news 
stories with an interpretation of the meaning of the results.
24
 
 The same is true for the publics’ understanding of the scientific process. In 
science, and especially clinical trials, investigators are not allowed to say that they have 
determined that an intervention is not associated with a certain outcome or, for example, 
that the MMR vaccine does not cause autism. This oftentimes causes confusion because it 
leaves the interpretation of the results up to the media and the public, i.e. that “there is no 
evidence that the MMR vaccine causes autism” does not imply that the MMR vaccine 
does not cause autism, only that there is no evidence to support this claim. Unfortunately, 
the public oftentimes misunderstands this type of statement, with people concluding that 
a correlation may exist, and that scientists simply cannot be sure either way.  
 All of these issues have contributed to the decrease in vaccination rates and 
especially MMR vaccination in the US but Offit does propose a couple of solutions. First, 
he proposes making it known to the media what is at stake if they keep reporting only one 
side of the story. Initiating a conversation about how reports on the correlation between 
the MMR vaccine and autism have a real effect on those who receive the vaccine as well 
as how watching your child suffer and die from the measles virus can be just as dramatic 
and emotional as your child developing autism from the vaccine, would help the public 
realize that not vaccinating your child is putting them in more danger than vaccinating 
them.
24
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 Similarly, informing the public on how results of clinical studies can be correlated 
to healthcare decisions and explaining how the scientific process works can help alleviate 
some of the confusion and panic that ensues when a study shows results that go against 
what has been previously thought. Lastly, and most importantly, scientists, physicians, 
and the media need to begin informing the public on the increasing incidence of measles 
in the US and the dangers associated with contracting the virus if individuals are not 
vaccinated. 
A pilot study on the effects of individually tailored education for MMR vaccine-hesitant 
parents on MMR Vaccination Intention 
 Along the same lines as the paper written by Paul Offit, a pilot study was 
conducted investigating educational programs regarding the increasing awareness and 
importance of the MMR vaccine and how those educational programs influenced a 
parent’s decision to vaccinate their child.25 In this study, a group of 77 parents who had 
originally been screened as vaccine-hesitant were given 1 of 2 interventions. The first 
intervention was an educational web-page which specifically addressed concerns that had 
been raised in the scientific and medical community about the vaccine. These included 
everything from side-effects that had been fraudulently reported, to the importance of 
protecting children against the measles virus. The second intervention was a similar 
educational web-page but only included information about the vaccine, similar to what 
the doctor provides to a patient before any vaccine. This information includes statistics on 
the efficacy of the vaccine, the vaccine schedule, and potential side effects.
25
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 Although larger studies are needed to definitively prove that a tailored educational 
program is more efficacious in changing the parent’s opinion on whether or not to 
vaccinate, the authors concluded that a tailored education strategy may be an effective 
way to improve vaccination compliance among vaccination-hesitant parents.
25
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Rationale for Study 
Due to the resurgence in the spread of measles, and because the decision to 
vaccinate against this virus are important and controversial issues with serious public 
health consequences, it would be beneficial to determine the proportion of people who 
are vaccinated with the MMR vaccine each year versus the proportion of people who 
contract the measles virus annually in the US. This study aimed to investigate the 
potential relationship between these two factors, as well as to examine the demographic 
characteristics and socio-economic status of unvaccinated individuals to determine if 
there are certain sub-populations who are not receiving the vaccine.  
This investigation will prove useful to policymakers and the CDC in terms of 
developing and implementing strategies to address the current measles epidemic in the 
US. 
Thesis Questions 
1. What is the relationship between the MMR vaccination coverage and the 
incidence of measles from 1996 to 2012 in the US? 
2. What is the relationship between demographic characteristics and socio-economic 
status and MMR vaccination coverage? 
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METHODS 
Institutional Review Board (IRB) approval was obtained from the Boston University 
Medical Campus IRB prior to initiating any research activities. 
Study Design 
This study aimed to determine the relationship between MMR vaccination 
coverage and incidence of measles in the US. The study also investigated if demographic 
characteristics and socio-economic status had any correlation to MMR vaccination 
coverage. 
This study was conducted using a retrospective cohort design where subjects were 
chosen based on exposure to the MMR vaccine and analyzed to determine the presence of 
the outcome variable, measles. 
Outcome Measures 
The primary outcome measure of this study was the relationship between MMR 
vaccination coverage and incidence of measles in the US as seen in Figure 3. 
 
FIGURE 3: PRIMARY OUTCOME MEASURES 
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The secondary outcome measure was to determine if certain sub-populations were 
at higher risk of not receiving the MMR vaccine (Figure 4). 
 
FIGURE 4: SECONDARY OUTCOME MEASURES 
 
The data that were collected to determine primary and secondary endpoints for 
this investigation is detailed below. Data for MMR vaccination coverage between 1996 
and 2012 in the US was obtained from the NIS, whereas data on the incidence of measles 
between 1996 and 2012 in the US was obtained from the CDC-WONDER publically 
available database.
26
  
Subject Population 
The criteria for qualification for this study included individuals who: 
1. Currently live or have lived in the US. 
2. Have partaken in any one of the NIS. 
3. Have contracted measles while living in the US. 
People who have lived in the US for the last 100 years could have potentially been 
included in the analysis. The study period begins in 1996, if an individual was diagnosed 
with measles at age 90 they would have been born in 1900. Although the MMR vaccine 
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was not licensed until well after that, individuals would have either contracted measles 
and become immune, or they would have received that vaccine when it became available. 
Lastly, data was only collected on the individuals who contracted measles. For the 
purposes of this paper, it was assumed that the US population during any particular year 
minus the cases of measles in that same year would amount to the people who did not 
contract measles in the US that year.  
Statistical Analysis 
Data Sources 
National Immunization Survey (NIS) 
Data were collected from multiple sources for this analysis. Immunization data 
were collected from the NIS publically available database. The NIS was established in 
1994 in order to monitor childhood immunization coverage. Sponsored by the National 
Center for Immunizations and Respiratory Diseases, the National Center for Health 
Statistics, and the CDC, the NIS collected immunization data from children who were 
between the ages of 19 and 35 months at the time that they took the survey. The survey 
consisted of a list-assisted random-digit-dialing telephone survey
27
 which was then 
followed by a mailed survey to the child’s immunization provider.27 
In 1998, the methodology used for analyzing the results of the NIS was improved. 
The new methodology in which the survey was conducted accounts for biases such as 
vaccination history nonresponse, where provider data were not obtained, by putting data 
into weighted groups on the likelihood that the group will have adequate data.
28
 This 
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methodology still introduced some bias but “the overall extent of bias reduction was 
0.5%, suggesting that provider nonresponse bias was small”28. 
Data were collected on MMR vaccination coverage (point estimate and 95% 
confidence interval (CI)) by state, poverty status, participation in the Vaccines for 
Children program (VFC), urbanicity, and race/ethnicity. VFC is a federally funded 
program which supplies vaccines to children who would not otherwise be able to get 
them. Children who are uninsured or underinsured and would not be able to afford the 
vaccine are eligible for this program.
29
 All data were collected from 1996–2012 and 
stratified by geographical location, national totals, the 50 states, and the District of 
Columbia. Descriptions of each data set are detailed below. 
 MMR vaccination coverage on a state level for each year from 1996–
2012, this included the 50 states as well as the District of Columbia and a 
national total. 
 MMR vaccination coverage for people who lived at or above the poverty 
line or below poverty. 
 MMR vaccination coverage was reported for children whose providers 
participated in the VFC program as well as children whose providers did 
not participate in the VFC program. 
 MMR vaccination coverage for levels of urbanicity. The levels of 
urbanicity included Metropolitan Statistical Area (MSA) Central City, 
MSA non-central city, and non-MSA central city. A MSA was defined as 
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an area which had “at least one urbanized area of 50,000 or more 
population, plus adjacent territory that had a high degree of social and 
economic integration with the core as measured by commuting ties”.30 
Similarly, the identification of central city (also known as a principal city) 
took into account incorporated places and census designated places.
30
 
MMR vaccination coverage reported for each of the three classifications 
was broken down by state for each year. 
 MMR vaccination coverage for race/ethnicity reported the MMR 
vaccination coverage by state for each of the following races/ethnicities; 
white, black, Hispanic, American Indian or Alaska Native, and Pacific 
Islander. 
Since all data mentioned above were reported as point estimates with 95% CI, 
total population numbers for each MMR vaccination coverage category and state were 
obtained from the US Census Bureau. 
Summary of Notifiable Diseases 
Data on the incidence of measles per year in the US was obtained from the 
MMWR: Summary of Notifiable Disease reports that were published by the Department 
of Health and Human Services and CDC. The data presented in these reports was 
collected from various sources including the Epidemiology Program Office, the CDC, 
and state and territorial health departments.
31
 The CDC encourages health professionals 
to report laboratory confirmed cases of measles to their local health department within 24 
hours.
32
 The data are then compiled in the National Electronic Telecommunications 
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System for Surveillance (NETSS). The CDC uses the compiled data to look for national 
trends for notifiable diseases.
31
  
The report included total reported cases of measles per year. Cases of measles 
were also reported by geographic region, including reports from the 50 states, the District 
of Columbia, and total US reported cases. 
Some categories of the data included population totals for the relevant year and 
variables but similar to the NIS data, the total number of residents was obtained from the 
US Census Bureau if not reported in the MMWR. 
 Although the data reported in the MMWR: Summary of Notifiable Diseases was 
very helpful in looking for trends, there were many caveats in using this data. Some 
diseases, which do not have severe clinical symptoms, might have been under-reported 
because they were either so uncommon that doctors would not think to diagnose them or 
the symptoms were treated while the underlying disease was never known. Similarly, 
reporting of these diseases depended on the facilities that were present to test for certain 
diseases, measures in place to determine the sensitivity and specificity of these tests, as 
well as how likely state and local officials were to actually report all cases of notifiable 
diseases. Lastly, it was hard to compare rates of measles incidence over a long time 
period due to constant innovation and introduction of new diagnostic tests. There could 
have been more people who were actually contracting measles or the development of 
technology could be simply detecting more cases of measles.
31
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Analysis Objectives 
The primary outcome in the study was the proportion of people who received the 
MMR vaccine each year compared to the proportion of people who contracted measles 
each year. The MMR vaccination coverage nationally each year was compared to the 
number of cases reported nationally each year. Similarly, MMR vaccination coverage by 
state each year was compared to reported cases of measles by state each year. 
The secondary objective of this study was to determine if there was a certain sub-
population of people who had different MMR vaccination coverage than other sub-
populations. A correlation model was applied to the data to determine if geographical 
location, poverty status, participation in VFC, urbanicity, or race/ethnicity had any 
correlation with decreased MMR vaccination coverage. 
Statistical Procedures 
The primary outcome measure for this study was analyzed by comparing the 
national MMR vaccine coverage each year with the national incidence of measles for the 
same year. The Pearson product-moment correlation model was then applied to the data 
to determine if there was a statistically significant association (p<0.05) between MMR 
vaccination coverage and measles incidence. The same analysis was then performed on 
state level data to determine if individual states had different or similar results compared 
to national totals.  In order to do this analysis, it was determined that even a decrease of 
2% in MMR vaccination rates would be significant enough to worry healthcare workers.
4
   
To analyze the secondary outcome measure, only data from the NIS were used. 
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The data were analyzed using a one-way ANOVA test to determine if a certain sub-
population of people were less likely to receive the MMR vaccine. The one-way ANOVA 
test was used to determine if there was evidence of significant differences between any of 
three or more independent groups. The ANOVA test tested the null hypothesis: 
𝐻0: µ1 = µ2 = µ3 = ⋯ = µ𝑘 
where µ = the group mean (mean incidence of measles for each sub-population) and k = 
the number of groups. This test determined if there was sufficient evidence to suggest 
that two population subgroups were statistically different from each other. When this was 
the case, a post hoc test was done to determine which two groups were different from 
each other.
33
 The post hoc test considered, if a p-value <0.05 was reported from the one-
way ANOVA, was the Tukey’s honest significant difference (HSD) test.   
Data were analyzed separately for poverty status, participation in VFC, 
urbanicity, and race/ethnicity. For each of these sub-populations state MMR vaccination 
coverage was compared to national MMR vaccination coverage. The results were 
considered to be statistically significant if the p-value was <0.05.  
Measures to Adjust for Multiplicity, Confounders, Heterogenicity, Etc. 
 All data obtained for this analysis were reported at a group level. There were 
many caveats with using aggregate data which included: unknown confounders, missing 
information, and difficulties in correlating the results to individual persons or regions. 
Unfortunately, the above mentioned caveats were inherent in the study design and type of 
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data used. Limitations to this study due to the type of data used are discussed in a later 
section. 
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RESULTS 
MMR vaccination coverage 
The first analysis that was performed was to determine the actual MMR 
vaccination coverage over the given time period. As depicted in Table 2 and  Figure 
5, MMR vaccination coverage between 1996 and 2012 ranged from 90.33% to 93%. 
MMR vaccination coverage hovered around 90% for 1996 and 1997 but in 1998 there 
was a sharp increase to 92% coverage. Rates slowly decreased to about 90% in 2000 (the 
point at which measles was declared eradicated from the US). MMR vaccination 
coverage increased to its highest level, 93%, in 2003 and 2004, while slight coverage 
increases were observed in 2005–2007. From 2006 to 2012 the MMR vaccination rates 
continued to decrease to 91%. 
MMR vaccination coverage was given as a point estimate with a 95% CI. The 
average MMR vaccination coverage, presented in Table 2 and  Figure 5, was used for 
this analysis. That percentage was then compared to the total population for that year and 
the number of people vaccinated was calculated (Table 2). A box-plot was created using 
national MMR vaccination coverage to pictorially present the national MMR vaccination 
coverage from 1996 to 2012 in the US.  
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TABLE 2: NATIONAL MMR VACCINATION COVERAGE STATISTICS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Year Population 
Percent MMR 
vaccination coverage 
Number of People 
Vaccinated 
1996 269,394,284 90.33 243,343,856 
1997 272,646,925 90.40 246,472,820 
1998 275,854,104 92.00 253,785,775 
1999 279,040,168 91.50 255,321,753 
2000 282,162,411 90.50 255,356,981 
2001 284,968,955 91.40 260,461,624 
2002 287,625,193 91.60 263,464,676 
2003 290,107,933 93.00 269,800,377 
2004 292,805,298 93.00 272,308,927 
2005 295,516,599 91.50 270,397,688 
2006 298,379,912 92.30 275,404,658 
2007 301,231,207 92.30 278,036,404 
2008 304,093,966 92.10 280,070,542 
2009 306,771,529 92.10 282,536,578 
2010 309,326,295 91.50 283,033,559 
2011 311,582,564 91.60 285,409,628 
2012 313,873,685 90.80 284,997,305 
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 FIGURE 5: NATIONAL MMR VACCINATION COVERAGE FROM 1996–2012  
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Measles Incidence 
Measles incidence was reported as the number of cases per year. The US 
population is presented in Table 3 for reference. A box-plot was also included to 
determine, pictorially, if any trends were seen in the incidence of measles over the 17 
years. Both Table 3 and Figure 6 show a steady decrease in measles incidence until 2008 
where the rate of measles more than tripled from the previous year. The incidence of 
measles then reduced by half until 2011 when another drastic increase was seen. 
TABLE 3: NATIONAL MEASLES INCIDENCE STATISTICS 
Year Population Measles Incidence 
1996 269,394,284 508 
1997 272,646,925 138 
1998 275,854,104 100 
1999 279,040,168 100 
2000 282,162,411 86 
2001 284,968,955 116 
2002 287,625,193 44 
2003 290,107,933 56 
2004 292,805,298 37 
2005 295,516,599 66 
2006 298,379,912 55 
2007 301,231,207 43 
2008 304,093,966 140 
2009 306,771,529 71 
2010 309,326,295 63 
2011 311,582,564 220 
2012 313,873,685 55 
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FIGURE 6: NATIONAL MEASLES INCIDENCE FROM 1996–2012 
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Primary Analysis 
Table 4 shows the correlation between MMR vaccination coverage and measles 
incidence in the US. The average percentage of MMR vaccination coverage values was 
converted to an approximate number of people vaccinated per state using the total 
population of that state. This was then compared to the amount of measles cases that were 
reported in that state each year. 
The national MMR vaccination coverage and measles incidence had a medium 
negative correlation of -0.45. While the p-value was just above the level of significance 
for the national level, Alaska, Colorado, Nevada, North Dakota, and Oregon displayed 
highly significant correlations between MMR vaccination coverage and measles 
incidence. Alaska, Colorado, Nevada, and Oregon all had medium negative correlations, 
similar to those seen on the national level. North Dakota, on the other hand, showed a 
medium positive correlation between MMR vaccination coverage and measles incidence. 
The full table of Pearson product-moment correlations by state can be found in Appendix 
XV. 
TABLE 4: MMR VACCINATION COVERAGE VS. MEASLES INCIDENCE 1996–2012 
State Correlation 95% CI P-value 
US National -0.45 -0.76, 0.04 0.070 
Alaska -0.54 -0.81, -0.08 0.025 
Colorado -0.54 -0.81, -0.08 0.026 
Nevada -0.54 -0.81, -0.08 0.025 
North Dakota 0.64 0.24, 0.86 0.005 
Oregon -0.53 -0.81, -0.06 0.029 
 
  
40 
Figure 7 is a scatter plot of MMR vaccination coverage vs. measles incidence for 
2011. This year was chosen to give a better picture of what current MMR vaccination 
coverage and measles incidence looks like in the US. During 2011, the average measles 
incidence was 91.6% and 220 cases of measles were reported. Each circle depicts a 
specific states MMR vaccination coverage compared to its measles incidence. The figure 
shows a high incidence of measles when MMR vaccination rates hovered around 91% 
with 8 states having 8 or more cases of measles during 2011. 
 
FIGURE 7: MMR VACCINATION COVERAGE VS. MEASLES INCIDENCE IN 2011 
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Secondary Analysis 
A secondary analysis was performed to determine if there was a specific sub-
population of people who were less likely to receive the MMR vaccine. Boxplots were 
generated to show the difference in vaccination coverage across different locations for 
each sub-population. A one-way ANOVA test was then conducted on all variables; 
location, poverty status, participation in VFC, urbanicity, and race/ethnicity. 
Subsequently, if the p-values from the one-way ANOVA tests were statistically 
significant, the Tukey HSD test was performed to narrow down which populations had 
MMR vaccination coverage that was different from the national averages. The MMR 
vaccination coverage values in Table 2 were used as US national values and compared to 
every sub-population to look for differences in vaccination coverage. Because the goal 
was to determine if specific populations had different values from the national averages, 
the use of overall national MMR vaccination coverage values instead of each sub-
populations’ national MMR vaccination coverage values was warranted for this analysis.
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MMR vaccination coverage vs. Location 
 
 
FIGURE 8: MMR VACCINATION COVERAGE BY LOCATION FROM 1996–20121
                                                          
1
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half of 
the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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Figure 8 depicts MMR vaccination coverage by state; the national MMR 
vaccination coverage ranged from about 90–93%. The red dashed line depicts the true 
average national MMR coverage (92%). The state which fell fully below this line was 
Nevada, indicating that there might be an issue with MMR vaccination coverage.  
Conversely, states, which were fully above this line included Connecticut, Massachusetts, 
and Rhode Island. The state with the lowest MMR vaccination coverage was Nevada, 
whose coverage ranged from 82–92%. The state with the highest MMR vaccination 
coverage was Vermont, whose coverage ranged from 92–98%. 
TABLE 5: STATE MMR VACCINATION COVERAGE COMPARED TO NATIONAL 
COVERAGE BETWEEN 1996 AND 2012 
State Difference Lower CI Upper CI Adjusted P-Value 
Alaska -2.96 -5.94 0.01 0.05 
Connecticut 3.99 1.02 6.97 0.0001 
Idaho -3.54 -6.51 -0.56 0.002 
Massachusetts 3.38 0.41 6.35 0.006 
Nevada -3.98 -6.50 -1.00 0.0001 
Rhode Island 3.48 0.51 6.45 0.003 
 
Since the one-way ANOVA resulted in a p-value much lower than 0.05, the 
Tukey HSD was run to determine exactly where the statistically significant differences 
were occurring in the US. Alaska, Idaho, and Nevada all had significantly lower 
vaccination coverage compared to the average MMR vaccination coverage, nationally. 
Conversely, Connecticut, Massachusetts, and Rhode Island had significantly higher 
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MMR vaccination coverage compared to the national average. The full table of Tukey 
HSD correlations by state can be found in Appendix XVI.  
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Figure 8 displays the MMR vaccination coverage of states from highest coverage to lowest coverage from left to right. 
The red dashed line depicts the true average of national MMR coverage. As mentioned above, Connecticut, Rhode Island, and 
Massachusetts have the highest MMR vaccination coverage while Alaska, Idaho, and Nevada have the lowest MMR 
vaccination coverage. 
 
FIGURE 9: MMR VACCINATION COVERAGE IN ORDER OF MOST VACCINATED STATES
2
 
                                                          
2
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half of 
the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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MMR vaccination coverage vs. Poverty Status 
People who lived at or Above the Poverty Line 
 
 
FIGURE 10: MMR VACCINATION COVERAGE FOR PEOPLE WHO LIVED AT OR ABOVE THE POVERTY LINE BY STATE FROM 
1996–20123 
                                                          
3
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half of 
the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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MMR vaccination coverage for people who lived at or above the poverty line is 
depicted in Figure 10.  The national MMR vaccination coverage ranged from about 91–
93%. The red dashed line depicts the true average national MMR coverage (92%). States 
which were fully above this line include Connecticut and Rhode Island. The state with 
the lowest range of MMR vaccination coverage was New Mexico, whose coverage 
ranged from 80–95%. The state with the highest MMR vaccination coverage was 
Vermont, whose coverage ranged from 87–98%. 
TABLE 6: STATE MMR VACCINATION COVERAGE VS. NATIONAL COVERAGE FOR 
PEOPLE WHO LIVED AT OR ABOVE THE POVERTY LEVEL FROM 1996–2012 
State Difference Lower CI Upper CI Adjusted P-Value 
Alaska -3.55 -6.76 -0.34 0.01 
Connecticut 4.15 0.94 7.36 0.0003 
Massachusetts 3.37 0.16 6.58 0.02 
Rhode Island 3.53 0.32 6.73 0.01 
 
When comparing the MMR vaccination coverage of people who lived at or above 
the poverty line from 1996 to 2012 to the national MMR vaccination coverage, Alaska 
had MMR vaccination coverage that was significantly lower than the national average, 
whereas Connecticut, Massachusetts, and Rhode Island had MMR vaccination coverage 
that was significantly higher than the national average (Table 6). The full table of Tukey 
HSD correlations for people who live at or above the poverty line can be found in 
Appendix XVII.
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People who lived Below the Poverty Line 
 
 
FIGURE 11: MMR VACCINATION COVERAGE FOR PEOPLE WHO LIVED BELOW THE POVERTY LINE BY STATE FROM 1996–
2012
4
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 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half of 
the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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MMR vaccination coverage for people who lived below the poverty line is 
depicted in Figure 11, with the national MMR vaccination coverage ranging from about 
87–93%. The red dashed line depicts the true average national MMR coverage (90%). No 
states were fully below this line, but states, which were fully above this line included 
Alaska, Delaware, Hawaii, Iowa, Maryland, Massachusetts, New Hampshire, North 
Dakota, South Dakota, Utah, Vermont, and Virginia. The state with the lowest MMR 
vaccination coverage was New Mexico, whose coverage ranged from 79–94%. The state 
with the highest MMR vaccination coverage was South Dakota, whose coverage ranged 
from 83–98%. 
No individual differences were found between MMR vaccination coverage for 
any particular state compared to the national coverage. The full table of Tukey HSD 
correlations for people who live below the poverty line can be found in Appendix XVII.
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MMR vaccination coverage by Participation in the Vaccines for Children Program 
Children whose provider participated in VFC 
 
 
FIGURE 12: MMR VACCINATION COVERAGE FOR CHILDREN WHOSE PROVIDERS PARTICIPATED IN THE VFC PROGRAM 
FROM 1997–20125
                                                          
5
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half of 
the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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Data on the VFC program was available from 1997 to 2012. National MMR 
vaccination coverage for children whose healthcare providers participated in the VFC 
program (Figure 12) ranged from about 91–94%. The red dashed line depicts the true 
average national MMR coverage (93%). No states were fully below this line, but states, 
which were fully above this line included Connecticut and Rhode Island. The state with 
the lowest MMR vaccination coverage was New Mexico, whose coverage ranged from 
84–96%. The state with the highest MMR vaccination coverage was Delaware, whose 
coverage ranged from 94–98%. 
TABLE 7: STATE MMR VACCINATION COVERAGE VS. NATIONAL COVERAGE FOR 
CHILDREN WHOSE PROVIDERS PARTICIPATED IN THE VFC PROGRAM FROM 1997–2012 
State Difference Lower CI Upper CI Adjusted P-Value 
Connecticut 4.79 1.56 8.02 0.000005 
Hawaii 3.27 0.04 6.50 0.04 
Massachusetts 3.69 0.46 6.92 0.005 
New Hampshire 3.23 -0.01 6.46 0.05 
North Carolina 3.63 0.39 6.86 0.007 
Rhode Island 3.96 0.73 7.19 0.001 
 
When MMR vaccination coverage for children whose healthcare providers 
participated in the VFC program was compared to the national MMR vaccination 
coverage, Connecticut, Hawaii, Massachusetts, New Hampshire, North Carolina, and 
Rhode Island all had MMR vaccination coverage that was significantly higher than the 
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national average. The full table of Tukey HSD correlations for children whose providers 
participated in the VFC program can be found in Appendix XVIII.
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Children whose provider did not participate in VFC 
 
 
FIGURE 13: MMR VACCINATION COVERAGE FOR CHILDREN WHOSE PROVIDERS DID NOT PARTICIPATE IN THE VFC 
PROGRAM FROM 1997–20126
                                                          
6
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half of 
the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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MMR vaccination coverage for children whose provider did not participate in the 
VFC program, depicted in Figure 13, ranged from about 90–93%%. The red dashed line 
depicts the true average national MMR coverage (92%). Alaska and South Carolina were 
fully below the national MMR vaccination coverage line whereas Colorado, Connecticut, 
DC, Maryland, Massachusetts, Mississippi, Nebraska, Ohio, Pennsylvania, Vermont and 
Virginia were fully above this line. The state with the lowest MMR vaccination coverage 
was Louisiana, whose coverage ranged from 83–97%. The state with the highest MMR 
vaccination coverage was Florida, whose coverage ranged from 91–98%. 
TABLE 8: STATE MMR VACCINATION COVERAGE VS. NATIONAL COVERAGE FROM 
1997–2012 FOR CHILDREN WHOSE PROVIDERS DID NOT PARTICIPATE IN THE VFC 
PROGRAM 
State Difference Lower CI Upper CI Adjusted P-Value 
Georgia 4.93 0.55 9.30 0.008 
Maryland 5.59 0.81 10.36 0.004 
Virginia -4.88 -9.36 -0.39 0.015 
 
When MMR vaccination coverage for children whose providers did not 
participate in the VFC program was compared to the national MMR vaccination 
coverage, Georgia and Maryland had MMR vaccination coverage that was significantly 
higher the national coverage, while Virginia had MMR vaccination coverage that was 
significantly lower than the national average. The full table of Tukey HSD correlations 
for children whose providers did not participate in the VFC program can be found in 
Appendix XVIII.
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MMR vaccination coverage vs. Urbanicity 
MSA Central City 
 
 
FIGURE 14: MMR VACCINATION COVERAGE FOR PEOPLE WHO LIVED IN A MSA CENTRAL CITY FROM 1996–20127 
                                                          
7
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half of 
the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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For people who lived in a MSA central city, the MMR vaccination coverage 
ranged from 89–93%. The red dashed line depicts the true average national MMR 
coverage (91%). The state with the lowest MMR vaccination coverage was Colorado, 
whose coverage ranged from 81–97%. The state with the highest MMR vaccination 
coverage was Nebraska, whose coverage ranged from 90–98%. 
No statistically significant differences were found when comparing MMR 
vaccination coverage for people who lived in a MSA central city in each individual state 
to the national MMR vaccination coverage. The full table of Tukey HSD correlations for 
people who lived in a MSA central city can be found in Appendix XIX. 
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MSA Non-Central City 
 
 
FIGURE 15: MMR VACCINATION COVERAGE FOR PEOPLE WHO LIVED IN A MSA NON-CENTRAL CITY FROM 1996–20128
                                                          
8
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half of 
the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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MMR vaccination coverage for people who lived in a MSA non-central city 
ranged from 91–93% (Figure 15). The red dashed line depicts the true average national 
MMR coverage (92%). Connecticut, North Dakota, and South Dakota were fully above 
this line. The state with the lowest MMR vaccination coverage was Louisiana, whose 
coverage ranged from 83–98%. The state with the highest MMR vaccination coverage 
was South Carolina, with MMR vaccination coverage from 91–99%. 
TABLE 9: STATE MMR VACCINATION COVERAGE VS. NATIONAL COVERAGE FROM 
1996–2012 FOR PEOPLE WHO LIVE IN A MSA NON-CENTRAL CITY 
State Difference Lower CI Upper CI Adjusted P-Value 
Connecticut 4.29 0.38 8.20 0.01 
Rhode Island 3.97 0.06 7.88 0.04 
 
When comparing MMR vaccination coverage in individual states to the national 
MMR vaccination coverage, Connecticut and Rhode Island had MMR vaccination 
coverage that was significantly higher than the national average. The full table of Tukey 
HSD correlations for people who lived in a MSA non-central city can be found in 
Appendix XIX.
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Non-MSA Central City 
 
 
FIGURE 16: MMR VACCINATION COVERAGE FOR PEOPLE WHO LIVED IN A NON-MSA CENTRAL CITY FROM 1996–20129
                                                          
9
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half of 
the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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The national MMR vaccination coverage for people who lived in a non-MSA 
central city ranged from 90–93%. The red dashed line depicts the true average national 
MMR coverage which is 91%. Illinois and Tennessee were the only states, which had 
MMR vaccination coverage where the full range was higher than the national average. 
West Virginia had one of the lowest MMR vaccination coverages ranging from 82–95%. 
Conversely, Oklahoma had one of the highest MMR vaccination coverages ranging from 
85–98%.  
When comparing MMR vaccination coverage in individual states to the national 
MMR vaccination coverage, no statistically significant differences were found. The full 
table of Tukey HSD correlations for people who lived in a non-MSA central city can be 
found in Appendix XIX.
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MMR vaccination coverage vs. Race 
White 
 
 
FIGURE 17: MMR VACCINATION COVERAGE FOR PEOPLE WHO IDENTIFIED AS WHITE FROM 1996–201210 
                                                          
10
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half 
of the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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National MMR vaccination coverage for people who identified as white in the US 
from 1996–2012 ranged from 91–93%. The red dashed line depicts the true average 
national MMR coverage, 92%. Connecticut, Massachusetts, and Rhode Island had MMR 
vaccination coverage where the full range was higher than the national average for people 
who identified as white. Alaska had one of the lowest MMR vaccination coverages 
ranging from 79–93%, while Vermont had one of the highest MMR vaccination 
coverages ranging from 93–99%, with an outlier at 88%.  
TABLE 10: STATE MMR VACCINATION COVERAGE VS. NATIONAL COVERAGE FROM 
1996–2012 FOR PEOPLE WHO IDENTIFIED AS WHITE 
State Difference Lower CI Upper CI Adjusted P-Value 
Alaska -5.54 -9.09 -1.99 0.0000007 
Connecticut 4.18 0.63 7.73 0.003 
Maryland 3.59 0.04 7.14 0.043 
Nevada -4.20 -7.74 -0.65 0.003 
Rhode Island 3.69 0.14 7.24 0.028 
When comparing the MMR vaccination coverage for people who identified as 
white in individual states to the national MMR vaccination coverage, Connecticut, 
Maryland, and Rhode Island had MMR vaccination coverage that was significantly 
higher than the national average, whereas Alaska and Nevada had MMR vaccination 
coverage that was significantly lower than the national average. The full table of Tukey 
HSD correlations for people who identified as white can be found in Appendix XX.
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Black 
 
 
FIGURE 18: MMR VACCINATION COVERAGE FOR PEOPLE WHO IDENTIFIED AS BLACK FROM 1996–201211
                                                          
11
 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half 
of the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
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Figure 18 shows the MMR vaccination coverage for people who identified as 
black in the US from 1996–2012. The national MMR vaccination coverage ranged from 
88–93%. The red dashed line depicts the true average national MMR vaccination 
coverage, which was 91%. Some data were missing for people who identified as black, 
however, California, Connecticut, Indiana, Massachusetts, New Jersey, New Mexico, 
North Carolina, and Virginia had MMR vaccination coverage where the full range was 
higher than the national average for people who identified as black. Michigan had one of 
the lowest MMR vaccination coverages ranging from 80–98%, while Massachusetts had 
one of the highest MMR vaccination coverages ranging from 93–99%. 
 
When comparing the MMR vaccination coverage, for people who identified as 
black, in individual states to the national MMR vaccination coverage, no statistically 
significant differences were found. The full table of Tukey HSD correlations for people 
who identified as black can be found in Appendix XX.
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Hispanic 
 
 
FIGURE 19: MMR VACCINATION COVERAGE FOR PEOPLE WHO IDENTIFIED AS HISPANIC FROM 1996–201212
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 Each box represents one state’s MMR vaccination coverage with the vertical lines indicating the 95% CI associated with the data. Half 
of the data fall inside the box and the other half fall either above or below the box. The open circles indicate outliers that fell more than 1.5 
interquartile ranges below or above the 25
th
 or 75
th
 percentile, respectively. 
  
66 
MMR vaccination coverage for people who identified as Hispanic in the US from 
1996–2012 (Figure 19) ranged from 88–94%. The red dashed line depicts the true 
average national MMR vaccination coverage, which was 93%. Some data were missing 
for people who identified as Hispanic, however, Delaware, Indiana, Louisiana, 
Massachusetts, Minnesota, Nebraska, Ohio, and Tennessee had MMR vaccination 
coverage where the full range was higher than the national average for people who 
identified as Hispanic. New Mexico had one of the lowest MMR vaccination coverages 
ranging from 80–95%, while Michigan had one of the highest MMR vaccination 
coverages ranging from 92–99%. 
TABLE 11: STATE MMR VACCINATION COVERAGE VS. NATIONAL COVERAGE FROM 
1996–2012 FOR PEOPLE WHO IDENTIFIED AS HISPANIC 
State Difference Lower CI Upper CI Adjusted P-Value 
Massachusetts 4.77 0.13 9.40 0.034 
 
When comparing the MMR vaccination coverage, for people who identified as 
Hispanic, in individual states to the national MMR vaccination coverage, Massachusetts 
had MMR vaccination coverage that was significantly higher than the national average. 
The full table of Tukey HSD correlations for people who identified as Hispanic can be 
found in Appendix XX. 
American Indian/Alaska Native 
National MMR vaccination coverage for people who identified as American 
Indian or Alaska Native ranged from 84–97%. Data were only available for Alaska, 
Montana, New Mexico, Oregon, and South Dakota. 
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When comparing the MMR vaccination coverage, for people who identified as 
American Indian or Alaska Native, in individual states to the national MMR vaccination 
coverage, Alaska and Montana both had MMR vaccination coverage that was 
significantly higher than the national average. Only 5 states had reported data for this 
race/ethnicity to the NIS. The full table of Tukey HSD correlations for people who 
identified as American Indian or Alaska Native can be found in Appendix XX 
Pacific Islander 
National MMR vaccination coverage for people who identified as Pacific Islander 
ranged from 87–99%. Only 6 states reported data to the National Immunization Survey 
for people identifying as Pacific Islander in the US. The full table of Tukey HSD 
correlations for people who identified as Pacific Islander can be found in Appendix XX.
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DISCUSSION 
This retrospective cohort study was designed to investigate the relationship 
between MMR vaccination coverage and incidence of measles in the US, and to assess 
whether demographic characteristics and socio-economic status had any correlation to 
MMR vaccination coverage.  For this reason, data for MMR vaccination coverage in the 
US from 1996–2012 were obtained from the NIS, while data pertaining to the incidence 
of measles (in the US from 1996–2012) were obtained from the CDC-WONDER 
database.
26
  
Primary Analysis 
On a national level, there was a medium negative correlation between MMR 
vaccination coverage and measles incidence. As the vaccination coverage increased, the 
measles rate decreased, and vice versa. MMR vaccination coverage was close to the 
standard vaccination coverage of 93% (needed to keep the population protected); but with 
coverage ranging from 90–93%, there is still room for improvement.  
At the state level, Alaska, Colorado, Idaho, Nevada, and Oregon exhibited similar 
negative correlations between MMR vaccination coverage and measles incidence at the 
national level. Conversely, a medium positive correlation between MMR vaccination 
coverage and measles incidence was observed in North Dakota, indicating that although 
the MMR vaccination coverage was low, so was the state’s incidence of measles. The 
raw data shows that North Dakota’s vaccination coverage ranged from 87.6–95.8% with 
an average coverage of 91.5%. Although the average MMR vaccination coverage does 
not seem especially low, a 2% difference from 93%, can significantly affect a 
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population’s risk of a measles outbreak.4 Even with low vaccination coverage, North 
Dakota only had 1 case of measles in the 17 years that data were collected for this 
analysis (APPENDIX I). The one measles case was reported in 2011 when vaccination 
coverage in North Dakota was at 95.8%, explaining how the measles did not spread. 
Travel into and out of North Dakota as well immigration rates in North Dakota will need 
to be investigated to determine why only one case of measles was reported in 17 years. 
Theoretically, if only a limited number of people were traveling into or out of North 
Dakota during this time, there would be a minimal chance that measles would have been 
brought into this population, explaining their very low incidence of measles despite low 
MMR vaccination coverage. 
Secondary Analysis 
Location 
On a state level, Alaska had MMR vaccination coverage that was lower than 
national MMR vaccination coverage where Connecticut, Massachusetts, and Rhode 
Island had MMR vaccination coverage that was higher than the national averages. States 
in the Pacific Northwest have a higher rate of vaccine exemption than states in the 
Northeast
34
 which could explain why vaccination rates are lower in Alaska than they are 
in Connecticut, Massachusetts, and Rhode Island. Furthermore, a report was published 
recently by the state of Alaska department of epidemiology stating that Alaska has 
consistently lower vaccination rates, across the board, compared to other states. The 
article mentions how Alaska needs to work harder at increasing vaccination coverage in 
their state.
35
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Poverty Status 
MMR vaccination coverage for people who lived at or above the poverty line was 
compared to national MMR vaccination coverage (Table 6). People who lived at or above 
the poverty line in Alaska had MMR vaccination coverage lower than the national 
average, whereas people who lived at or above the poverty line in Connecticut, 
Massachusetts, and Rhode Island had MMR vaccination coverage that was above the 
national average.  
While the one-way ANOVA test comparing the MMR vaccination coverage for 
people who lived below the poverty line to the national MMR vaccination coverage 
resulted in a p-value <0.05, there were no statistically significant differences between the 
MMR vaccination coverages for each state compared to the national averages. 
Differences in MMR vaccination coverage were found between individual states but for 
the purposes of this analysis, only the comparison of state MMR vaccination coverage to 
national MMR vaccination coverage is valid. The reason for this comparison is too 
determine which states are statistically different from the national averages. Data which 
conclude that two individual states have statistically different MMR vaccination 
coverages do not show the full picture of which states are truly at risk.  
The results summarized above were expected because it was hypothesized that 
people living below the poverty line would have a lower MMR vaccination coverage. 
Previous studies have reported that people of lower poverty level would have less access 
to and less education about the importance of vaccines in general. Specifically, Pruitt et 
al. investigated the effect that poverty status had on HPV vaccination in 2010. It was 
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discovered that higher state-level poverty is associated with lower vaccination 
coverage.
36
 
Participation in Vaccine for Children 
Data for MMR vaccination coverage for children whose providers participated in 
VFC was available from 1997 until 2012.  Connecticut, Hawaii, Massachusetts, New 
Hampshire, North Carolina, and Rhode Island all had MMR vaccination coverage that 
was higher than the national average. This result was expected because the VFC program 
was put in place to give underinsured and uninsured children access to childhood 
vaccines. It would be interesting to see the ratio of underinsured children to number of 
providers who participated in the VFC program in the above-mentioned states. Since the 
VFC program is clearly working well in these states, the ratio of underinsured children to 
participating providers might need to be applies to other states. 
For children whose providers did not participate in VFC, Georgia, Maryland, and 
Virginia had MMR vaccination coverage that was higher than the national average. It 
would be interesting to determine the number of underinsured children in these states. If 
this number is low, maybe other programs are in place in this states to increase MMR 
vaccination coverage. 
Urbanicity 
While the p-value from the one-way ANOVA was <0.05 for people who lived in 
a MSA central city, MSA non-central city, and non-MSA central city, there was no 
statistically significant difference between the MMR vaccination coverage for MSA 
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central cities or non-MSA central cities compared to the national MMR vaccination 
coverage. For people who lived in a MSA non-central city in Connecticut and Rhode 
Island, MMR vaccination coverage was higher than the national MMR vaccination 
coverage (Table 9). This is not surprising because Connecticut and Rhode Island have the 
highest overall MMR vaccination coverage. The differences in urbanicity could be due to 
the fact that vaccination rates among children who live in areas similar to a MSA-central 
city as well as a non-MSA central city historically have lower vaccination rates than 
those who live in a MSA non-central city.
37
  
Race/Ethnicity 
MMR vaccination coverage for people who identified as white was higher in 
Connecticut, Maryland, and Rhode Island when compared to the national MMR 
vaccination coverage. While in Alaska and Nevada, MMR vaccination coverage was 
lower than national coverage. These results are also not surprising because, overall, 
Connecticut, Maryland, and Rhode Island had higher vaccination coverage than Alaska 
and Nevada. This could be due to the increased vaccine exemptions in the latter two 
states.
34
 Studies comparing MMR vaccination coverage to race, independent of other 
factors, need to be completed to determine the true effect of race on MMR vaccination 
coverage. 
While the p-value was <0.05 for the comparison of MMR vaccination coverage 
for people who identified as black to the national MMR vaccination coverage, there was 
no statistically significant difference in state level MMR vaccination coverage and 
national level MMR vaccination coverage. These findings were consistent with previous 
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studies looking at factors associated with un-vaccination in different communities. While 
people who identify as black were commonly under-vaccinated, they were not usually 
un-vaccinated.
38
 
For people who identified as Hispanic, the MMR vaccination coverage in 
Massachusetts was higher than the national MMR vaccination coverage (Table 11). 
Massachusetts’ state-wide high MMR vaccination coverage could be why this group has 
higher coverage than national averages for people who identify as Hispanic but there 
have not been any studies looking directly at the correlation between race and vaccination 
coverage without taking many other factors into account. More research needs to be done 
on why people who identify as Hispanic in Massachusetts have a higher MMR 
vaccination coverage than national MMR vaccination coverage for people who identify 
as Hispanic across the US. 
Since the dataset for populations of people who identified as American Indian or 
Alaska Native as well as Pacific Islander were very limited, it was hard to make 
comparisons to national MMR vaccination coverage. Additional data are needed on these 
sub-populations to further analyze if a correlation exists.  
Potential Bias & Limitations  
There was no bias in this study because the nature of the data affected all groups 
equally. The nature of the aggregate data primarily resulted in limitations to the analysis. 
Since the data were not collected solely for the purposes of this analysis, there were some 
inconsistencies among different variables and how the data were collected from year to 
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year. These limitations were accounted for by selecting the years with the majority of 
data available for all categories. If the data were collected consistently throughout all of 
the years, the data set would be much larger and there would be a greater likelihood of 
seeing more robust results. For example, data have not yet been published from the NIS 
or the MMWR: Summary of Notifiable Diseases for the full years of 2013 and 2014. 
Anecdotal data has been published on recent outbreaks in the US. A report published in 
the MMWR investigated the measles outbreak in California which began at Disneyland 
in December 2014 and continues to spread as of February 2015. It was reported that a 
total of 110 cases have been reported in CA as well as 15 additional cases in surrounding 
states, 1 case in Mexico, and 10 cases reported in Canada.
39
 While it has been reported 
that the incidence of measles in these two years has been astronomically high,
4
 it would 
have been of benefit to compare MMR vaccination coverage for these two years to the 
large increase in measles incidence in 2013 and 2014. 
Similarly, the two populations that were compared in this analysis were not 
necessarily the same. The NIS data were obtained from a very specific population; 
parents of children who were randomly selected to fill out the NIS and who actually 
completed it. In contrast, the data on measles incidence were broader, encompassing all 
individuals in the US who had contracted measles. Most importantly, age was not 
accounted for in the analysis. Comparisons were made between children who were 
vaccinated in a specific year to people who contracted measles in that same year. While 
this provided some insight into how easily measles can be spread and how well the MMR 
vaccine prevents it, it did not account for an individual’s vaccination status and their 
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incidence of measles. More precise data needs to be collected so that an analysis can be 
performed on the individuals who refused vaccination and those people who contracted 
measles. This analysis would allow for a more in-depth discussion of where the measles 
outbreak occurred, what the MMR vaccination coverage was in that location, as well as a 
multitude of other potentially contributing factors. 
Lastly, there were data that were missing from the NIS data-set. Missing data 
could have led to an under-estimation of the trends that were seen in the different sub-
populations. With a more precise data-set, it would be more likely to see trends in 
different sub-populations such as individuals who identify as American Indian or Alaska 
Native as well as Pacific Islander, where minimal data was available. 
Other limitations to this study include confounders that were not considered for 
the purposes of this analysis. The increase in travel into and out of the US as well as 
immigration into the US have a large impact on the potential cases of measles that are 
reported. If vaccination rates are already low and travelers/immigrants bring measles into 
the US, a higher number of measles cases are likely to be reported. This would not 
change the fact that MMR vaccination coverage is low, but it does add to the need for 
universal vaccination coverage. This confounder was not investigated due to the limited 
nature of the data and should be considered in in future investigations. 
Future Directions  
Future studies should be performed in order to mitigate the limitations mentioned 
above.  In this analysis, significant correlations were found between MMR vaccination 
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coverage and measles incidence in some states as well as certain sub-populations. An 
analysis should be conducted using individual data to determine the accuracy of the 
results presented here. Data collected on an individual level would allow researchers to 
clearly see correlations between MMR vaccination coverage and measles incidence in the 
US. Having access to the actual number of people vaccinated in a certain location and for 
different confounders would allow for a more accurate analysis of MMR vaccination 
coverage data. A case-control study could then be used to compare individual level data 
on people who contracted measles and look back to determine the MMR vaccination 
coverage for that specific location and year when they contracted measles. Correlating 
individuals who contracted measles with specific MMR vaccination coverage data will 
more precisely determine correlations between the two factors. 
Another potential study to expand upon the analysis presented here would be to 
choose a specific sub-population that was shown as having statistically significant MMR 
vaccination coverage that was lower than the national averages and determine why this 
occurs. In a similar retrospective cohort study, subjects would be chosen based on their 
MMR vaccination coverage with measles incidence as the outcome variable. Looking 
deeper into a specific populations and determining risk factors for lower MMR 
vaccination coverage would help healthcare workers and policymakers implement 
programs that would specifically target at-risk populations and increase MMR 
vaccination coverage on a national level. 
Once the data in this study are corroborated with individual level data, 
policymakers would need to work with healthcare providers to implement specific 
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programs tailored to each sub-population that is at risk for not receiving the MMR 
vaccine. One example would be to include better education for parents who are faced 
with the decision to vaccinate their children. Parents need to be aware of not only the 
risks of receiving the MMR vaccine but more importantly, the severe risks and 
complications of their child contracting the measles virus. A hand-out, similar to the one 
given with facts about the MMR vaccine, should be given with each vaccine with the 
facts about the disease it will be preventing. This would allow parents to make a truly 
informed decision about vaccinating their children with the MMR as well as all vaccines 
for highly communicable diseases. 
A second example of changes that can be made as a result of this study and 
further studies would be for policymakers to institute stricter policies with respect to 
vaccine exemptions. There needs to be a middle-ground where medical and religious 
exemptions can be considered but any other exemption would need strong support to be 
accepted. A policy similar to how colleges require proof of immunization in order for 
students to enroll would be a beneficial policy to add to public schools. For example, “the 
Commonwealth of Massachusetts requires that all full-time students submit proof of 
immunization”.40 Specifically, Boston University requires 6 different immunizations be 
completed before a student can come to campus. This policy only allows for medical 
exemptions signed by a physician and religious exemptions put in writing and signed by 
the student. Students with exemptions will be required to leave campus in the event of 
any outbreak.
41
 State-mandated policies such as the one mentioned above could be one 
way to initiate higher vaccination coverage nationwide.  
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CONCLUSIONS 
The objective of this study was to investigate the relationship between MMR 
vaccination coverage and incidence of measles in the US, and to assess whether 
demographic characteristics and socio-economic status had any correlation with MMR 
vaccination coverage. Results from this study suggest that regional differences in MMR 
vaccination rates spanning across multiple sub-populations are associated with the 
increasing measles incidence in the US. These correlations need to be investigated further 
to determine what specific programs can be put in place to increase MMR vaccination 
rates state-wide and among high risk sub-populations. 
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APPENDIX I 
Measles Incidence by State 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 508 138 100 100 86 116 44 56 37 66 55 43 140 71 63 220 55 
AL 0 1 1 0 0 0 12 0 0 0 0 0 0 0 0 0 0 
AK 63 0 33 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
AZ 8 5 11 1 0 1 0 1 0 1 0 0 14 0 1 2 2 
AR 0 0 0 5 1 0 0 0 0 0 0 0 2 0 0 0 4 
CA 46 24 9 17 19 40 5 5 6 4 6 4 17 9 27 31 8 
CO 7 0 0 0 2 0 0 0 1 0 1 0 0 0 0 0 0 
CT 2 1 0 2 0 1 0 0 0 0 0 0 0 0 1 1 1 
DE 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 1 1 
DC 0 2 0 0 0 0 0 0 0 0 0 0 1 2 0 N 1 
FL 1 8 2 2 2 0 2 0 1 0 4 5 1 5 1 8 0 
GA 3 1 2 0 0 1 3 1 1 0 0 0 1 1 1 0 2 
HA 49 4 0 3 3 7 1 19 3 1 0 2 4 0 4 0 0 
ID 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 
IL 3 7 1 2 3 3 1 1 1 2 0 1 32 0 0 3 0 
IN 0 0 3 2 0 4 2 0 0 33 1 0 0 0 0 14 15 
IA 1 0 0 0 0 0 0 0 3 0 0 0 0 1 0 1 0 
KS 1 0 0 0 2 0 0 0 0 0 1 0 0 0 0 6 6 
KY 0 0 0 2 0 2 0 0 0 0 0 0 0 0 1 1 0 
LA 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 
ME 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
MD 2 2 1 0 0 3 0 1 1 0 2 0 0 4 0 2 0 
MA 12 16 2 8 0 3 0 0 2 0 19 1 2 2 3 24 0 
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MI 3 2 10 6 3 0 0 2 0 1 1 3 4 0 0 2 1 
MN 19 8 0 1 1 4 2 0 0 0 1 1 0 1 3 26 0 
MS 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
MO 3 1 0 0 0 2 2 0 2 0 1 0 1 6 3 0 0 
MT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
NE 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
NV 5 2 0 1 7 0 1 0 0 0 0 0 0 0 1 1 0 
NH 0 1 0 1 3 0 0 1 0 1 1 0 0 0 0 1 0 
NJ 3 3 8 0 0 1 1 2 2 2 1 1 1 2 0 4 2 
NM 17 0 0 0 0 0 0 0 0 0 0 1 1 0 0 4 2 
NY 23 16 4 5 23 11 7 7 5 7 10 7 30 18 8 32 5 
NC 2 2 1 0 0 0 0 1 2 0 0 3 0 0 0 2 0 
ND 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 
OH 6 0 1 0 3 3 1 2 0 3 0 0 0 1 2 0 1 
OK 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
OR 14 0 0 12 0 3 0 3 0 2 2 1 1 0 0 3 1 
PA 12 8 4 0 1 8 1 9 0 0 2 3 1 14 2 13 2 
RI 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 
SC 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
SD 0 8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
TN 2 0 1 0 0 0 0 0 0 1 0 0 0 1 0 3 0 
TX 26 7 0 7 0 1 1 0 0 3 0 7 0 1 0 6 0 
UT 118 1 0 0 3 0 0 0 0 0 0 0 0 0 0 13 1 
VT 2 0 1 0 3 1 0 0 0 0 0 0 0 0 0 1 0 
VA 3 1 2 18 2 1 0 0 0 0 0 0 1 1 3 7 0 
WA 38 2 1 5 3 15 1 0 7 2 2 3 19 1 1 4 0 
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WV 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 
WI 9 1 1 0 1 0 1 1 0 2 0 0 6 0 0 2 0 
WY 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 
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APPENDIX II 
MMR vaccination coverage by Location 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 90.6 90.4 92.0 91.5 90.5 91.4 91.6 93.0 93.0 91.5 92.3 92.3 92.1 92.1 91.5 91.6 90.8 
AL 90.6 93.8 95.0 90.1 87.8 94.0 91.6 91.2 91.8 94.1 94.0 95.0 93.6 93.6 95.4 94.0 93.1 
AK 84.5 87.4 91.1 90.7 88.8 87.8 88.7 90.7 89.7 90.8 85.7 89.7 88.4 88.4 88.4 90.8 86.2 
AZ 84.8 88.0 88.0 87.4 87.7 88.7 88.9 91.5 92.9 88.8 87.7 89.0 92.2 92.2 87.7 86.7 88.3 
AR 85.5 92.3 87.9 86.9 88.4 90.3 92.8 90.6 94.6 89.0 85.8 92.5 92.2 92.2 90.5 93.7 92.3 
CA 90.7 88.8 91.2 92.8 90.8 91.3 90.4 92.8 93.1 91.6 92.8 94.6 92.7 92.7 91.4 91.0 91.5 
CO 89.4 94.1 92.9 90.4 87.2 92.1 90.7 85.6 90.8 93.2 88.3 91.2 92.3 92.3 89.3 88.4 91.5 
CT 96.7 93.7 96.6 95.4 95.9 93.9 95.3 98.4 95.0 95.2 96.5 95.3 95.3 95.3 97.8 95.0 94.8 
DE 90.4 91.1 94.1 94.2 90.2 93.6 95.2 93.0 94.5 95.2 96.4 94.8 93.1 93.1 94.0 90.6 94.4 
DC 92.9 89.7 92.7 91.2 86.2 91.9 91.2 92.8 94.6 91.6 92.2 95.2 89.7 89.7 94.7 93.5 93.0 
FL 89.6 90.1 92.0 91.7 89.1 91.4 91.1 95.2 95.4 92.0 91.2 92.3 91.7 91.7 94.1 90.8 91.0 
GA 91.9 91.2 91.7 91.5 91.1 90.1 93.0 90.7 91.9 92.9 91.0 91.4 92.7 92.7 91.5 94.1 91.9 
HA 92.9 90.4 94.4 94.1 93.7 90.6 96.4 93.6 94.7 89.7 89.9 93.8 94.8 94.8 93.2 94.2 95.0 
ID 83.4 88.0 89.7 86.1 88.0 88.6 86.9 92.9 91.7 86.5 88.0 86.1 86.1 86.1 87.2 89.5 93.3 
IL 89.5 89.0 91.2 91.4 91.5 89.0 94.4 93.6 95.0 93.0 89.2 93.1 91.0 91.0 90.5 90.8 91.6 
IN 85.5 88.5 92.9 89.1 87.7 91.1 91.1 92.5 91.5 91.2 89.6 90.4 88.0 88.0 92.3 90.6 90.0 
IA 92.4 89.8 92.1 91.1 92.7 89.2 92.3 91.1 92.9 91.7 90.3 93.0 91.4 91.4 93.8 86.7 93.3 
KS 86.8 93.7 90.8 89.9 87.1 90.4 93.9 89.4 92.3 92.7 92.7 93.1 91.9 91.9 90.0 91.0 88.5 
KY 91.6 89.5 91.6 93.7 88.6 91.6 88.0 95.5 91.0 90.2 92.5 90.8 90.2 90.2 89.5 91.4 89.2 
LA 88.0 88.1 88.3 89.8 87.7 84.7 87.4 88.4 88.7 89.2 88.9 92.9 94.2 94.2 89.7 92.6 90.5 
ME 95.3 95.3 93.6 92.0 94.0 94.2 92.3 94.1 91.7 92.2 92.2 90.2 91.8 91.8 90.9 90.3 91.2 
MD 91.7 95.3 89.1 95.8 90.9 92.9 95.4 93.7 94.8 93.6 96.3 97.1 94.5 94.5 90.5 95.2 92.5 
MA 97.2 95.6 96.0 94.0 96.1 92.8 95.5 97.7 96.0 97.0 96.6 93.3 94.4 94.4 92.3 93.1 93.7 
MI 89.7 89.2 90.4 89.8 88.9 88.6 93.3 92.5 91.8 93.7 92.2 89.5 88.1 88.1 91.1 87.6 91.4 
MN 95.7 91.7 92.4 95.7 92.5 90.8 92.2 92.6 91.7 91.4 92.3 94.9 91.8 91.8 92.7 96.0 90.1 
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MS 93.1 90.7 93.0 92.3 90.3 93.3 91.1 94.7 94.4 91.0 88.5 87.2 89.3 89.3 93.8 89.6 93.4 
MO 87.2 90.1 92.8 88.1 92.9 90.0 94.8 94.5 93.8 90.3 95.7 89.0 91.7 91.7 90.4 88.2 92.7 
MT 87.6 87.0 91.4 93.1 89.9 94.7 85.3 90.7 91.2 93.6 87.3 89.6 85.9 85.9 85.1 87.8 91.5 
NE 91.2 89.4 90.2 91.8 91.5 90.9 93.2 91.0 92.7 94.8 91.4 94.0 91.9 91.9 94.2 95.3 89.0 
NV 82.0 87.9 91.6 88.7 88.0 86.0 89.4 89.2 87.4 85.7 85.1 86.3 88.0 88.0 87.0 90.5 89.8 
NH 94.0 95.5 94.8 93.3 94.9 94.3 93.9 94.6 93.5 88.3 92.9 96.6 94.8 94.8 95.8 92.0 93.7 
NJ 90.9 93.6 96.1 94.1 88.5 91.1 92.8 93.5 94.6 85.3 91.2 91.2 89.9 89.9 86.1 91.3 94.8 
NM 89.6 84.5 85.5 87.5 83.0 87.7 92.5 93.9 89.9 91.2 89.1 90.6 90.6 90.6 88.8 93.1 88.8 
NY 95.1 92.5 95.1 94.9 94.1 92.5 94.4 95.1 95.5 92.9 95.9 93.6 92.2 92.2 89.3 91.0 90.2 
NC 89.7 94.4 95.6 92.5 94.8 96.4 94.9 95.7 95.6 94.4 97.6 96.9 92.2 92.2 94.5 92.3 89.0 
ND 89.4 90.6 87.6 90.8 91.6 92.5 90.7 90.9 92.6 92.3 91.7 95.2 90.6 90.6 92.6 95.8 90.6 
OH 93.2 89.2 91.4 90.3 89.1 91.8 91.3 95.6 93.1 93.1 93.5 90.7 93.9 93.9 93.6 93.3 90.3 
OK 88.4 87.1 94.1 88.8 89.6 93.8 86.4 88.0 90.6 89.8 94.1 89.9 92.3 92.3 91.0 94.0 90.0 
OR 86.2 88.4 89.8 86.1 91.1 89.4 86.6 92.4 93.7 82.7 88.7 88.9 92.0 92.0 92.8 90.6 87.3 
PA 91.4 92.1 94.4 94.3 92.0 95.5 92.2 94.1 95.0 93.6 94.0 93.8 92.2 92.2 92.3 92.8 87.0 
RI 96.1 95.8 96.5 95.8 93.1 94.8 96.0 93.6 95.6 95.2 96.1 94.7 93.7 93.7 95.8 96.6 94.3 
SC 94.8 90.6 94.4 90.9 92.1 94.7 92.6 91.6 92.0 87.3 93.9 92.5 88.5 88.5 91.7 89.3 93.2 
SD 93.2 89.9 89.8 93.0 91.3 93.7 95.5 91.3 93.7 94.4 94.3 95.0 93.7 93.7 92.1 89.2 93.3 
TN 89.7 90.4 93.2 89.6 90.6 94.2 92.5 94.6 91.3 92.0 93.0 94.5 95.6 95.6 93.9 91.1 92.2 
TX 88.4 87.6 89.6 87.9 87.2 90.4 87.7 91.4 89.2 89.1 92.1 90.4 93.7 93.7 91.8 94.3 89.7 
UT 87.4 86.1 90.4 92.3 89.7 89.1 94.0 88.6 89.8 89.0 92.4 90.9 90.8 90.8 85.5 88.8 87.3 
VT 93.7 95.3 96.4 99.4 93.1 95.6 94.7 96.4 94.4 92.6 95.1 93.6 88.1 88.1 92.7 95.3 91.7 
VA 88.0 89.5 90.1 89.4 91.3 91.0 90.3 92.9 96.6 93.3 93.6 90.9 92.3 92.3 92.3 89.0 94.3 
WA 91.7 91.1 90.0 89.3 90.2 89.3 89.6 93.5 92.3 90.6 87.5 90.5 91.2 91.2 89.8 89.3 84.8 
WV 87.6 91.5 92.5 93.3 92.4 93.8 93.6 88.7 94.6 85.7 91.1 96.2 88.3 88.3 92.0 85.8 84.6 
WI 90.2 91.3 92.0 94.2 91.0 92.3 92.9 94.2 93.6 91.6 94.0 91.4 94.3 94.3 93.2 94.9 89.3 
WY 87.6 84.4 89.5 92.6 91.4 91.6 89.7 90.8 92.7 89.4 87.7 87.5 87.6 87.6 92.5 85.6 91.2 
  
  
 
8
4
 
APPENDIX III 
 
MMR vaccination coverage for people who lived at or above the poverty line 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 90.3 90.4 92.0 91.5 90.5 91.4 91.6 93.0 93.0 91.5 92.3 92.3 92.1 92.1 91.5 91.6 90.8 
AL 92.8 93.9 96.1 89.8 89.7 92.1 92.7 92.1 95.6 96.8 97.1 95.0 95.8 95.8 95.3 94.9 93.5 
AK 81.2 88.5 91.1 93.0 86.9 89.3 88.8 91.5 88.1 90.2 86.0 88.2 87.3 87.3 85.3 89.8 85.1 
AZ 88.3 89.1 90.5 88.8 86.8 89.3 89.3 92.9 93.1 88.5 90.2 87.4 92.9 92.9 89.6 90.4 89.8 
AR 87.9 91.4 92.1 88.9 88.5 91.1 93.0 91.0 91.7 88.9 88.2 91.9 95.2 95.2 92.1 94.0 91.5 
CA 92.3 91.5 94.6 94.1 90.3 91.1 89.0 92.6 93.7 90.8 93.3 92.8 92.8 92.8 90.9 88.3 90.0 
CO 88.9 96.0 91.4 92.8 88.4 93.1 91.6 87.3 90.8 92.0 88.4 89.7 92.7 92.7 89.4 85.6 88.8 
CT 95.1 92.9 97.0 95.8 97.3 95.2 96.6 99.1 95.3 95.5 95.9 95.1 94.3 94.3 97.2 97.0 94.9 
DE 92.6 93.0 92.4 93.4 91.9 91.8 94.5 93.7 94.6 95.8 97.1 94.6 90.6 90.6 93.7 93.4 93.5 
DC 95.5 94.7 93.9 95.1 94.4 93.9 92.9 92.0 94.2 90.4 92.0 92.7 92.6 92.6 97.0 93.5 94.7 
FL 90.9 92.6 91.4 92.5 87.6 91.7 90.1 96.4 94.6 92.4 92.3 93.7 90.0 90.0 92.9 90.3 92.6 
GA 93.7 90.9 92.8 91.9 90.6 90.5 94.7 90.1 88.5 94.1 92.0 93.1 91.3 91.3 91.2 96.1 94.8 
HA 90.8 91.9 94.9 93.2 92.7 89.7 96.6 94.0 95.6 88.9 91.9 94.5 95.0 95.0 93.5 93.8 94.5 
ID 84.2 91.3 89.1 88.4 86.1 88.9 86.5 93.9 93.4 87.3 90.2 87.3 87.4 87.4 88.1 87.8 95.6 
IL 90.1 90.7 92.9 91.6 92.1 90.1 94.3 95.7 95.4 95.2 90.2 93.8 91.5 91.5 91.1 90.5 91.8 
IN 88.5 90.6 94.1 90.0 89.9 91.8 93.1 93.3 91.4 92.6 92.0 92.6 87.1 87.1 90.0 91.3 91.2 
IA 93.4 90.0 93.0 90.7 93.2 90.9 92.4 91.7 95.4 91.4 90.5 93.4 93.9 93.9 93.0 90.8 94.2 
KS 89.3 94.9 93.4 90.0 87.6 93.5 93.5 88.5 90.2 92.7 92.5 93.6 93.2 93.2 88.6 90.2 88.8 
KY 93.6 92.5 94.1 93.8 88.7 91.6 93.3 95.2 91.5 90.4 93.2 91.9 89.5 89.5 89.9 97.9 89.8 
LA 91.4 90.6 92.4 90.4 85.5 86.1 85.5 86.2 89.0 90.7 91.7 93.5 91.8 91.8 86.8 92.1 89.6 
ME 95.5 96.0 96.1 94.2 94.7 93.5 94.5 95.0 91.7 91.4 91.5 94.3 91.1 91.1 90.3 90.7 92.6 
MD 93.4 96.3 89.1 97.2 91.8 92.5 97.8 95.7 93.4 92.9 95.8 97.0 94.1 94.1 92.0 95.7 94.9 
MA 96.3 96.4 97.3 94.4 96.7 92.9 94.9 97.0 95.0 97.7 96.4 93.7 93.1 93.1 90.3 96.2 93.8 
MI 89.7 91.7 92.2 91.9 88.5 91.6 93.5 93.7 95.2 94.6 93.4 91.4 87.6 87.6 89.8 95.2 92.7 
  
 
8
5
 
MN 95.1 92.0 93.3 95.9 92.2 89.1 93.3 93.0 92.2 92.4 91.2 95.0 92.5 92.5 93.7 97.4 92.6 
MS 90.3 91.0 92.0 93.7 88.7 94.4 91.0 92.9 96.8 89.2 89.8 88.8 89.1 89.1 92.5 93.3 93.9 
MO 92.9 91.8 92.4 92.1 92.4 91.2 95.2 95.2 94.6 90.8 96.7 91.1 91.2 91.2 90.8 88.6 93.1 
MT 88.5 87.5 89.0 92.9 89.4 94.5 84.9 93.1 91.6 91.7 88.3 88.7 84.9 84.9 84.2 90.7 93.9 
NE 93.1 91.3 90.9 93.4 93.9 91.9 94.5 93.4 92.5 94.1 90.7 92.1 92.6 92.6 94.9 95.6 88.2 
NV 86.6 89.2 92.2 90.3 89.4 85.1 89.1 92.8 86.3 87.9 85.1 88.0 89.2 89.2 87.8 90.2 89.2 
NH 93.7 96.1 94.7 94.3 94.7 94.8 94.6 95.4 93.3 89.3 93.1 96.7 94.9 94.9 95.8 91.0 94.2 
NJ 92.9 95.1 95.5 93.8 89.3 93.0 93.2 93.8 94.9 89.0 92.0 94.3 90.3 90.3 88.0 91.6 94.3 
NM 88.6 80.3 91.4 90.2 85.1 86.1 96.0 95.7 92.7 94.4 91.6 91.5 87.4 87.4 87.1 92.4 88.3 
NY 95.0 95.4 96.0 95.2 96.4 92.6 95.0 93.3 95.4 93.0 96.9 94.6 91.7 91.7 90.3 90.7 92.2 
NC 89.1 96.6 93.8 93.9 94.5 96.2 95.5 96.2 95.6 94.4 97.9 96.0 90.0 90.0 94.4 93.3 88.0 
ND 90.6 91.2 89.2 89.6 92.1 92.3 91.8 93.2 93.0 92.2 93.6 94.9 92.4 92.4 91.6 94.8 91.9 
OH 95.7 88.7 92.2 92.2 91.2 92.8 92.2 96.4 93.9 93.0 93.3 89.5 93.0 93.0 95.4 91.2 88.6 
OK 92.0 89.8 95.1 87.9 91.3 95.3 85.0 89.5 88.3 91.7 93.0 90.2 93.2 93.2 92.5 92.5 89.0 
OR 90.4 91.7 88.4 86.3 90.3 91.6 89.9 91.7 92.6 81.9 90.5 85.6 91.1 91.1 91.8 90.5 85.8 
PA 94.8 92.6 92.6 93.2 92.8 96.2 93.2 96.5 96.5 95.8 94.7 94.0 92.3 92.3 93.4 91.8 89.0 
RI 96.1 95.0 98.6 94.9 94.4 96.4 96.5 94.6 93.9 94.3 96.6 94.4 93.9 93.9 94.9 95.4 94.1 
SC 94.4 91.6 97.5 90.4 90.3 93.2 95.3 90.1 95.1 87.0 96.5 91.8 92.5 92.5 91.2 87.0 94.8 
SD 93.8 91.9 88.5 93.0 90.6 94.8 95.7 88.4 95.4 96.4 94.5 93.6 92.5 92.5 93.3 90.3 92.2 
TN 91.5 92.0 94.0 89.3 91.5 94.5 92.4 93.8 92.0 93.0 94.2 96.8 95.7 95.7 95.0 89.9 94.1 
TX 89.7 90.2 92.0 91.2 88.5 90.5 86.2 90.6 91.3 90.4 92.5 91.7 94.6 94.6 90.3 95.4 91.3 
UT 87.1 86.5 90.4 94.3 89.4 89.0 95.6 90.9 90.1 89.7 93.3 90.1 89.6 89.6 88.5 88.0 90.4 
VT 94.6 95.7 96.0 99.4 91.7 95.2 95.5 96.2 95.0 91.9 94.6 94.1 87.4 87.4 92.3 95.4 90.8 
VA 88.4 90.5 90.5 89.1 90.1 91.9 89.2 94.4 96.9 93.2 94.2 92.4 92.5 92.5 93.5 89.0 95.3 
WA 94.2 92.2 90.1 89.1 89.9 91.5 90.6 95.5 93.3 89.3 88.2 89.6 89.5 89.5 88.3 90.4 85.0 
WV 87.5 89.0 94.3 92.8 94.8 92.6 91.7 90.8 93.3 88.0 88.7 96.8 92.2 92.2 93.3 87.6 84.8 
WI 90.1 92.4 93.4 94.9 92.0 93.3 93.4 93.1 93.0 93.6 93.1 89.8 96.3 96.3 93.3 93.2 92.7 
WY 90.3 81.9 89.7 94.9 91.2 92.2 87.5 91.3 92.0 89.1 92.4 86.6 89.2 89.2 91.2 90.0 90.9 
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APPENDIX IV 
 
MMR vaccination coverage for people who lived below the poverty line 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 87.2 85.7 90.1 90.0 88.9 89.1 90.2 92.0 91.3 89.3 91.1 91.3 92.3 92.3 91.3 91.3 89.9 
AL 91.8 93.2 89.8 93.0 80.5 98.2 NA 87.0 NA NA NA 94.7 91.4 91.4 94.8 93.6 94.6 
AK 89.9 NA NA NA 93.5 NA NA NA 95.0 NA NA 93.9 91.0 91.0 99.2 96.8 NA 
AZ 74.6 83.2 84.4 85.4 88.2 88.3 89.3 90.6 92.1 88.2 83.6 96.7 93.6 93.6 87.1 NA 87.3 
AR NA 91.6 82.3 NA 90.0 86.5 89.9 89.5 96.7 NA NA 94.9 87.9 87.9 86.9 93.3 92.6 
CA 89.6 78.2 90.9 93.1 92.0 90.1 90.3 95.2 92.0 91.4 93.9 97.6 91.4 91.4 91.0 93.4 94.4 
CO NA NA 95.5 NA NA 85.8 NA NA 88.2 96.9 NA NA 92.2 92.2 90.0 93.6 95.7 
CT NA NA 92.4 97.3 94.7 NA NA NA NA NA NA NA 98.3 98.3 NA 89.0 94.1 
DE 92.4 NA 96.2 93.8 NA 97.3 95.8 NA 92.0 NA NA 98.5 NA NA 97.1 NA 95.2 
DC NA 87.7 92.0 89.0 NA 91.8 NA 98.4 96.1 NA 91.3 98.8 NA NA NA 93.7 92.0 
FL 86.7 89.3 94.1 92.1 90.9 93.9 93.0 92.0 96.5 89.4 89.3 91.4 94.6 94.6 94.4 92.6 87.4 
GA 86.0 88.4 90.2 89.6 90.0 87.9 87.4 93.0 98.0 95.7 87.7 90.6 97.1 97.1 92.8 91.0 87.6 
HA 95.1 94.9 95.1 95.0 95.2 90.6 93.2 NA 97.4 93.5 NA 96.8 92.5 92.5 90.9 94.2 96.0 
ID NA NA 91.3 NA 91.0 NA 87.5 92.1 NA 86.7 NA NA NA NA NA 92.2 94.5 
IL 87.8 NA 83.7 95.3 89.5 84.8 93.0 92.7 92.0 86.5 86.3 90.5 92.6 92.6 92.3 92.5 91.1 
IN NA NA 88.0 NA NA 88.2 90.7 NA NA NA NA 83.9 NA NA 96.3 88.6 87.7 
IA NA NA NA 93.1 93.3 NA NA NA NA NA NA NA NA NA NA NA 90.3 
KS NA NA NA NA NA NA 94.4 89.9 NA NA 92.8 NA NA NA NA 96.2 87.2 
KY NA NA 82.7 92.5 NA 90.7 NA 95.1 NA NA 94.5 87.2 91.4 91.4 88.8 NA 87.7 
LA 85.0 83.2 84.6 92.2 88.6 82.4 88.7 89.8 87.0 86.4 89.1 91.3 97.8 97.8 92.5 95.1 92.4 
ME 97.0 98.0 NA 86.1 93.3 96.2 NA 94.1 NA NA NA NA 93.7 93.7 93.6 88.3 NA 
MD NA 93.1 NA 91.3 NA 93.4 91.9 NA 97.4 95.4 97.4 NA 93.9 93.9 NA 94.1 NA 
MA 98.7 96.3 91.4 95.2 97.5 90.0 97.7 99.3 98.4 NA 96.5 NA NA NA NA NA 94.4 
MI NA 90.0 91.4 86.1 85.2 NA 91.7 88.4 NA 90.4 NA NA 90.0 90.0 95.3 NA 91.4 
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MN NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MS 95.3 90.5 91.4 91.7 91.4 91.6 90.9 95.6 95.2 96.0 86.1 NA 90.6 90.6 95.0 85.4 92.3 
MO NA 91.0 97.4 NA 96.2 NA NA 90.4 NA 87.6 NA NA 94.2 94.2 92.0 87.2 91.9 
MT NA 89.6 96.9 92.9 97.5 97.4 NA 84.9 90.0 NA NA 95.9 NA NA NA NA NA 
NE NA NA NA NA NA NA 95.8 NA 90.3 98.7 93.0 98.7 NA NA 90.7 NA 90.0 
NV NA NA NA NA NA 88.3 NA 84.5 92.0 NA NA 82.9 NA NA 87.8 93.0 91.6 
NH NA NA 93.0 NA NA NA NA NA NA NA NA NA NA NA NA 93.8 NA 
NJ NA NA 96.1 98.2 NA NA 95.8 93.8 92.0 NA 92.8 NA 94.8 94.8 NA 88.3 94.8 
NM 92.5 93.0 80.1 NA 79.4 88.6 NA 87.6 85.4 88.3 89.3 87.0 93.6 93.6 90.6 93.9 89.0 
NY 91.7 93.4 91.9 96.2 91.0 92.3 96.3 98.5 94.1 92.9 96.9 90.7 92.1 92.1 85.7 90.1 87.2 
NC NA 89.2 99.0 87.4 92.9 94.4 95.9 93.4 98.3 94.7 94.5 97.8 95.1 95.1 94.1 93.4 90.9 
ND 92.0 NA NA 95.3 NA 92.4 NA NA 92.6 NA NA 95.8 NA NA 95.5 99.7 NA 
OH 87.6 88.7 88.0 82.6 83.6 85.9 90.6 90.3 88.1 91.5 94.0 93.8 95.2 95.2 87.9 95.8 91.5 
OK NA NA NA 90.7 87.7 94.2 NA NA 92.9 83.7 96.2 88.9 NA NA NA 96.3 91.8 
OR NA 87.5 93.3 NA 92.9 NA NA 94.4 97.7 NA NA NA 93.8 93.8 94.0 90.3 89.6 
PA NA 83.8 96.6 97.4 89.4 90.4 NA NA 93.3 NA 94.0 93.0 90.4 90.4 90.7 94.6 83.8 
RI 98.8 96.9 91.1 NA 88.6 84.7 93.9 NA 98.4 97.3 96.5 95.0 NA NA 97.5 98.1 94.8 
SC NA 88.2 92.4 92.1 93.8 98.9 NA 91.8 NA 86.3 93.1 92.8 NA NA 93.1 91.4 91.8 
SD NA NA 90.7 91.2 90.4 NA NA 97.1 NA NA 93.5 98.4 97.2 97.2 NA NA 94.6 
TN 86.2 89.6 87.6 90.1 92.2 93.8 94.0 96.4 89.5 91.8 89.0 91.6 94.5 94.5 90.5 95.1 91.1 
TX 88.0 81.1 89.0 82.5 83.5 89.8 88.3 92.3 86.4 87.2 90.4 87.1 92.9 92.9 93.2 92.9 87.1 
UT NA NA 94.2 NA NA NA NA NA 90.0 NA NA 92.3 NA NA NA NA NA 
VT NA 95.1 98.4 NA NA NA NA NA 95.5 NA NA NA NA NA NA 94.9 92.7 
VA NA 91.8 NA 92.2 95.7 NA 93.8 NA NA NA 90.2 NA NA NA 90.3 NA NA 
WA 88.8 91.4 87.4 88.6 93.1 85.0 85.0 89.3 89.6 92.2 85.9 92.1 93.2 93.2 92.8 85.8 NA 
WV 87.8 91.8 87.8 92.6 87.4 95.3 96.8 NA 95.4 NA 97.0 94.7 NA NA 88.4 83.3 83.1 
WI 91.4 81.2 82.7 88.6 84.0 87.0 93.1 96.8 93.6 NA 97.5 NA NA NA NA 97.5 NA 
WY NA 90.8 88.1 88.6 89.2 89.6 96.7 NA 93.6 NA NA 90.9 NA NA NA NA 90.3 
  
 
8
8
 
 
APPENDIX V 
 
MMR vaccination coverage for children whose providers participated in the VFC program 
 
 
‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 90.8 92.3 92.0± 91.1 91.8 91.9 93.9 93.8 92.1 93.2 94.0 93.4 93.4 93.1 93.5 92.4 
AL 94.5 95.3 90.9 87.3 94.4 91.6 90.6 92.3 93.9 93.5 95.1 96.4 96.4 95.5 95.2 95.3 
AK 86.8 92.4 94.2 93.1 92.2 90.3 95.4 90.3 94.6 89.0 92.0 90.6 90.6 93.2 94.0 89.1 
AZ 89.1 88.2 89.2 90.1 90.1 89.1 92.9 94.1 89.7 88.1 90.2 93.3 93.3 90.1 88.7 88.6 
AR 93.7 88.2 87.8 89.9 90.3 93.9 90.6 94.6 93.1 91.1 93.9 94.1 94.1 92.2 96.7 94.0 
CA 89.7 91.0 94.4 90.4 92.0 90.7 94.5 93.3 93.4 92.8 96.6 94.8 94.8 95.7 93.5 93.0 
CO 95.2 95.2 91.7 90.4 92.6 92.0 86.7 91.8 95.8 93.6 94.5 91.3 91.3 91.0 94.1 92.3 
CT 94.3 97.4 96.8 96.8 96.4 96.5 99.2 94.1 96.9 96.7 97.5 95.5 95.5 98.1 95.9 96.6 
DE 90.2 94.4 94.4 93.1 94.5 96.0 92.5 96.1 96.3 99.6 94.7 92.2 92.2 94.8 92.3 95.3 
DC 88.9 92.3 91.1 85.1 90.8 90.2 93.3 94.2 90.5 92.6 94.9 89.7 89.7 93.1 93.5 95.3 
FL 90.5 92.7 92.0 90.0 91.7 91.2 95.1 97.5 90.8 90.6 95.7 92.2 92.2 95.3 93.0 92.2 
GA 91.1 91.5 91.9 91.1 90.3 93.2 91.3 91.8 92.8 91.9 91.1 93.3 93.3 91.6 93.6 92.0 
HA 91.8 94.5 94.8 93.8 91.7 97.3 95.8 96.3 90.6 94.9 94.8 97.7 97.7 94.6 95.9 97.7 
ID 88.8 89.9 86.7 89.0 89.7 87.3 93.6 94.0 86.8 90.9 91.1 88.4 88.4 90.7 90.3 96.7 
IL 88.5 92.7 91.3 90.9 90.3 95.5 95.7 95.2 92.3 90.0 95.5 92.4 92.4 91.1 95.5 95.2 
IN 89.2 92.2 89.4 90.6 89.8 90.9 93.2 91.2 90.7 94.0 94.0 90.5 90.5 94.1 91.8 94.3 
IA 90.6 92.0 91.2 92.7 89.2 93.3 91.2 93.6 93.3 92.5 94.6 95.6 95.6 95.3 87.0 93.1 
KS 93.5 90.1 92.9 87.3 90.4 94.0 90.7 95.1 92.5 90.3 95.9 93.4 93.4 93.3 89.1 91.7 
KY 89.1 90.8 94.4 90.2 92.4 88.6 96.0 91.4 91.1 93.6 93.2 89.6 89.6 88.9 94.3 90.2 
LA 90.2 88.5 89.7 86.4 82.5 87.8 89.6 90.9 89.9 91.8 93.1 95.1 95.1 89.7 92.4 92.0 
ME 95.7 93.1 93.4 94.2 94.0 92.6 94.0 93.8 91.0 93.3 94.0 93.9 93.9 94.5 92.9 93.8 
MD 94.9 91.4 96.6 91.9 93.2 95.8 94.0 95.2 93.3 95.9 99.1 97.6 97.6 90.7 95.4 95.3 
MA 95.1 95.7 96.6 96.1 92.7 96.0 98.4 98.0 97.2 96.8 93.0 94.1 94.1 92.1 95.2 95.5 
MI 92.7 92.4 91.4 90.9 90.6 94.7 93.7 94.1 93.9 93.7 91.5 90.1 90.1 95.1 90.9 95.0 
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MN 91.5 92.0 96.1 93.4 92.3 94.3 93.3 91.8 93.5 91.7 98.1 92.8 92.8 93.9 98.1 89.0 
MS 92.6 92.9 91.2 90.5 94.7 90.9 96.3 95.4 92.7 90.4 90.3 90.9 90.9 94.9 90.0 93.4 
MO 89.9 93.9 88.5 92.4 89.7 94.8 95.0 94.7 91.2 95.3 91.4 91.7 91.7 93.5 90.1 95.5 
MT 86.8 91.2 92.9 88.8 94.7 89.7 91.2 92.2 94.1 88.4 91.0 88.1 88.1 88.1 90.8 95.0 
NE 89.6 91.7 93.4 91.4 93.4 93.0 91.9 93.8 95.2 93.8 94.3 93.0 93.0 95.7 95.7 91.7 
NV 88.4 94.5 89.6 88.0 87.5 91.6 90.1 88.8 86.7 85.8 87.2 89.2 89.2 88.2 92.9 90.6 
NH 94.6 94.7 94.2 96.3 94.5 93.0 95.2 96.6 89.5 96.2 97.5 95.7 95.7 95.7 95.6 94.2 
NJ 94.8 97.0 92.8 87.2 91.9 92.3 94.8 93.5 87.4 92.0 91.3 90.1 90.1 89.3 94.7 98.3 
NM 87.3 85.0 87.4 84.2 88.5 96.8 95.8 89.6 90.6 91.6 93.8 92.1 92.1 91.7 94.5 90.4 
NY 93.3 94.9 94.3 95.8 93.4 94.2 96.6 96.1 93.0 94.7 94.8 93.8 93.8 90.4 94.0 90.6 
NC 94.5 96.1 93.4 95.3 97.0 94.5 96.5 97.9 95.0 98.7 97.6 93.2 93.2 96.3 95.3 91.1 
ND 92.1 89.9 91.6 91.9 93.7 90.8 92.0 93.8 94.7 93.4 95.5 93.6 93.6 92.6 96.2 94.9 
OH 90.0 90.9 89.4 89.1 91.1 91.7 96.2 93.8 93.3 92.1 90.5 93.3 93.3 94.7 94.7 92.2 
OK 86.9 94.9 90.6 90.6 94.1 87.5 88.0 91.5 90.3 93.4 90.0 95.9 95.9 91.4 96.5 92.3 
OR 88.5 88.8 86.1 92.0 90.8 87.6 92.6 95.1 89.3 92.0 92.8 92.9 92.9 94.7 91.3 88.2 
PA 92.5 95.1 96.2 93.0 95.5 92.4 94.8 94.7 94.2 96.8 96.0 93.1 93.1 92.2 94.5 88.4 
RI 97.4 97.0 97.0 94.3 94.9 95.4 95.8 96.3 94.9 95.9 94.1 94.9 94.9 96.7 96.8 94.7 
SC 92.4 95.6 89.8 93.7 95.9 92.8 92.0 92.2 87.7 93.8 94.7 91.0 91.0 92.5 90.5 93.8 
SD 89.8 90.0 93.4 92.5 93.1 94.1 93.1 93.7 95.5 94.9 95.6 95.0 95.0 94.4 92.8 94.9 
TN 91.5 93.3 90.7 90.9 94.2 93.7 95.3 92.0 94.3 95.0 97.9 97.6 97.6 96.2 91.4 94.6 
TX 87.4 90.6 87.4 89.7 90.5 87.2 92.2 90.6 89.2 93.7 91.9 94.2 94.2 92.7 95.7 91.8 
UT 86.8 91.5 96.6 90.4 91.6 95.2 92.8 92.3 91.1 94.6 96.1 91.7 91.7 88.9 91.4 86.5 
VT 95.6 95.3 99.2 92.8 95.8 93.4 97.1 96.1 93.0 96.2 93.7 89.6 89.6 94.6 96.5 92.3 
VA 89.0 89.6 91.8 91.1 90.3 88.9 91.8 96.7 93.0 93.8 92.3 95.5 95.5 92.0 88.0 94.8 
WA 90.4 90.1 90.7 91.4 90.1 90.6 93.7 94.4 89.6 88.9 94.0 93.7 93.7 91.7 90.3 84.4 
WV 91.0 93.2 93.0 91.8 94.1 94.5 89.9 94.7 86.9 92.5 96.5 89.7 89.7 92.3 87.5 88.1 
WI 91.9 92.7 93.7 89.6 92.0 93.3 95.0 93.4 92.9 94.5 93.9 97.0 97.0 95.4 96.2 90.5 
WY 86.2 89.2 93.2 92.5 92.1 90.1 91.0 93.7 90.1 89.6 89.8 89.1 89.1 93.1 87.4 93.0 
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APPENDIX VI 
 
MMR vaccination coverage for children whose providers did not participate in the VFC program 
 
  ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 92.4 92.3 91.5 90.6 90.4 92.2 91.5 92.7 90.5 92.4 93.4 90.6 90.6 90.2 87.1 91.8 
AL 92.4 93.7 90.8 92.6 91.5 91.2 94.8 NA 92.8 NA 96.6 97.2 97.2 97.6 90.4 NA 
AK 90.6 91.0 NA NA NA 88.4 NA 90.3 NA NA NA NA NA NA NA NA 
AZ 89.6 NA NA NA NA NA 96.3 NA NA 92.9 NA NA NA NA NA NA 
AR NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
CA 92.5 93.2 88.1 91.0 89.2 90.2 88.3 93.1 87.8 94.5 93.4 85.2 85.2 NA NA 96.1 
CO NA NA NA NA 94.4 NA NA 93.7 NA NA NA 99.0 99.0 NA NA NA 
CT 92.6 97.2 95.6 95.1 97.1 97.0 96.2 NA NA NA NA NA NA NA NA NA 
DE NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
DC 94.3 NA 96.8 NA 94.8 97.1 91.8 94.5 94.9 93.0 92.2 98.0 98.0 99.3 95.0 92.2 
FL 96.6 91.2 95.7 NA 96.1 93.4 98.6 NA 99.9 96.0 99.3 92.6 92.6 NA NA NA 
GA 93.3 98.5 95.9 98.7 NA 93.1 NA 99.4 98.6 NA 99.3 98.6 98.6 89.6 96.2 NA 
HA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
ID NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
IL 92.9 NA 96.1 96.9 87.1 95.2 88.5 97.1 95.7 NA 95.8 92.9 92.9 92.3 NA 86.4 
IN 90.3 94.0 96.6 NA 94.5 90.3 NA 94.4 NA 88.5 92.4 NA NA 96.6 NA NA 
IA 91.7 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
KS 95.3 92.0 85.2 87.8 95.6 93.7 NA NA 94.1 97.5 90.7 96.3 96.3 NA 94.1 92.7 
KY 93.1 98.8 93.6 NA 90.5 NA 97.2 NA NA 93.1 NA 97.8 97.8 97.2 NA 98.9 
LA 83.7 94.2 90.5 96.2 94.3 96.6 NA NA 90.3 86.6 92.7 NA NA NA 98.4 NA 
ME 93.4 95.7 91.3 93.0 96.1 NA 96.9 NA NA NA NA NA NA NA NA NA 
MD 96.4 NA 96.1 NA 99.5 NA 97.6 98.0 NA 98.3 97.2 NA NA 95.8 NA 96.9 
MA 98.1 95.9 94.3 95.2 92.9 93.2 97.4 97.0 NA NA NA NA NA NA NA NA 
MI NA 86.7 87.6 NA NA NA NA NA NA 99.1 NA NA NA NA NA NA 
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MN 94.9 89.4 92.6 92.2 NA NA 98.8 95.8 NA NA NA NA NA NA NA NA 
MS NA NA 98.0 92.9 NA NA NA NA NA NA NA NA NA NA NA NA 
MO NA NA NA 95.6 NA 91.6 92.3 93.6 NA 98.6 93.1 95.9 95.9 90.3 90.1 97.2 
MT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NE NA NA NA 97.3 NA 95.2 NA NA NA 93.5 NA NA NA NA NA NA 
NV NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NH 97.3 96.6 93.3 87.8 96.3 95.8 95.9 93.1 NA NA NA NA NA NA NA NA 
NJ 93.1 96.3 97.6 93.7 92.6 95.3 96.5 99.3 NA NA 98.1 91.4 91.4 NA 87.0 93.0 
NM NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NY 93.6 95.2 95.4 92.7 90.1 97.6 88.0 96.8 92.3 98.8 93.4 NA NA 97.8 NA NA 
NC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
ND NA NA NA NA NA NA NA 98.0 NA NA NA NA NA NA NA NA 
OH 92.0 94.0 94.3 93.0 93.1 92.3 95.7 96.0 95.7 96.1 92.9 98.8 98.8 NA NA 95.9 
OK NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
OR NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
PA 96.2 NA 96.6 95.8 95.1 95.4 NA 98.7 93.4 NA NA 93.6 93.6 97.4 97.0 NA 
RI 93.0 94.7 92.9 90.7 NA NA NA 95.4 NA NA NA NA NA NA NA NA 
SC NA NA NA NA NA NA NA NA NA 89.9 NA NA NA NA NA NA 
SD 95.1 88.7 92.9 NA NA NA NA NA NA NA NA NA NA NA NA NA 
TN 87.7 93.5 88.7 92.3 97.9 96.1 90.3 87.2 NA 93.3 NA 96.8 96.8 91.8 93.8 NA 
TX 90.8 89.7 93.6 85.3 91.8 NA 90.9 88.2 91.5 88.4 91.5 96.9 96.9 NA 97.1 86.6 
UT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
VT 95.5 97.9 NA 94.7 96.6 96.8 97.2 94.0 95.9 NA NA NA NA NA NA NA 
VA NA 96.8 NA 97.1 93.2 94.9 98.1 NA 96.5 96.9 98.9 NA NA 94.9 97.4 97.9 
WA 91.5 90.5 87.3 90.7 91.8 87.3 95.5 88.9 95.8 NA NA NA NA NA NA NA 
WV NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WI 95.0 90.1 95.0 93.9 86.3 90.5 89.8 94.2 92.9 93.5 97.4 96.9 96.9 91.0 NA NA 
WY NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
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APPENDIX VII 
 
MMR vaccination coverage for people who lived in a MSA central city 
  
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 89.5 89.8 91.3 91.3 89.7 90.9 90.2 93.2 92.8 91.6 92.5 91.8 92.6 92.6 92.4 92.0 90.1 
AL 88.5 96.1 94.9 89.6 87.7 95.4 92.9 86.8 89.3 95.2 98.2 93.1 92.9 92.9 96.9 93.8 92.7 
AK 84.4 86.4 91.4 90.8 92.0 92.2 86.9 90.9 91.5 89.7 87.2 91.2 NA NA 84.8 87.9 85.1 
AZ 84.8 86.6 86.2 84.9 86.3 88.1 88.4 90.4 91.8 87.1 87.1 87.5 93.5 93.5 85.3 88.3 92.1 
AR NA 87.7 86.0 NA 92.9 95.3 NA 95.1 94.8 NA NA 94.3 91.3 91.3 88.6 94.1 89.2 
CA 91.7 90.5 89.3 94.9 87.9 93.9 84.4 95.1 95.1 94.1 95.8 95.5 94.1 94.1 93.6 91.7 90.6 
CO 87.0 94.6 94.5 92.2 87.3 88.6 93.9 80.5 87.7 95.2 87.8 97.7 NA NA 91.5 89.9 91.9 
CT 94.7 91.8 94.1 95.2 95.3 88.4 90.7 97.0 96.1 98.3 98.0 94.5 95.4 95.4 98.3 94.1 92.9 
DE 89.8 90.3 95.0 95.7 89.9 92.5 93.9 88.9 92.3 95.2 96.0 98.6 91.2 91.2 96.7 91.3 98.0 
DC 92.9 89.7 92.7 91.2 86.2 91.9 91.2 92.8 94.6 91.6 92.1 95.2 89.7 89.7 94.7 93.5 93.0 
FL 88.6 88.3 92.3 94.9 88.6 90.6 90.4 97.4 95.6 91.2 91.2 93.1 90.5 90.5 95.2 89.7 88.4 
GA 87.9 91.0 93.6 NA 88.0 89.0 NA 90.4 89.1 94.7 88.8 NA NA NA 94.1 90.5 89.5 
HA 97.6 90.9 94.8 93.2 96.3 93.7 95.6 95.4 93.5 NA 86.2 97.9 94.7 94.7 91.4 94.5 96.9 
ID NA 90.1 NA 93.1 91.3 NA NA 96.2 90.2 87.1 87.9 84.3 90.2 90.2 92.8 88.6 95.4 
IL 87.9 87.4 88.0 87.7 88.2 87.8 91.0 92.4 95.0 90.9 88.1 91.8 90.4 90.4 89.1 89.3 89.9 
IN 82.0 87.2 91.8 87.3 87.0 93.0 91.8 93.5 91.4 NA 88.5 91.9 88.5 88.5 96.2 90.6 90.2 
IA 90.0 93.2 93.3 84.6 91.9 93.2 91.2 94.7 95.6 95.5 NA 96.6 89.0 89.0 92.6 NA 91.3 
KS 86.6 91.2 87.5 89.6 86.4 93.2 96.1 86.0 94.0 92.2 93.6 89.7 92.4 92.4 92.6 NA 88.1 
KY NA 89.3 93.8 94.8 92.1 92.6 NA 95.7 NA 92.9 96.5 91.2 NA NA NA 99.7 93.4 
LA 81.6 83.8 90.1 90.1 88.3 82.4 86.2 87.4 89.5 88.8 93.9 88.3 94.2 94.2 89.8 95.1 87.5 
ME NA 91.6 98.0 91.1 94.0 NA 95.2 NA NA NA NA NA NA NA 94.7 92.1 NA 
MD 94.5 95.7 91.3 93.1 91.3 92.0 96.1 94.5 95.2 95.0 97.5 98.0 92.3 92.3 88.5 93.5 94.8 
MA NA 95.1 95.2 95.7 91.9 90.3 89.5 97.2 95.0 97.8 98.9 NA 94.3 94.3 NA NA 92.1 
MI 87.5 82.3 85.8 86.8 88.9 92.2 95.3 92.7 89.4 95.0 87.7 NA 91.7 91.7 95.7 90.0 99.1 
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MN 96.7 93.3 96.6 96.4 96.4 91.8 93.1 97.0 91.5 86.8 92.4 95.7 94.0 94.0 95.9 95.5 NA 
MS NA 88.6 88.8 NA NA 95.4 NA 94.9 95.6 91.4 94.0 NA 89.5 89.5 91.8 NA NA 
MO NA 94.9 93.0 91.5 92.9 85.1 98.3 91.3 93.2 91.9 98.4 NA 96.0 96.0 92.3 88.6 89.4 
MT 81.4 88.3 94.7 93.7 88.7 96.2 84.7 86.1 86.7 96.6 88.5 87.2 NA NA NA 87.3 92.7 
NE 95.3 90.0 90.1 92.8 93.5 91.3 92.2 92.0 96.1 97.6 96.1 99.3 93.3 93.3 92.2 94.8 89.5 
NV 82.7 87.9 90.4 87.9 87.7 84.2 87.2 88.1 88.9 84.1 85.7 86.4 87.5 87.5 89.2 89.4 92.4 
NH NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 98.3 NA 
NJ NA 92.1 90.8 NA NA NA 95.1 95.7 97.7 NA NA NA NA NA NA 91.6 96.4 
NM 86.9 86.6 83.2 86.0 85.7 87.7 91.3 95.9 90.1 91.3 90.3 92.4 91.5 91.5 86.3 94.8 86.5 
NY 94.2 93.1 95.3 95.6 93.6 91.3 94.7 96.4 94.2 91.7 95.9 93.1 94.0 94.0 90.4 92.1 91.3 
NC NA 96.0 96.4 91.6 95.4 93.6 97.1 92.2 94.0 93.4 98.1 96.9 95.5 95.5 91.2 95.1 86.4 
ND 86.7 92.6 91.7 89.4 90.5 95.9 NA 91.8 96.9 92.0 96.0 97.5 96.8 96.8 95.4 98.3 94.9 
OH 91.6 87.1 89.7 92.1 86.1 93.6 89.5 95.5 91.2 92.9 92.6 93.0 95.9 95.9 94.9 94.7 88.5 
OK 90.9 83.2 91.5 89.8 90.5 92.6 94.9 NA 92.8 85.1 96.4 NA 90.4 90.4 93.1 96.3 92.6 
OR 91.6 89.3 91.3 87.9 94.3 84.3 85.1 93.7 94.2 83.9 86.8 86.9 91.5 91.5 90.7 95.7 85.4 
PA 87.3 93.0 95.7 97.4 93.6 92.0 94.4 91.3 98.0 95.4 94.9 91.3 93.7 93.7 93.2 93.2 84.4 
RI 94.1 97.2 92.8 96.0 92.7 90.8 95.0 96.5 95.2 94.8 98.1 94.9 90.4 90.4 95.4 98.3 94.6 
SC 96.1 90.1 93.7 91.3 96.1 97.9 90.8 94.6 NA NA 97.9 94.5 84.9 84.9 91.6 89.0 97.2 
SD 91.8 88.6 96.7 93.8 93.6 93.6 93.5 91.5 94.8 94.9 92.7 98.7 96.1 96.1 NA 92.1 93.0 
TN 87.0 89.1 90.5 87.4 88.9 93.4 91.2 94.3 91.9 92.0 93.3 92.6 95.0 95.0 90.3 93.2 91.3 
TX 90.3 88.0 89.9 86.6 88.5 89.5 84.4 91.1 89.8 90.8 90.9 88.2 92.8 92.8 92.8 94.8 89.3 
UT 87.2 83.2 89.0 88.9 91.4 89.5 98.4 92.6 92.6 87.9 95.9 91.7 96.1 96.1 85.2 89.3 NA 
VT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
VA NA NA 90.8 95.4 NA NA NA NA 95.8 95.1 95.7 92.6 95.5 95.5 94.0 91.9 96.3 
WA 92.1 92.8 89.3 87.3 89.5 89.6 89.4 93.2 92.0 89.5 88.1 94.0 90.4 90.4 92.4 87.3 85.0 
WV NA 92.4 NA 96.7 95.7 97.8 94.8 NA 98.8 89.6 92.8 98.8 88.4 88.4 88.3 NA NA 
WI 91.5 94.5 89.8 94.2 86.8 91.2 93.0 93.6 95.0 91.7 95.2 96.5 94.3 94.3 94.3 96.2 87.6 
WY 86.7 80.4 95.7 91.3 93.8 92.8 89.9 92.9 89.4 89.8 91.8 NA 87.1 87.1 91.7 NA 93.6 
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APPENDIX VIII 
 
MMR vaccination coverage for people who lived in a MSA non-central city 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 91.4 90.8 92.4 92.1 91.0 92.0 93.3 93.1 93.5 91.8 92.5 92.8 92.3 92.3 90.5 91.2 91.0 
AL 94.6 94.2 96.6 91.1 82.4 92.5 90.4 98.6 96.3 94.4 90.9 98.0 95.5 95.5 95.4 94.4 93.1 
AK NA NA NA NA NA NA NA NA NA 96.5 NA 84.6 NA NA 87.6 NA NA 
AZ 87.7 92.2 89.2 89.2 91.3 88.0 90.7 93.7 95.2 89.7 88.1 90.7 89.7 89.7 90.8 NA 82.6 
AR 90.9 91.2 86.1 88.5 79.4 82.4 92.8 89.3 93.2 92.6 NA 93.5 93.7 93.7 92.1 87.2 91.2 
CA 90.0 88.1 92.2 91.6 92.1 91.2 94.1 91.7 92.4 88.9 90.4 94.2 92.5 92.5 88.4 89.7 92.5 
CO 92.4 94.1 92.6 89.1 88.1 93.6 89.6 86.5 93.7 91.1 NA 87.0 97.0 97.0 86.9 88.6 93.1 
CT 97.5 94.5 98.0 95.5 96.1 95.9 97.0 98.9 94.0 95.4 95.4 95.1 94.4 94.4 97.6 95.7 95.5 
DE 91.9 93.9 93.8 90.4 88.5 92.6 95.1 96.9 97.2 93.8 95.3 94.0 93.9 93.9 94.6 88.7 91.3 
DC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
FL 89.4 92.7 92.4 89.6 89.8 93.6 93.0 92.5 94.6 93.8 91.8 90.4 93.9 93.9 90.0 91.2 93.3 
GA 90.8 90.9 89.8 90.0 92.9 91.6 93.8 88.6 94.0 91.6 92.0 93.5 91.9 91.9 90.1 94.3 91.2 
HA 91.6 89.7 91.7 96.1 91.2 88.0 98.0 91.9 93.5 88.8 92.9 93.2 92.4 92.4 93.8 96.9 93.6 
ID 91.1 91.9 95.5 83.8 NA 86.1 85.5 94.4 96.4 90.6 NA 87.7 89.4 89.4 83.9 94.2 93.2 
IL 93.0 89.4 92.6 94.0 92.1 90.5 96.4 94.2 94.8 96.2 94.1 95.4 90.2 90.2 91.8 92.7 92.1 
IN 89.8 88.3 90.4 91.8 86.9 88.8 92.3 95.1 95.6 98.6 88.4 89.7 90.7 90.7 88.5 90.9 88.6 
IA NA 91.6 93.0 91.9 97.3 86.2 93.5 NA NA 96.0 88.1 91.5 93.0 93.0 95.2 NA 95.3 
KS 93.4 92.6 92.6 92.3 90.5 92.3 94.6 NA 90.7 94.7 93.4 95.9 92.8 92.8 87.3 91.7 91.3 
KY 93.2 92.4 93.6 94.5 88.0 88.9 93.3 92.0 92.5 NA 90.5 95.1 94.6 94.6 91.5 95.3 91.3 
LA 94.0 91.7 87.4 88.1 84.3 81.9 90.1 90.5 86.9 89.5 92.8 98.1 96.2 96.2 89.0 91.9 89.6 
ME 94.2 94.6 95.6 90.3 92.7 92.2 91.3 90.1 91.7 89.1 90.2 87.1 90.9 90.9 89.9 95.1 91.2 
MD 91.7 95.5 88.6 96.2 91.2 92.8 95.4 92.9 94.3 93.5 94.9 96.5 94.9 94.9 90.9 95.5 91.1 
MA 97.5 95.6 96.2 93.8 96.5 93.0 96.0 97.8 96.4 96.9 95.9 96.8 94.4 94.4 90.2 95.0 94.3 
MI 90.9 90.9 92.7 90.1 88.3 86.7 92.6 91.8 92.1 94.4 95.3 89.0 83.9 83.9 86.5 85.5 87.5 
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MN 95.7 91.0 91.5 97.6 85.0 91.2 88.2 92.6 94.6 NA 95.1 91.3 89.5 89.5 91.5 95.8 90.2 
MS 89.5 NA 96.4 92.2 91.9 NA NA NA NA NA 88.7 93.5 NA NA 92.4 NA 92.1 
MO 85.2 90.3 93.2 85.6 94.4 92.6 97.0 96.6 95.4 92.1 96.1 93.1 93.1 93.1 89.6 89.6 95.8 
MT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NE 90.0 NA NA 95.5 NA 92.0 NA NA NA 93.5 NA 95.8 95.9 95.9 97.1 92.9 90.5 
NV NA 87.6 95.6 92.5 91.8 91.4 90.4 93.0 85.9 87.4 NA NA 87.0 87.0 87.8 0.8 NA 
NH 92.6 95.7 96.9 93.0 95.0 95.1 95.5 96.4 93.0 91.2 94.4 97.6 91.7 91.7 93.9 93.6 97.4 
NJ 91.9 93.8 96.6 94.9 89.3 92.2 92.5 93.0 94.3 85.4 93.7 90.2 91.0 91.0 87.1 91.2 94.4 
NM 92.0 NA 91.2 88.5 NA 89.1 99.0 NA 93.4 NA 88.9 NA NA NA 91.5 90.4 NA 
NY 97.0 91.5 94.0 93.8 93.7 94.6 92.8 93.8 97.5 94.1 94.3 95.2 88.8 88.8 87.0 89.4 87.1 
NC 92.9 97.7 96.5 92.2 94.3 99.2 96.0 NA 97.8 96.9 94.7 96.7 95.7 95.7 95.8 91.0 86.1 
ND NA 92.6 NA NA NA NA NA 97.5 96.9 NA NA 94.1 97.2 97.2 NA NA NA 
OH 93.2 90.6 91.7 92.3 89.5 90.5 93.5 98.5 94.2 94.5 93.9 88.7 93.0 93.0 96.2 90.0 92.1 
OK 87.4 91.2 95.2 87.2 NA 95.7 85.6 NA 88.0 91.0 90.8 94.8 93.5 93.5 NA 86.1 88.9 
OR 84.8 84.6 90.3 90.7 92.5 95.0 90.1 93.7 92.6 NA NA NA 89.6 89.6 92.7 NA 92.1 
PA 93.1 91.1 92.0 94.6 90.8 97.4 90.5 97.6 94.7 92.1 94.1 95.7 89.1 89.1 92.8 94.4 88.3 
RI 97.4 94.9 98.9 95.6 93.3 97.3 96.8 91.5 97.0 95.4 95.2 94.5 96.0 96.0 96.0 95.4 94.2 
SC 93.7 90.5 92.6 90.9 90.7 92.7 96.4 89.4 94.5 91.8 93.8 92.1 88.4 88.4 91.9 85.4 92.7 
SD NA 93.5 NA 96.2 NA NA NA NA NA 94.5 NA 93.0 96.6 96.6 NA NA 95.8 
TN 92.9 88.1 94.1 85.2 90.9 95.1 90.7 95.7 91.0 92.7 94.4 92.9 96.1 96.1 96.9 89.2 91.4 
TX 86.5 85.5 89.2 93.2 88.4 92.2 93.9 91.6 87.5 86.0 94.2 93.3 94.7 94.7 91.2 95.9 90.1 
UT 85.3 86.2 93.4 94.1 88.2 89.3 96.0 85.0 88.2 92.0 91.7 90.7 88.1 88.1 84.5 87.9 92.4 
VT 95.6 96.3 95.1 NA 93.1 96.4 95.0 97.4 NA 88.9 97.7 NA 91.4 91.4 94.8 94.7 93.8 
VA 89.3 90.3 86.8 90.0 93.2 92.8 88.4 93.8 96.4 94.2 92.5 90.7 96.8 96.8 93.4 87.4 93.2 
WA 93.0 90.2 90.5 89.2 89.1 88.2 90.3 93.3 91.8 93.1 89.1 83.3 91.4 91.4 87.0 90.1 83.4 
WV 87.0 92.2 95.2 88.7 89.9 95.7 87.0 NA 96.1 90.6 88.7 96.0 89.9 89.9 89.5 86.0 NA 
WI 89.2 90.9 93.2 94.1 95.0 94.4 93.5 92.5 93.8 94.5 93.1 90.6 97.5 97.5 94.4 95.0 90.5 
WY NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
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APPENDIX IX 
 
MMR vaccination coverage for people who lived in a non-MSA central city  
 
 
’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 90.5 90.6 92.4 90.4 90.8 90.8 90.2 92.3 92.4 90.4 91.5 92.3 90.4 90.4 91.4 91.5 92.4 
AL 89.6 90.8 93.4 89.4 93.6 94.1 91.5 88.4 89.6 91.6 91.6 93.4 92.2 92.2 92.9 93.7 93.7 
AK 88.1 87.9 91.5 90.4 88.6 85.2 89.2 89.8 88.7 88.0 88.0 92.1 90.6 90.6 90.9 97.8 93.2 
AZ NA 84.1 90.5 94.0 84.5 93.6 86.3 89.7 90.0 96.3 90.3 NA NA NA NA NA NA 
AR 90.4 94.6 89.7 90.4 91.1 92.5 95.8 89.6 95.2 94.9 93.1 90.7 91.8 91.8 90.5 96.5 95.9 
CA NA NA NA NA NA NA NA NA NA NA 94.4 NA NA NA NA NA NA 
CO NA 93.5 90.3 88.8 85.4 94.4 NA 94.9 90.0 91.1 NA NA 91.0 91.0 88.2 NA NA 
CT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 94.6 NA 
DE 88.9 NA 92.5 98.6 94.6 97.8 NA 95.8 94.2 97.7 NA 92.8 93.2 93.2 86.4 94.5 NA 
DC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
FL 95.6 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
GA 96.5 91.6 93.6 94.5 90.9 87.7 92.9 93.9 NA 93.6 91.5 96.1 99.1 99.1 92.1 98.3 96.7 
HA 90.1 90.9 98.8 90.9 96.0 91.2 94.6 94.9 97.1 86.1 NA 91.6 97.3 97.3 94.5 90.2 95.8 
ID 81.5 86.5 88.8 85.8 88.7 89.8 88.8 91.0 90.0 82.5 89.4 86.6 NA NA NA 86.1 91.5 
IL NA 93.6 94.3 90.8 98.5 NA 95.0 94.6 95.8 NA NA NA 97.7 97.7 NA NA 96.1 
IN 84.9 91.0 97.9 87.9 89.8 91.1 88.4 NA NA NA 94.1 NA NA NA 90.8 90.0 91.9 
IA 95.5 87.1 91.0 95.0 90.9 88.0 92.5 89.8 94.6 86.4 94.6 91.6 92.2 92.2 93.7 91.5 94.1 
KS 83.3 96.5 91.6 88.2 85.0 87.1 91.6 96.3 92.5 91.6 91.4 93.6 90.5 90.5 90.0 93.3 86.7 
KY 92.6 88.3 89.0 92.8 87.3 92.3 87.2 96.7 93.0 90.2 90.3 87.8 83.9 83.9 87.7 85.5 84.8 
LA 89.1 88.4 86.3 92.7 92.2 90.0 85.8 NA 90.1 89.8 NA 93.5 92.2 92.2 90.5 90.2 98.1 
ME 95.1 97.1 89.1 94.5 95.7 94.6 92.3 96.4 90.1 96.2 96.1 93.1 94.4 94.4 90.1 84.5 92.3 
MD NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MI 90.5 94.9 94.0 95.5 90.3 88.5 92.7 95.1 94.9 90.4 92.8 NA NA NA 91.0 NA 89.0 
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MN 94.5 90.6 88.0 91.3 97.9 88.9 96.8 87.4 89.3 NA 88.3 98.0 92.3 92.3 NA 97.8 99.1 
MS 95.5 91.5 93.5 92.9 91.4 93.8 92.4 96.7 95.9 94.5 87.4 86.0 91.6 91.6 95.0 93.4 98.3 
MO 92.3 85.8 91.8 88.9 91.2 91.1 89.2 92.7 91.4 84.9 NA NA NA NA 90.0 85.5 92.4 
MT 91.0 86.4 89.7 94.0 90.0 94.3 86.5 92.5 93.1 92.9 85.9 90.2 86.8 86.8 85.8 89.5 90.5 
NE 87.7 88.0 90.4 89.8 89.0 89.9 94.8 90.3 91.3 93.3 87.8 88.2 88.3 88.3 95.3 97.9 87.5 
NV NA NA 93.9 85.8 NA 86.2 NA NA NA NA NA NA NA NA NA 94.8 NA 
NH 98.8 94.8 88.7 94.1 94.9 92.2 89.4 91.6 94.3 84.7 89.5 94.0 96.4 96.4 97.0 87.7 87.3 
NJ NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NM 91.5 80.2 85.8 89.0 82.5 87.3 90.8 88.5 88.6 92.4 88.1 91.4 90.1 90.1 90.0 93.3 91.5 
NY 93.2 93.3 NA 95.1 NA NA NA 91.5 96.4 NA 97.6 NA 92.9 92.9 90.0 NA 93.5 
NC 93.5 89.8 93.7 94.0 94.3 96.5 90.9 94.4 95.0 92.7 98.8 97.1 85.1 85.1 97.9 NA 99.0 
ND 91.4 88.6 89.4 93.6 92.4 91.6 91.3 88.6 88.4 93.6 89.4 94.4 86.4 86.4 90.6 95.7 85.9 
OH 97.0 91.5 96.2 82.8 95.0 90.1 90.2 NA 95.5 90.4 95.1 91.3 90.9 90.9 NA 97.4 91.1 
OK 87.0 87.6 95.1 89.4 91.9 92.7 NA 90.2 90.6 92.9 94.7 93.6 93.3 93.3 96.3 99.3 87.8 
OR 81.6 92.3 87.1 NA 83.5 88.7 82.8 88.5 94.8 90.1 94.5 93.6 95.3 95.3 97.1 88.2 86.9 
PA 95.0 93.2 97.2 NA 92.5 97.2 93.1 NA NA 94.9 NA 93.3 97.9 97.9 88.4 87.8 NA 
RI NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
SC 94.9 91.2 97.4 90.6 89.6 94.1 NA 90.8 94.1 NA 89.7 91.3 92.5 92.5 91.7 96.1 NA 
SD 92.9 90.0 87.3 92.2 90.2 93.5 96.7 91.9 93.3 94.1 93.7 94.1 92.0 92.0 95.8 NA 92.9 
TN 90.7 94.2 95.4 96.7 92.5 94.2 95.3 94.1 90.8 91.2 NA 99.0 95.9 95.9 94.8 NA 95.6 
TX NA 90.7 89.3 NA NA 89.5 NA 92.4 90.9 NA 92.7 94.4 95.5 95.5 88.6 88.4 89.8 
UT 91.3 90.4 88.0 93.8 89.0 88.3 NA NA 87.2 NA NA NA NA NA NA 91.5 NA 
VT 93.0 95.2 97.1 99.0 92.7 95.8 94.6 95.5 92.2 95.9 94.4 95.9 86.4 86.4 93.7 95.3 90.6 
VA 87.6 94.2 NA NA 92.4 92.6 96.5 95.0 97.8 NA 92.7 NA NA NA NA NA NA 
WA 88.4 88.9 90.6 94.6 94.5 91.2 88.1 94.5 94.7 NA 86.8 97.1 94.0 94.0 88.8 95.5 NA 
WV 88.4 90.9 89.8 94.8 92.6 92.0 95.4 87.8 93.0 80.8 92.2 95.3 87.2 87.2 94.6 87.1 88.4 
WI 89.1 87.2 94.5 94.2 93.2 92.5 92.0 96.7 91.5 88.0 93.7 NA NA NA 89.9 92.0 89.8 
WY 87.9 86.4 86.4 93.1 90.9 91.3 89.7 90.0 94.9 89.1 85.4 88.2 87.9 87.9 92.8 87.1 90.4 
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APPENDIX X 
 
MMR vaccination coverage for people who identified as white 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 91.4 91.4 93.1 92.4 91.5 91.7 92.6 93.2 93.5 91.4 92.8 92.1 91.3 91.3 90.6 91.1 90.9 
AL 92.3 93.6 95.9 92.0 89.7 93.2 93.4 92.7 95.8 94.6 93.0 95.2 95.5 95.5 94.5 94.8 92.3 
AK 87.1 84.3 91.3 92.4 88.7 87.9 89.2 86.7 85.7 88.7 80.9 89.5 79.0 79.0 85.9 85.4 82.1 
AZ 86.5 91.6 92.3 89.6 85.3 90.9 90.2 92.4 92.8 87.5 88.0 93.6 92.0 92.0 86.1 86.4 84.5 
AR 89.1 91.3 90.0 89.7 87.6 90.1 90.6 92.8 94.2 85.9 87.2 93.3 94.6 94.6 90.2 95.7 91.4 
CA 93.7 90.3 92.7 92.9 93.7 88.5 90.7 89.6 93.1 88.8 94.2 94.4 88.2 88.2 87.6 89.3 89.7 
CO 89.3 94.9 94.6 90.8 88.8 90.9 93.6 86.1 89.2 92.7 81.5 87.0 91.4 91.4 87.4 85.2 88.7 
CT 98.3 93.3 97.9 96.8 96.8 96.5 96.6 98.9 94.7 93.8 95.1 96.1 94.3 94.3 97.2 95.8 92.6 
DE 94.2 91.9 96.3 96.4 92.1 94.3 95.1 94.9 93.4 95.1 96.5 93.3 91.1 91.1 89.8 92.4 95.4 
DC NA NA NA 97.7 97.7 94.2 96.2 95.4 97.5 94.3 92.5 92.1 92.5 92.5 96.4 87.7 94.5 
FL 91.1 93.3 93.2 89.8 88.4 90.3 90.1 96.7 95.8 84.9 90.6 92.4 92.0 92.0 92.4 88.4 96.1 
GA 92.8 92.6 92.0 91.1 91.5 90.9 93.6 90.0 91.5 94.7 90.5 91.0 91.7 91.7 94.1 95.8 89.5 
HA 91.7 89.9 90.1 88.0 NA 86.4 98.4 88.6 96.6 NA NA 90.9 NA NA 91.3 NA 89.7 
ID 82.9 88.9 88.3 87.8 88.8 88.9 88.0 93.5 91.9 86.4 90.8 86.0 85.2 85.2 88.3 88.4 94.0 
IL 88.2 91.5 96.5 93.9 93.9 91.9 95.6 93.9 96.2 95.4 91.8 93.5 93.6 93.6 88.1 90.8 94.1 
IN 85.6 90.0 93.4 91.4 87.5 90.9 91.4 91.9 93.1 91.9 88.8 89.7 87.1 87.1 90.6 91.3 90.3 
IA 93.5 90.0 93.8 92.2 91.2 89.2 93.6 92.1 91.7 90.5 92.0 94.3 92.4 92.4 92.5 87.0 94.8 
KS 88.1 93.7 94.0 89.6 88.8 91.5 93.2 91.1 90.4 92.9 92.2 94.4 93.7 93.7 91.0 91.2 85.6 
KY 94.2 89.6 92.0 94.3 88.3 91.9 90.5 94.9 93.8 89.8 92.3 92.8 89.1 89.1 90.5 91.9 90.5 
LA 92.1 86.5 91.4 89.6 88.2 81.9 86.5 87.2 89.9 89.5 91.0 94.5 92.8 92.8 87.9 91.3 90.4 
ME 95.2 95.4 94.1 92.3 94.2 93.7 91.5 94.2 90.7 91.9 94.2 90.4 92.7 92.7 90.0 88.9 91.6 
MD 93.5 97.2 90.0 97.8 93.7 93.5 97.0 94.9 94.8 91.7 99.0 97.3 96.9 96.9 87.2 98.6 98.9 
MA 97.2 96.2 95.6 95.7 97.4 94.5 95.5 97.5 94.7 96.5 95.7 94.4 93.0 93.0 91.7 96.4 92.9 
MI 92.2 90.8 95.2 90.7 90.1 90.2 93.8 93.0 90.8 93.5 94.8 90.8 87.5 87.5 88.6 89.9 89.2 
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MN 96.6 92.7 92.9 94.9 93.6 90.9 91.7 90.9 91.4 88.0 94.3 93.5 91.1 91.1 95.2 97.0 92.6 
MS 93.2 91.5 91.8 94.2 90.8 91.8 89.9 94.3 95.5 89.4 89.4 87.2 89.0 89.0 93.4 91.8 90.0 
MO 88.1 90.7 92.9 88.3 91.8 89.7 96.6 96.0 93.0 90.0 98.4 89.5 89.9 89.9 88.9 86.2 95.2 
MT 87.4 87.1 90.8 93.4 91.3 94.0 87.0 90.0 93.5 91.7 85.3 88.6 85.1 85.1 88.2 84.4 90.8 
NE 92.2 89.4 89.7 91.4 92.4 93.6 94.5 93.7 91.7 94.7 93.2 92.7 92.5 92.5 93.8 95.4 90.4 
NV 87.9 89.8 94.6 88.4 89.2 86.5 88.5 90.4 89.2 88.6 84.7 82.7 85.8 85.8 84.8 85.8 83.9 
NH 93.9 95.7 94.7 93.5 94.4 93.9 93.9 95.3 93.2 89.2 91.9 96.1 94.9 94.9 95.5 93.0 94.8 
NJ 89.1 93.7 96.3 95.2 91.6 92.7 92.8 92.7 94.4 85.4 92.0 93.7 90.0 90.0 86.0 94.1 95.2 
NM 85.7 90.2 86.4 90.6 83.6 87.8 89.4 93.1 88.4 90.5 90.8 81.9 NA NA 83.0 NA 89.9 
NY 94.2 92.8 94.3 95.9 97.0 94.2 93.6 95.1 96.8 92.3 96.6 91.0 90.5 90.5 88.9 87.5 89.8 
NC 90.4 93.8 95.9 92.8 95.3 96.8 94.5 98.3 NA 96.8 96.3 95.0 91.0 91.0 93.3 92.5 91.4 
ND 90.3 91.7 86.6 90.8 90.7 92.3 93.1 92.6 91.1 92.8 92.7 94.6 90.3 90.3 92.0 95.2 93.3 
OH 94.1 89.8 91.3 89.9 91.1 92.4 90.6 96.7 93.0 92.1 93.9 89.8 92.6 92.6 92.8 94.7 91.6 
OK 86.4 90.3 94.9 88.6 90.6 93.9 87.7 82.6 91.2 90.7 93.3 88.9 90.9 90.9 87.4 92.6 88.0 
OR 87.4 86.4 89.8 87.2 90.1 88.7 85.7 90.6 93.4 83.6 90.9 85.2 91.2 91.2 94.0 87.5 86.6 
PA 92.5 93.3 94.5 94.1 91.1 96.0 94.7 95.8 96.8 96.1 93.7 93.7 92.6 92.6 92.1 92.3 85.3 
RI 96.0 96.0 97.7 96.9 94.0 96.2 98.0 94.1 95.1 94.7 94.2 95.5 93.0 93.0 95.2 95.6 95.4 
SC 96.6 91.0 93.1 91.1 92.6 94.7 93.9 88.4 93.4 90.4 94.8 93.1 91.0 91.0 91.5 87.0 95.4 
SD 91.6 90.3 89.4 92.0 91.4 93.1 96.6 89.4 94.7 95.5 94.5 94.1 94.0 94.0 89.9 89.7 91.8 
TN 91.7 92.1 93.9 89.1 91.6 95.2 94.2 95.8 90.8 92.5 94.3 98.0 95.3 95.3 95.9 91.4 94.1 
TX 88.0 85.9 89.6 93.8 86.3 90.0 92.1 91.0 91.3 91.7 92.3 89.5 92.5 92.5 90.5 94.4 91.2 
UT 86.1 86.8 90.2 92.5 89.3 87.8 95.0 88.0 89.0 87.0 91.3 91.1 90.6 90.6 87.0 87.4 86.1 
VT 93.7 95.9 97.0 99.3 93.0 95.7 95.4 96.8 94.7 92.1 94.5 93.0 87.9 87.9 92.4 95.2 92.7 
VA 89.2 90.3 91.8 91.1 92.7 92.9 93.1 93.2 96.0 91.3 98.0 92.0 93.3 93.3 88.3 89.6 94.5 
WA 91.3 91.3 89.9 90.0 91.4 88.2 88.6 94.4 90.2 91.4 84.3 88.4 92.6 92.6 89.8 86.8 85.0 
WV 86.7 92.1 92.6 93.4 92.0 94.2 93.3 89.1 94.4 86.6 90.7 96.1 88.2 88.2 92.0 85.1 84.9 
WI 90.8 90.6 92.7 94.7 93.0 92.8 94.1 93.5 93.8 93.7 94.0 90.8 94.0 94.0 93.3 95.5 90.1 
WY 86.7 83.7 89.9 93.4 92.2 91.0 90.6 91.4 91.5 88.8 90.4 86.4 87.6 87.6 93.1 NA 89.7 
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APPENDIX XI 
 
MMR vaccination coverage for people who identified as black 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 89.7 89.0 88.8 89.8 87.9 89.1 90.3 92.1 90.7 91.9 90.9 91.5 92.0 92.0 92.1 90.8 90.9 
AL 86.6 97.3 92.6 87.3 84.4 95.5 86.9 93.7 NA 94.7 94.4 95.0 NA NA 94.8 94.5 96.4 
AK NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
AZ NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
AR NA 93.2 85.2 NA 92.8 90.4 95.7 NA 93.1 NA NA 90.9 NA NA NA NA NA 
CA NA NA NA NA NA NA NA 96.8 NA 90.3 98.1 96.1 NA NA NA NA NA 
CO NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
CT NA 92.0 93.4 NA 97.3 NA NA NA NA NA NA NA NA NA NA NA NA 
DE NA NA 89.5 93.7 87.1 93.8 97.8 NA 94.7 NA 96.9 NA 96.8 96.8 NA NA 90.4 
DC 91.3 87.2 91.7 88.6 82.9 91.0 89.3 91.3 94.0 90.3 91.6 95.4 87.0 87.0 92.7 93.4 89.7 
FL 89.5 89.5 89.9 94.3 89.6 89.8 95.4 90.2 94.6 99.4 86.7 95.6 89.1 89.1 99.1 NA NA 
GA 91.0 91.7 90.3 94.1 88.3 90.6 90.3 95.6 NA 89.7 87.8 89.0 90.7 90.7 89.6 89.5 96.2 
HA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
ID NA NA NA NA NA NA NA NA NA NA NA 87.4 NA NA NA NA NA 
IL 92.2 NA NA 88.8 86.1 86.8 87.3 NA 88.5 89.5 NA 92.5 89.3 89.3 90.4 91.1 NA 
IN NA NA 95.0 NA NA 93.8 92.8 NA NA NA 95.0 NA NA NA NA NA NA 
IA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
KS NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
KY NA NA NA NA NA NA NA NA NA NA NA 91.4 NA NA NA NA NA 
LA 84.2 88.8 85.7 93.0 88.3 86.4 87.5 92.4 87.4 87.9 85.4 NA 98.1 98.1 92.1 96.6 92.5 
ME NA NA NA NA NA NA NA NA NA NA NA 97.9 NA NA NA NA NA 
MD 91.8 90.8 87.4 94.2 86.4 90.0 95.8 NA 94.3 95.5 92.1 NA 93.1 93.1 91.0 89.9 93.1 
MA 96.1 NA 99.7 93.0 92.4 98.2 NA 99.7 94.8 NA 96.4 NA NA NA NA NA NA 
MI 80.4 86.9 NA 85.0 87.1 81.5 91.3 88.7 NA 95.3 NA NA NA NA NA 99.1 NA 
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MN NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MS 93.3 90.2 93.9 89.4 90.3 94.9 92.2 94.6 95.3 93.4 90.5 NA 88.6 88.6 94.3 88.3 95.7 
MO NA NA NA NA NA NA NA NA NA NA NA NA NA NA 96.4 96.1 NA 
MT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NE NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NV NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NH NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NJ 94.4 98.0 97.1 NA NA NA NA 97.5 98.6 NA 93.8 94.6 NA NA NA NA NA 
NM NA NA NA NA NA NA NA NA NA NA NA 98.2 95.7 95.7 NA NA NA 
NY NA NA 93.6 93.4 92.1 91.0 97.1 94.0 91.7 97.3 98.7 NA 90.9 90.9 90.5 94.7 91.0 
NC 94.9 93.8 96.9 92.0 92.7 95.6 97.4 NA NA NA NA NA NA NA 92.9 95.0 NA 
ND NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
OH 88.2 89.4 89.9 93.1 NA 90.3 93.7 94.7 91.8 96.8 NA NA NA NA NA NA NA 
OK NA NA NA NA NA NA NA NA NA NA NA 97.2 NA NA NA NA NA 
OR NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
PA 89.6 86.9 94.3 98.1 94.2 90.8 92.8 92.3 NA 93.7 94.8 88.9 NA NA 91.3 96.9 96.6 
RI NA NA NA NA NA NA NA NA NA NA NA NA 91.4 91.4 NA NA NA 
SC 93.3 88.7 95.5 88.1 92.1 97.2 91.5 94.1 88.7 NA 94.8 NA NA NA 96.1 94.4 89.6 
SD NA NA NA NA NA NA NA NA NA NA NA 87.7 NA NA NA NA NA 
TN 84.4 85.2 89.7 93.1 90.4 90.1 86.6 89.9 91.0 90.7 92.7 NA 93.7 93.7 NA 90.4 NA 
TX 91.0 90.7 86.1 NA 86.3 87.6 NA 90.8 85.3 88.1 NA NA NA NA 88.1 91.3 89.6 
UT NA NA NA NA NA NA NA NA NA NA NA NA 95.2 95.2 NA NA NA 
VT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
VA NA NA NA NA 92.9 NA NA NA NA 97.0 91.4 NA NA NA 96.1 NA 98.5 
WA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WV NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WI 83.3 93.3 85.4 89.3 NA 86.1 89.9 98.9 NA NA 96.2 NA NA NA NA NA NA 
WY NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
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APPENDIX XII 
 
MMR vaccination coverage for people who identified as Hispanic 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 88.2 88.4 91.0 90.2 90.0 92.1 90.5 92.7 93.2 91.1 92.0 92.6 92.8 92.8 92.9 92.4 90.7 
AL NA NA NA NA NA NA 98.8 NA NA NA NA NA NA NA NA NA NA 
AK NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
AZ 82.1 82.9 82.0 83.0 88.8 86.9 87.0 89.9 92.8 90.4 88.0 87.9 95.3 95.3 89.1 NA 91.4 
AR NA NA NA NA NA 91.6 NA NA NA NA NA 91.1 NA NA NA NA 97.6 
CA 88.2 87.6 91.7 93.4 90.9 93.7 90.8 92.9 93.1 92.1 91.1 94.8 94.0 94.0 94.3 92.2 91.3 
CO 88.0 93.5 94.0 93.2 88.2 94.5 86.4 86.6 93.4 93.9 98.4 97.6 93.1 93.1 88.6 94.3 94.2 
CT 93.0 NA 92.7 90.1 97.8 89.2 94.2 96.3 96.8 97.6 NA 97.7 96.5 96.5 NA 92.6 98.7 
DE NA NA NA NA NA 92.6 94.4 94.4 97.2 95.0 94.8 NA NA NA 92.6 94.6 95.1 
DC 94.8 NA NA NA NA 95.3 92.3 97.5 94.4 89.5 92.9 97.9 95.5 95.5 97.6 NA 98.8 
FL NA 86.6 94.3 92.6 90.3 94.8 87.0 96.0 94.4 97.5 94.7 89.2 91.1 91.1 93.3 93.1 87.2 
GA NA NA 97.4 NA 95.6 NA 96.1 NA 99.5 92.6 94.7 94.5 96.0 96.0 91.4 98.1 NA 
HA NA NA NA 97.5 NA NA 98.1 97.8 94.6 NA 87.7 NA 96.5 96.5 92.4 94.1 97.0 
ID NA NA 95.1 NA NA NA NA NA 91.1 NA NA NA NA NA NA NA NA 
IL 89.1 91.2 87.3 87.2 89.2 83.7 96.5 96.3 97.3 88.8 92.6 95.1 87.1 87.1 95.1 90.9 90.8 
IN NA NA NA NA NA NA NA 97.4 NA NA NA 94.2 NA NA NA NA NA 
IA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
KS NA NA NA 92.5 91.9 NA 95.0 87.8 NA NA 93.0 NA NA NA NA NA 92.8 
KY NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
LA NA NA NA NA NA NA 92.2 NA NA 95.4 NA NA NA NA NA NA NA 
ME NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MD NA NA NA NA NA 95.7 NA 99.2 NA 91.5 94.5 97.4 94.3 94.3 NA 95.6 NA 
MA 97.9 93.3 93.6 NA 96.7 NA 98.9 97.7 98.5 98.1 97.4 NA NA NA NA 92.0 NA 
MI NA NA NA 91.1 NA NA 95.4 NA 99.8 NA 92.1 NA NA NA NA NA NA 
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MN NA NA NA NA NA NA NA NA 97.2 NA NA NA 92.4 92.4 NA NA NA 
MS NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MO NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NE NA NA 94.8 92.0 NA NA NA NA 95.8 96.7 NA NA NA NA NA NA NA 
NV NA 85.0 90.3 89.5 86.7 87.1 93.1 87.3 88.6 84.6 88.7 88.3 88.3 88.3 90.6 95.1 94.0 
NH NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NJ NA 90.4 93.6 95.8 89.6 95.6 97.3 92.9 92.7 85.8 88.9 NA NA NA 90.6 94.0 94.4 
NM 91.0 80.0 83.3 87.4 84.9 86.1 92.5 93.6 92.4 90.5 87.3 94.3 91.6 91.6 89.4 95.6 87.4 
NY 93.2 96.4 96.6 92.8 90.3 93.7 93.7 95.8 96.0 91.8 93.5 96.6 94.7 94.7 87.9 95.3 91.4 
NC NA NA NA 97.5 NA 94.8 NA 96.7 89.7 NA 98.0 99.3 95.0 95.0 NA NA NA 
ND NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
OH NA NA NA NA 97.6 NA 95.1 NA 96.9 NA 98.3 NA NA NA NA NA NA 
OK NA NA NA NA 93.6 90.2 NA NA 95.3 NA 93.5 NA 95.2 95.2 95.4 96.9 94.3 
OR NA 93.4 89.3 NA 91.6 91.1 87.0 94.2 96.2 NA NA 93.0 98.7 98.7 97.7 98.1 92.6 
PA NA NA 94.0 NA 96.8 96.9 95.3 NA NA NA 93.0 NA 93.3 93.3 93.3 87.9 NA 
RI 94.7 91.4 92.0 98.7 90.4 95.9 95.1 98.5 97.4 97.7 99.1 NA 92.4 92.4 95.4 97.6 95.9 
SC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 95.3 
SD NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
TN NA NA 94.5 NA NA 95.8 94.7 97.4 94.7 93.6 NA NA NA NA NA NA NA 
TX 88.1 87.2 90.5 84.8 87.4 91.8 85.6 92.1 89.2 89.2 93.1 91.2 93.9 93.9 93.4 95.5 89.4 
UT NA NA NA NA 88.4 95.3 NA NA 98.1 NA NA 90.4 NA NA NA 91.0 NA 
VT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
VA NA NA NA NA NA NA NA NA NA 93.4 NA 89.4 NA NA NA NA NA 
WA 93.1 92.6 93.0 92.6 90.1 94.2 95.1 92.3 97.7 NA 95.1 93.3 91.6 91.6 NA 93.1 NA 
WV NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WI 96.1 94.7 95.2 NA 91.7 96.7 NA 91.4 94.2 NA 91.2 NA NA NA NA NA NA 
WY NA 95.5 NA NA 90.5 94.3 NA NA 94.5 NA NA NA NA NA NA 99.1 NA 
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APPENDIX XIII 
 
MMR vaccination coverage for people who identified as American Indian or Alaska Native 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 88.9 92.3 91.4 91.7 86.9 94.2 84.3 91.8 88.8 89.7 89.3 96.2 95.8 95.8 93.4 94.8 92.0 
AL NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
AK NA NA 91.2 93.5 91.1 95.8 90.5 97.0 95.4 NA 94.7 96.1 98.3 98.3 98.7 98.6 99.2 
AZ NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
AR NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
CA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
CO NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
CT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
DE NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
DC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
FL NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
GA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
HA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
ID NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
IL NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
IN NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
IA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
KS NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
KY NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
LA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
ME NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MD NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MI NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
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MN NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MS NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MO NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 97.0 99.0 
NE NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NV NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NH NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NJ NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NM NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NY NA NA NA NA NA NA NA NA NA NA NA NA 92.6 92.6 NA NA NA 
NC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
ND NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
OH NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
OK NA NA NA NA NA NA NA 95.0 NA NA NA NA NA NA NA NA NA 
OR NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
PA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
RI NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
SC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
SD NA 94.3 92.8 NA NA NA NA NA NA NA NA NA NA NA NA 94.7 95.6 
TN NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
TX NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
UT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
VT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
VA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WV NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WI NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WY NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
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APPENDIX XIV 
 
MMR vaccination coverage for people who identified as Pacific Islander 
 
  ’96 ‘97 ‘98 ‘99 ‘00 ‘01 ‘02 ‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11 ‘12 
US 93.3 89.9 92.2 92.7 89.6 90.2 94.3 NA NA 90.3 94.3 87.6 97.0 97.0 96.9 98.7 NA 
AL NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
AK NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
AZ NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
AR NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
CA 95.2 88.6 93.5 94.9 NA 89.5 NA NA NA NA NA NA NA NA NA NA NA 
CO NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
CT NA NA NA NA NA NA NA NA NA NA NA NA 97.6 97.6 NA NA NA 
DE NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
DC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
FL NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
GA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
HA 98.2 91.0 95.0 95.3 96.0 92.3 97.5 88.1 95.3 95.4 NA NA NA NA 92.8 96.7 96.4 
ID NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
IL NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
IN NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
IA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
KS NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
KY NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
LA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
ME NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MD NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MA 98.3 99.5 NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MI NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
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MN NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MS NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MO NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
MT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NE NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NV NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NH NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NJ NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NM NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
NY NA NA NA NA 90.8 NA NA NA NA NA NA NA NA NA NA NA NA 
NC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
ND NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
OH NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
OK NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
OR NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
PA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
RI NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
SC NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
SD NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
TN NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
TX NA 95.4 NA 95.9 97.3 NA NA NA NA NA NA NA NA NA NA NA NA 
UT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
VT NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
VA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WA 96.6 96.5 NA NA NA 91.2 NA NA NA NA NA NA NA NA NA NA NA 
WV NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WI NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
WY NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA 
  
108 
APPENDIX XV 
MMR vs. Measles Correlation 
State T-value DF P-value 95% CI Correlation 
US National -1.9518 15 0.06989 -0.76517174, 0.03905054 -0.4500412 
Alabama -0.7806 15 0.4472 -0.6194037, 0.3127655 -0.1975816 
Alaska -2.4854 15 0.02522 -0.81036896, -0.08028484 -0.5400884 
Arizona -0.8191 15 0.4255 -0.6253699, 0.3039528 -0.2069219 
Arkansas 0.0345 15 0.9729 -0.4737574, 0.4874734 0.00891812 
California -1.7159 15 0.1068 -0.74136970, 0.09385397 -0.4050634 
Colorado -2.4731 15 0.02584 -0.80944443, -0.07761439 -0.5381823 
Connecticut -1.3594 15 0.1941 -0.7003543, 0.1777411 -0.331198 
Delaware -0.0535 15 0.9581 -0.4911909, 0.4699577 -0.01380545 
District of 
Columbia 
-0.1911 15 0.851 -0.5176732, 0.4418191 -0.04929354 
Florida -0.0268 15 0.979 -0.4859434, 0.4753108 -0.006913323 
Georgia -1.1059 15 0.2862 -0.6671613, 0.2374170 -0.2745585 
Hawaii -1.5182 15 0.1497 -0.7194136, 0.1402851 -0.3649685 
Idaho -1.9332 15 0.07231 -0.76338805, 0.04333226 -0.4466143 
Illinois -0.256 15 0.8014 -0.5298089, 0.4282612 -0.06596108 
Indiana 1.3019 15 0.2126 -0.1913036, 0.6931299 0.3186398 
Iowa 0.1072 15 0.9161 -0.4590857, 0.5016381 0.02766315 
Kansas 0.6703 15 0.5129 -0.3378071, 0.6018416 0.170525 
Kentucky 0.4565 15 0.6546 -0.3852717, 0.5658583 0.1170478 
Louisiana 0.1164 15 0.9088 -0.4571962, 0.5034256 0.03005265 
Maine -0.4914 15 0.6303 -0.5719151, 0.3776197 -0.1258707 
Maryland -0.1272 15 0.9005 -0.5054861, 0.4550073 -0.03281367 
Massachusetts -0.6297 15 0.5384 -0.5952156, 0.3469217 -0.160483 
Michigan -1.2342 15 0.2361 -0.6843941, 0.2072645 -0.3036279 
Minnesota 0.7953 15 0.4389 -0.3094155, 0.6216844 0.2011431 
Mississippi N/A 0 N/A N/A N/A 
Missouri 1.1838 15 0.2549 -0.2191361, 0.6777261 0.2922951 
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Montana -1.716 15 0.1067 -0.74138068, 0.09382979 -0.4050838 
Nebraska N/A 0 N/A N/A N/A 
Nevada -2.4966 15 0.02467 -0.81120205, -0.08270017 -0.5418084 
New Hampshire -1.1382 15 0.2729 -0.6715861, 0.2298376 -0.2819548 
New Jersey 0.8695 15 0.3983 -0.2923868, 0.6330387 0.2190407 
New Mexico -0.4474 15 0.661 -0.5642810, 0.3872431 -0.1147618 
New York -0.9199 14 0.3732 -0.6567243, 0.2914596 -0.2387382 
North Carolina -0.6331 15 0.5362 -0.5957798, 0.3461525 -0.1613345 
North Dakota 3.2535 15 0.005344 0.2353280, 0.8584618 0.6432188 
Ohio -0.1587 15 0.876 -0.5115208, 0.4485291 -0.04094209 
Oklahoma -1.681 15 0.1134 -0.7376415, 0.1020028 -0.3981627 
Oregon -2.415 15 0.02897 -0.80502408, -0.06499003 -0.529107 
Pennsylvania -0.5731 15 0.575 -0.585814, 0.359556 -0.1463873 
Rhode Island -0.2965 15 0.7709 -0.5372660, 0.4197106 -0.07633298 
South Carolina -1.7247 15 0.1051 -0.74230546, 0.09179094 -0.4068014 
South Dakota 1.8219 15 0.08848 -0.75237483, 0.06912888 -0.425659 
Tennessee -0.1186 15 0.9072 -0.5038346, 0.4567626 -0.03060017 
Texas -1.6296 15 0.124 -0.7320168, 0.1140871 -0.3878242 
Utah -1.7065 15 0.1085 -0.74037218, 0.09604529 -0.4032133 
Vermont -1.0144 15 0.3265 -0.6543332, 0.2587850 -0.2533755 
Virginia -1.1979 15 0.2495 -0.6796080, 0.2158123 -0.2954826 
Washington -0.9063 15 0.3791 -0.6385662, 0.2838789 -0.2278556 
West Virginia -0.1595 15 0.8754 -0.5116731, 0.4483643 -0.04114801 
Wisconsin -1.1869 15 0.2537 -0.6781439, 0.2183999 -0.2930021 
Wyoming 0.4852 15 0.6346 -0.3789902, 0.5708379 0.1242963 
 
  
  
110 
APPENDIX XVI 
Correlation between MMR vaccination coverage and location 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama -1.205882353 -4.178516241 1.76675154 0.999997 
Alaska 2.964705882 -0.007928006 5.93733977 0.0519207 
Arizona 2.805882353 -0.166751536 5.77851624 0.1059206 
Arkansas 1.217647059 -1.75498683 4.19028095 0.999996 
California -0.117647059 -3.090280947 2.85498683 1 
Colorado 1.088235294 -1.884398594 4.06086918 0.9999999 
Connecticut -3.994117647 -6.966751536 -1.02148376 0.0001023 
Delaware -1.747058824 -4.719692712 1.22557506 0.9788613 
District of Columbia -0.270588235 -3.243222124 2.70204565 1 
Florida -0.129411765 -3.102045653 2.84322212 1 
Georgia -0.182352941 -3.15498683 2.79028095 1 
Hawaii -1.647058824 -4.619692712 1.32557506 0.9926111 
Idaho 3.535294118 0.562660229 6.50792801 0.0022207 
Illinois 0.2 -2.772633888 3.17263389 1 
Indiana 1.658823529 -1.313810359 4.63145742 0.9915472 
Iowa 0.176470588 -2.7961633 3.14910448 1 
Kansas 0.711764706 -2.260869183 3.68439859 1 
Kentucky 0.770588235 -2.202045653 3.74322212 1 
Louisiana 2.052941176 -0.919692712 5.02557506 0.8185683 
Maine -0.876470588 -3.849104477 2.0961633 1 
Maryland -2.094117647 -5.066751536 0.87851624 0.779896 
Massachusetts -3.382352941 -6.35498683 -0.40971905 0.0056029 
Michigan 1.311764706 -1.660869183 4.28439859 0.9999652 
Minnesota -1.064705882 -4.037339771 1.90792801 0.9999999 
Mississippi 0.188235294 -2.784398594 3.16086918 1 
Missouri 0.252941176 -2.719692712 3.22557506 1 
Montana 2.388235294 -0.584398594 5.36086918 0.444583 
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Nebraska -0.364705882 -3.337339771 2.60792801 1 
Nevada 3.976470588 1.0038367 6.94910448 0.0001161 
New Hampshire -2.323529412 -5.2961633 0.64910448 0.5201741 
New Jersey 0.194117647 -2.778516241 3.16675154 1 
New Mexico 2.429411765 -0.543222124 5.40204565 0.3984257 
New York -1.664705882 -4.637339771 1.30792801 0.9909694 
North Carolina -2.382352941 -5.35498683 0.59028095 0.4513238 
North Dakota 0.123529412 -2.849104477 3.0961633 1 
Ohio -0.535294118 -3.507928006 2.43733977 1 
Oklahoma 1.058823529 -1.913810359 4.03145742 1 
Oregon 2.323529412 -0.649104477 5.2961633 0.5201741 
Pennsylvania -1.217647059 -4.190280947 1.75498683 0.999996 
Rhode Island -3.482352941 -6.45498683 -0.50971905 0.0030779 
South Carolina -0.023529412 -2.9961633 2.94910448 1 
South Dakota -1.111764706 -4.084398594 1.86086918 0.9999998 
Tennessee -0.929411765 -3.902045653 2.04322212 1 
Texas 1.411764706 -1.560869183 4.38439859 0.9997563 
Utah 2.076470588 -0.8961633 5.049104477 0.7969219 
Vermont -2.235294118 -5.20792801 0.737339771 0.6250628 
Virginia 0.064705882 -2.90792801 3.037339771 1 
Washington 1.547058824 -1.42557506 4.519692712 0.9979302 
West Virginia 1.070588235 -1.90204565 4.043222124 0.9999999 
Wisconsin -0.970588235 -3.94322212 2.002045653 1 
Wyoming 2.282352941 -0.69028095 5.25498683 0.569224 
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Correlation between MMR vaccination coverage and poverty status 
People who lived at or above the poverty line 
 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama -2.415882353 -5.622623821 0.790859115 0.6200966 
Alaska 3.548823529 0.342082061 6.755564998 0.0095514 
Arizona 1.654705882 -1.552035586 4.86144735 0.998281 
Arkansas 0.313529412 -2.893212056 3.52027088 1 
California -0.174705882 -3.38144735 3.032035586 1 
Colorado 1.078235294 -2.128506174 4.284976762 1 
Connecticut -4.151176471 -7.357917939 -0.944435003 0.0002853 
Delaware -1.721764706 -4.928506174 1.484976762 0.9960215 
District of Columbia -2.01 -5.216741468 1.196741468 0.9434134 
Florida -0.239411765 -3.446153233 2.967329703 1 
Georgia -0.568823529 -3.775564997 2.637917939 1 
Hawaii -1.680588235 -4.887329703 1.526153233 0.997596 
Idaho 2.648823529 -0.557917939 5.855564998 0.3703274 
Illinois -0.621764706 -3.828506174 2.584976762 1 
Indiana 0.666470588 -2.54027088 3.873212056 1 
Iowa -0.815882353 -4.022623821 2.390859115 1 
Kansas 0.248823529 -2.957917939 3.455564998 1 
Kentucky -0.498235294 -3.704976762 2.708506174 1 
Louisiana 1.931176471 -1.275564997 5.137917939 0.9686839 
Maine -1.545294118 -4.752035586 1.66144735 0.9996499 
Maryland -2.692352941 -5.899094409 0.514388527 0.3287428 
Massachusetts -3.368823529 -6.575564997 -0.162082061 0.0236277 
Michigan -0.139411765 -3.346153233 3.067329703 1 
Minnesota -1.498235294 -4.704976762 1.708506174 0.9998393 
Mississippi 0.084117647 -3.122623821 3.290859115 1 
Missouri -0.786470588 -3.993212056 2.42027088 1 
Montana 2.307647059 -0.899094409 5.514388527 0.7336503 
Nebraska -1.045294118 -4.252035586 2.16144735 1 
Nevada 2.960588235 -0.246153233 6.167329703 0.1364184 
New Hampshire -2.562941176 -5.769682645 0.643800292 0.4588309 
New Jersey -0.786470588 -3.993212056 2.42027088 1 
New Mexico 1.866470588 -1.34027088 5.073212056 0.9820406 
New York -2.204117647 -5.410859115 1.002623821 0.8271541 
North Carolina -2.204117647 -5.410859115 1.002623821 0.8271541 
North Dakota -0.521764706 -3.728506174 2.684976762 1 
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Ohio -0.845294118 -4.052035586 2.36144735 1 
Oklahoma 0.495882353 -2.710859115 3.702623821 1 
Oregon 2.160588235 -1.046153233 5.367329703 0.8603114 
Pennsylvania -1.986470588 -5.193212056 1.22027088 0.9521317 
Rhode Island -3.527647059 -6.734388527 -0.320905591 0.0106655 
South Carolina -0.780588235 -3.987329703 2.426153233 1 
South Dakota -1.145294118 -4.352035586 2.06144735 1 
Tennessee -1.615882353 -4.822623821 1.590859115 0.9989898 
Texas 0.407647059 -2.799094409 3.614388527 1 
Utah 1.495882353 -1.710859115 4.702623821 0.9998457 
Vermont -2.074705882 -5.28144735 1.132035586 0.9136914 
Virginia -0.333529412 -3.54027088 2.873212056 1 
Washington 1.278235294 -1.928506174 4.484976762 0.9999983 
West Virginia 0.442941176 -2.763800292 3.649682645 1 
Wisconsin -1.527647059 -4.734388527 1.679094409 0.9997367 
Wyoming 1.666470588 -1.54027088 4.873212056 0.9979942 
 
People who lived below the poverty line 
State  Difference Lower CI Upper CI Adjusted P- Value 
Alabama -0.20321267 -5.5229706 5.11654526 1 
Alaska -2.144558824 -8.33509021 4.04597257 1 
Arizona 3.755441176 -1.2737703 8.78465265 0.6332147 
Arkansas 1.642941176 -3.67681675 6.9626991 1 
California 0.119411765 -4.83301335 5.07183688 1 
Colorado -0.590392157 -6.54246638 5.36168207 1 
Connecticut -3.228487395 -9.71273395 3.25575916 0.9990312 
Delaware -3.72372549 -9.67579972 2.22834874 0.9396614 
District of Columbia -1.437058824 -7.19125682 4.31713917 1 
Florida -0.251176471 -5.20360158 4.70124864 1 
Georgia 0.460588235 -4.49183688 5.41301335 1 
Hawaii -2.550392157 -7.66523482 2.5644505 0.9989988 
Idaho 0.885798319 -5.59844824 7.37004488 1 
Illinois 1.442941176 -3.5862703 6.47215265 1 
Indiana 2.585798319 -3.89844824 9.07004488 0.9999973 
Iowa -0.590392157 -9.63224198 8.45145767 1 
Kansas -0.457058824 -7.80269235 6.8885747 1 
Kentucky 1.442941176 -4.31125682 7.19713917 1 
Louisiana 2.001764706 -2.95066041 6.95418982 0.999996 
Maine -1.757058824 -7.51125682 3.99713917 1 
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Maryland -2.537058824 -8.29125682 3.21713917 0.9999525 
Massachusetts -4.302513369 -9.8896024 1.28457567 0.5517034 
Michigan 1.652032086 -3.93505695 7.23912112 1 
Minnesota NA  NA NA NA 
Mississippi -0.207058824 -5.2362703 4.82215265 1 
Missouri -0.567058824 -6.32125682 5.18713917 1 
Montana -1.494558824 -7.68509021 4.69597257 1 
Nebraska -2.242773109 -8.72701967 4.24147345 1 
Nevada 3.057226891 -3.42701967 9.54147345 0.9997321 
New Hampshire -1.757058824 -12.55061912 9.03650147 1 
New Jersey -2.497058824 -8.25125682 3.25713917 0.9999692 
New Mexico 2.849607843 -2.26523482 7.9644505 0.9904202 
New York -0.892352941 -5.84477805 4.06007217 1 
North Carolina -2.488308824 -7.5175203 2.54090265 0.9991602 
North Dakota -3.114201681 -9.59844824 3.37004488 0.9995807 
Ohio 1.625294118 -3.32713099 6.57771923 1 
Oklahoma 0.265163399 -5.68691083 6.21723762 1 
Oregon -1.087058824 -6.84125682 4.66713917 1 
Pennsylvania 0.273710407 -5.04604752 5.59346833 1 
Rhode Island -3.095520362 -8.41527829 2.22423757 0.979656 
South Carolina -0.49872549 -5.94263998 4.945189 1 
South Dakota -2.834836601 -8.78691083 3.11723762 0.9996571 
Tennessee 0.025294118 -4.92713099 4.97771923 1 
Texas 3.137058824 -1.81536629 8.08948393 0.9288021 
Utah -0.52372549 -9.56557532 8.51812434 1 
Vermont -3.677058824 -11.02269235 3.6685747 0.9989071 
Virginia -0.690392157 -7.54671426 6.16592994 1 
Washington 2.055441176 -2.9737703 7.08465265 0.9999944 
West Virginia 0.7660181 -4.55373983 6.08577603 1 
Wisconsin 1.333850267 -4.25323877 6.9209393 1 
Wyoming 0.77627451 -5.17579972 6.72834874 1 
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Correlation between MMR vaccination coverage and participation in VFC 
Children whose provider participated in the VFC program 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama -1.912500 -5.143551 1.318551459 0.9760364 
Alaska -0.012500 -3.243551 3.218551459 1 
Arizona 1.425000 -1.806051 4.656051459 0.999965 
Arkansas -0.662500 -3.893551 2.568551459 1 
California -1.437500 -4.668551 1.793551459 0.9999555 
Colorado -0.743750 -3.974801 2.487301459 1 
Connecticut -4.787500 -8.018551 -1.556448541 0.0000047 
Delaware -2.562500 -5.793551 0.668551459 0.4794652 
District of Columbia 0.150000 -3.081051 3.381051459 1 
Florida -0.943750 -4.174801 2.287301459 1 
Georgia -0.262500 -3.493551 2.968551459 1 
Hawaii -3.268750 -6.499801 -0.037698541 0.0423104 
Idaho 1.581250 -1.649801 4.812301459 0.9994823 
Illinois -1.056250 -4.287301 2.174801459 1 
Indiana 0.075000 -3.156051 3.306051459 1 
Iowa -0.825000 -4.056051 2.406051459 1 
Kansas -0.375000 -3.606051 2.856051459 1 
Kentucky 0.262500 -2.968551 3.493551459 1 
Louisiana 1.431250 -1.799801 4.662301459 0.9999605 
Maine -1.906250 -5.137301 1.324801459 0.9772856 
Maryland -3.143750 -6.374801 0.087301459 0.072566 
Massachusetts -3.687500 -6.918551 -0.456448541 0.0052896 
Michigan -0.825000 -4.056051 2.406051459 1 
Minnesota -1.687500 -4.918551 1.543551459 0.9977372 
Mississippi -0.650000 -3.881051 2.581051459 1 
Missouri -0.731250 -3.962301 2.499801459 1 
Montana 1.031250 -2.199801 4.262301459 1 
Nebraska -1.437500 -4.668551 1.793551459 0.9999555 
Nevada 2.456250 -0.774802 5.687301459 0.5953784 
New Hampshire -3.225000 -6.456051 0.006051459 0.051341 
New Jersey -0.618750 -3.849801 2.612301459 1 
New Mexico 1.012500 -2.218551 4.243551459 1 
New York -2.256250 -5.487301 0.974801459 0.7968857 
North Carolina -3.625000 -6.856051 -0.393948541 0.007392 
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North Dakota -1.418750 -4.649801 1.812301459 0.9999691 
Ohio -0.543750 -3.774801 2.687301459 1 
Oklahoma -0.137500 -3.368551 3.093551459 1 
Oregon 0.750000 -2.481051 3.981051459 1 
Pennsylvania -2.181250 -5.412301 1.049801459 0.8566602 
Rhode Island -3.962500 -7.193551 -0.731448541 0.0011082 
South Carolina -0.737500 -3.968551 2.493551459 1 
South Dakota -1.887500 -5.118551 1.343551459 0.9807282 
Tennessee -2.412500 -5.643551 0.818551459 0.6427811 
Texas 0.537500 -2.693551 3.768551459 1 
Utah -0.100000 -3.331051459 3.131051 1 
Vermont -2.700000 -5.931051459 0.531052 0.340152 
Virginia -0.406250 -3.637301459 2.824801 1 
Washington 0.618750 -2.612301459 3.849801 1 
West Virginia 0.137500 -3.093551459 3.368551 1 
Wisconsin -1.962500 -5.193551459 1.268551 0.9640117 
Wyoming 1.150000 -2.081051459 4.381051 1 
 
Children whose provider did not participate in the VFC program 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama -2.028846154 -6.30467367 2.2469814 0.9983443 
Alaska 1.65 -4.75144263 8.0514426 1 
Arizona -1.208333333 -8.41291931 5.9962526 1 
Arkansas NA NA NA NA 
California 1.167857143 -3.02287077 5.3585851 1 
Colorado -4.8 -11.20144263 1.6014426 0.5628395 
Connecticut -4.103571429 -9.29285918 1.0857163 0.4314318 
Delaware NA NA NA NA 
District of Columbia -3.410714286 -7.6014422 0.7800136 0.3623334 
Florida -3.911363636 -8.39652833 0.5738011 0.216559 
Georgia -4.925 -9.29801783 -0.5519822 0.0081361 
Hawaii NA NA NA NA 
Idaho NA NA NA NA 
Illinois -1.336538462 -5.61236598 2.9392891 0.9999999 
Indiana -1.341666667 -6.11302029 3.429687 1 
Iowa 0.025 -11.77867698 11.828677 1 
Kansas -1.451923077 -5.7277506 2.8239044 0.9999993 
Kentucky -4.075 -8.69114593 0.5411459 0.1948199 
Louisiana -0.625 -5.24114593 3.9911459 1 
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Maine -2.675 -8.15686796 2.806868 0.9972215 
Maryland -5.586111111 -10.35746473 -0.8147575 0.0039862 
Massachusetts -3.775 -8.73353614 1.1835361 0.5253867 
Michigan 0.591666667 -6.61291931 7.7962526 1 
Minnesota -2.225 -7.70686796 3.256868 0.9999369 
Mississippi -3.725 -12.31343652 4.8634365 0.9997273 
Missouri -2.293181818 -6.77834651 2.1919829 0.9937345 
Montana NA NA NA NA 
Nebraska -3.608333333 -10.81291931 3.5962526 0.9955935 
Nevada NA NA NA NA 
New Hampshire -2.7875 -7.74603614 2.1710361 0.9730787 
New Jersey -2.528846154 -6.80467367 1.7469814 0.9474123 
New Mexico NA NA NA NA 
New York -2.583333333 -6.95635116 1.7896845 0.9481649 
North Carolina NA NA NA NA 
North Dakota -6.275 -18.07867698 5.528677 0.988219 
Ohio -3.175 -7.36572791 1.0157279 0.5373992 
Oklahoma NA NA NA NA 
Oregon NA NA NA NA 
Pennsylvania -3.984090909 -8.4692556 0.5010738 0.1842555 
Rhode Island -1.615 -7.48201908 4.2520191 1 
South Carolina 1.825 -9.97867698 13.628677 1 
South Dakota -0.508333333 -7.71291931 6.6962526 1 
Tennessee -1.059615385 -5.3354429 3.2162121 1 
Texas 0.353571429 -3.83715649 4.5442993 1 
Utah NA NA NA NA 
Vermont -4.35 -9.3085361 0.60853614 0.2057799 
Virginia -4.875 -9.3601647 -0.38983531 0.0148206 
Washington 0.691666667 -4.079687 5.46302029 1 
West Virginia NA NA NA NA 
Wisconsin -1.375 -5.5657279 2.81572791 0.9999997 
Wyoming NA NA NA NA 
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Correlation between MMR vaccination coverage and urbanicity 
People who lived in a MSA central city 
State Difference Upper CI Lower CI Adjusted P-Value 
Alabama -1.115882353 -5.38165555 3.14989084 1 
Alaska 2.81627451 -1.5893971 7.22194612 0.9226848 
Arizona 3.295882353 -0.96989084 7.56165555 0.5470272 
Arkansas -0.07372549 -4.76284324 4.61539226 1 
California -0.845294118 -5.11106731 3.42047908 1 
Colorado 0.95627451 -3.4493971 5.36194612 1 
Connecticut -3.074705882 -7.34047908 1.19106731 0.7244096 
Delaware -1.680588235 -5.94636143 2.58518496 0.9999984 
District of Columbia -0.280588235 -4.54636143 3.98518496 1 
Florida 0.084117647 -4.18165555 4.34989084 1 
Georgia 1.092941176 -3.59617658 5.78205893 1 
Hawaii -2.563308824 -6.89522198 1.76860433 0.9746706 
Idaho 1.073710407 -3.50846504 5.65588586 1 
Illinois 1.919411765 -2.34636143 6.18518496 0.9999279 
Indiana 1.680441176 -2.65147198 6.01235433 0.999999 
Iowa -0.470392157 -4.87606377 3.93527945 1 
Kansas 0.917941176 -3.41397198 5.24985433 1 
Kentucky -2.175240642 -6.98768184 2.63720056 0.9999186 
Louisiana 2.748823529 -1.51694967 7.01459672 0.9143553 
Maine -2.171344538 -7.7565527 3.41386362 0.999999 
Maryland -2.215882353 -6.48165555 2.04989084 0.9977587 
Massachusetts -2.764751131 -7.34692658 1.81742432 0.9656659 
Michigan 0.905441176 -3.42647198 5.23735433 1 
Minnesota -2.550808824 -6.88272198 1.78110433 0.9765878 
Mississippi -0.307058824 -5.26343939 4.64932174 1 
Missouri -1.210392157 -5.61606377 3.19527945 1 
Montana 2.157226891 -2.33125619 6.64570997 0.9996159 
Nebraska -1.851176471 -6.11694967 2.41459672 0.999973 
Nevada 4.160588235 -0.10518496 8.42636143 0.0701744 
New Hampshire -6.657058824 -19.4543784 6.14026076 0.9976905 
New Jersey -2.557058824 -8.14226698 3.02814934 0.9998863 
New Mexico 2.348823529 -1.91694967 6.61459672 0.9927903 
New York -1.939411765 -6.20518496 2.32636143 0.9999052 
North Carolina -2.632058824 -6.96397198 1.69985433 0.9618559 
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North Dakota -2.307058824 -6.63897198 2.02485433 0.9962433 
Ohio -0.404117647 -4.66989084 3.86165555 1 
Oklahoma 0.27627451 -4.1293971 4.68194612 1 
Oregon 1.99 -2.27577319 6.25577319 0.9998161 
Pennsylvania -1.445294118 -5.71106731 2.82047908 1 
Rhode Island -2.898235294 -7.16400849 1.3675379 0.8421413 
South Carolina -1.06372549 -5.4693971 3.34194612 1 
South Dakota -2.200808824 -6.53272198 2.13110433 0.9986137 
Tennessee 0.09 -4.17577319 4.35577319 1 
Texas 1.613529412 -2.65224378 5.87930261 0.9999996 
Utah 0.705441176 -3.62647198 5.03735433 1 
Virginia -2.775240642 -7.58768184 2.03720056 0.9834493 
Washington 1.507647059 -2.75812614 5.77342025 1 
West Virginia -1.89872549 -6.58784324 2.79039226 0.9999964 
Wisconsin -1.280588235 -5.54636143 2.98518496 1 
Wyoming 1.37627451 -3.0293971 5.78194612 1 
 
People who lived in a MSA non-central city 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama -2.115882353 -6.027688 1.795923077 0.9940429 
Alaska 2.07627451 -5.065672 9.218221425 1 
Arizona 1.736691177 -2.235766 5.709148369 0.9999542 
Arkansas 1.780441177 -2.192016 5.752898369 0.9999121 
California 0.319411765 -3.592394 4.231217195 1 
Colorado 0.367941177 -3.604516 4.340398369 1 
Connecticut -4.292352941 -8.204158 -0.380547511 0.0114354 
Delaware -1.639411765 -5.551217 2.272393665 0.9999855 
District of Columbia NA NA NA NA 
Florida -0.468823529 -4.380629 3.442981901 1 
Georgia -0.057058824 -3.968864 3.854746606 1 
Hawaii -1.045294118 -4.9571 2.866511312 1 
Idaho 1.43627451 -2.603821 5.476369785 0.9999999 
Illinois -1.280588235 -5.192394 2.631217195 1 
Indiana 0.754705882 -3.1571 4.666511312 1 
Iowa -1.095520362 -5.297473 3.106432717 1 
Kansas -0.788308824 -4.760766 3.184148369 1 
Kentucky -0.938308824 -4.910766 3.034148369 1 
Louisiana 1.160588235 -2.751217 5.072393665 1 
Maine 0.048823529 -3.862982 3.960628959 1 
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Maryland -1.933529412 -5.845335 1.978276018 0.9990739 
Massachusetts -3.692352941 -7.604158 0.219452489 0.1048342 
Michigan 2.107647059 -1.804158 6.019452489 0.994469 
Minnesota -0.250808824 -4.223266 3.721648369 1 
Mississippi -0.444558824 -5.334316 4.445197964 1 
Missouri -0.874705882 -4.786511 3.037099548 1 
Montana NA NA NA NA 
Nebraska -2.267058824 -6.812166 2.278048362 0.9988675 
Nevada 1.781402715 -2.42055 5.983355794 0.9999801 
New Hampshire -2.751176471 -6.662982 1.160628959 0.7700664 
New Jersey -0.268823529 -4.180629 3.642981901 1 
New Mexico 0.087385621 -4.614019 4.78879064 1 
New York -0.91 -4.821805 3.00180543 1 
North Carolina -3.307058824 -7.279516 0.665398369 0.3425469 
North Dakota -4.27372549 -9.689375 1.141923898 0.4827902 
Ohio -1.027647059 -4.939452 2.884158371 1 
Oklahoma 1.007226891 -3.108808 5.123262056 1 
Oregon 1.004479638 -3.197473 5.206432717 1 
Pennsylvania -1.145294118 -5.0571 2.766511312 1 
Rhode Island -3.968823529 -7.880629 -0.057018099 0.0406801 
South Carolina 0.119411765 -3.792394 4.031217195 1 
South Dakota -3.528487395 -8.650243 1.593268173 0.8104369 
Tennessee -0.91 -4.821805 3.00180543 1 
Texas 0.578235294 -3.33357 4.490040724 1 
Utah 2.166470588 -1.745334842 6.078276 0.9907754 
Vermont -2.757058824 -6.873093988 1.358976 0.8578028 
Virginia -0.474705882 -4.386511312 3.4371 1 
Washington 1.972352941 -1.939452489 5.884158 0.998567 
West Virginia 0.81627451 -3.223820766 4.85637 1 
Wisconsin -1.868823529 -5.780628959 2.042982 0.9995758 
Wyoming NA NA NA NA 
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People who lived in a non-MSA central city 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama -0.647058824 -4.97476353 3.68064588 1 
Alaska 1.182352941 -3.14535176 5.51005765 1 
Arizona 1.287647059 -3.74069142 6.31598553 1 
Arkansas -1.4 -5.7277047 2.9277047 1 
California -3.182352941 -16.16546706 9.80076117 1 
Colorado 0.435828877 -4.44648049 5.31813824 1 
Connecticut -3.382352941 -16.36546706 9.60076117 1 
Delaware -2.643891403 -7.29259197 2.00480916 0.9829969 
District of Columbia NA NA NA NA 
Florida -4.382352941  -17.36546706 8.60076117 1 
Georgia -3.038602941 -7.43340784 1.35620196 0.7940035 
Hawaii -2.363602941 -6.75840784 2.03120196 0.9935707 
Idaho 3.574789916 -0.97885803 8.12843786 0.4884783 
Illinois -4.192352941 -9.22069142 0.83598553 0.3332489 
Indiana 0.50855615 -4.37375322 5.39086552 1 
Iowa -0.588235294 -4.91594 3.73946941 1 
Kansas 0.647058824 -3.68064588 4.97476353 1 
Kentucky 2.2 -2.1277047 6.5277047 0.9978494 
Louisiana 0.477647059 -3.99198714 4.94728126 1 
Maine -2.076470588 -6.40417529 2.25123412 0.9993775 
Maryland NA NA NA NA 
Massachusetts NA NA NA NA 
Michigan -1.059276018 -5.70797658 3.58942455   
Minnesota -1.615686275 -6.08532047 2.85394793 0.9999997 
Mississippi -1.805882353 -6.13358706 2.52182235 0.9999803 
Missouri 1.433031674 -3.21566889 6.08173224 1 
Montana 1.458823529 -2.86888118 5.78652823 1 
Nebraska 0.758823529 -3.56888118 5.08652823 1 
Nevada 1.042647059 -5.96903594 8.05433006 1 
New Hampshire -1.241176471 -5.56888118 3.08652823 1 
New Jersey NA NA NA NA 
New Mexico 2.329411765 -1.99829294 6.65711647 0.9934736 
New York -2.422352941 -7.45069142 2.60598553 0.9993189 
North Carolina -2.394852941 -6.78965784 1.99995196 0.9918366 
North Dakota 0.764705882 -3.56299882 5.09241059 1 
Ohio -1.142352941 -5.61198714 3.32728126 1 
Oklahoma -1.013602941 -5.40840784 3.38120196 1 
Oregon 1.198897059 -3.19590784 5.59370196 1 
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Pennsylvania -2.815686275 -7.57288176 1.94150921 0.9682845 
Rhode Island NA NA NA NA 
South Carolina -1.389495798 -5.94314374 3.16415214 1 
South Dakota -1.444852941 -5.83965784 2.94995196 1 
Tennessee -3.202352941 -7.67198714 1.26728126 0.7198145 
Texas -0.257352941 -5.01454842 4.49984254 1 
Utah 1.280147059 -4.12948382 6.68977794 1 
Vermont -2.529411765 -6.85711647 1.79829294 0.9737869 
Virginia -2.382352941 -7.79198382 3.02727794 0.9999196 
Washington -0.895686275 -5.36532047 3.57394793 1 
West Virginia 0.776470588 -3.55123412 5.10417529 1 
Wisconsin -0.518067227 -5.07171517 4.03558072 1 
Wyoming 1.841176471 -2.48652823 6.16888118 0.999967 
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APPENDIX XX 
Correlation between MMR vaccination coverage and race/ethnicity 
White 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama -2.121764706 -5.670674053 1.42714464 0.9720165 
Alaska 5.537058824 1.988149476 9.08596817 0.0000007 
Arizona 2.131176471 -1.417732877 5.68008582 0.969988 
Arkansas 0.566470588 -2.982438759 4.11537994 1 
California 0.725294118 -2.82361523 4.27420347 1 
Colorado 2.025294118 -1.52361523 5.57420347 0.9872318 
Connecticut -4.180588235 -7.729497583 -0.6316789 0.0027356 
Delaware -2.080588235 -5.629497583 1.46832111 0.9796711 
District of Columbia -2.728487395 -6.462680195 1.0057054 0.697593 
Florida 0.025294118 -3.52361523 3.57420347 1 
Georgia -0.415882353 -3.9647917 3.13302699 1 
Hawaii 0.588395722 -3.415313987 4.59210543 1 
Idaho 3.213529412 -0.335379936 6.76243876 0.1676568 
Illinois -1.445294118 -4.994203465 2.10361523 0.9999966 
Indiana 1.525294118 -2.02361523 5.07420347 0.9999834 
Iowa -0.31 -3.858909347 3.23890935 1 
Kansas 0.166470588 -3.382438759 3.71537994 1 
Kentucky 0.142941176 -3.405968171 3.69185052 1 
Louisiana 2.025294118 -1.52361523 5.57420347 0.9872318 
Maine -0.927647059 -4.476556406 2.62126229 1 
Maryland -3.586470588 -7.135379936 -0.0375612 0.0429736 
Massachusetts -3.527647059 -7.076556406 0.02126229 0.0544025 
Michigan 0.548823529 -3.000085818 4.09773288 1 
Minnesota -1.204117647 -4.753026995 2.3447917 1 
Mississippi 0.337058824 -3.211850524 3.88596817 1 
Missouri 0.166470588 -3.382438759 3.71537994 1 
Montana 2.601764706 -0.947144642 6.15067405 0.68947 
Nebraska -0.933529412 -4.482438759 2.61537994 1 
Nevada 4.195882353 0.646973005 7.7447917 0.0025279 
New Hampshire -2.404117647 -5.953026995 1.1447917 0.8516116 
New Jersey -0.41 -3.958909347 3.13890935 1 
New Mexico 3.692941176 -0.041251623 7.42713398 0.0583733 
New York -1.357058824 -4.905968171 2.19185052 0.9999995 
North Carolina -2.425808824 -6.029743303 1.17812566 0.8616812 
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North Dakota -0.145294118 -3.694203465 3.40361523 1 
Ohio -0.651176471 -4.200085818 2.89773288 1 
Oklahoma 1.707647059 -1.841262289 5.25655641 0.999661 
Oregon 2.848823529 -0.700085818 6.39773288 0.4467325 
Pennsylvania -1.721764706 -5.270674053 1.82714464 0.9995853 
Rhode Island -3.686470588 -7.235379936 -0.1375612 0.0283077 
South Carolina -0.651176471 -4.200085818 2.89773288 1 
South Dakota -0.827647059 -4.376556406 2.72126229 1 
Tennessee -1.957058824 -5.505968171 1.59185052 0.9932331 
Texas 0.901764706 -2.647144642 4.45067405 1 
Utah 2.478235294 6.027144642 -1.07067405 0.7973669 
Vermont -2.31 1.238909347 -5.85890935 0.906763 
Virginia -0.745294118 2.80361523 -4.29420347 1 
Washington 1.866470588 5.415379936 -1.68243876 0.9974009 
West Virginia 1.078235294 4.627144642 -2.47067405 1 
Wisconsin -1.380588235 2.168321112 -4.92949758 0.9999992 
Wyoming 2.017941176 5.621875656 -1.5859933 0.9909705 
 
Black 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama -0.792773109 -5.25362 3.668073 1 
Alaska NA NA NA NA 
Arizona NA NA NA NA 
Arkansas 0.028655462 -5.52216 5.579474 1 
California -3.682058824 -10.5508 3.186729 0.9810114 
Colorado NA NA NA NA 
Connecticut -2.590392157 -10.3306 5.149855 0.9999981 
Delaware -2.107058824 -7.03292 2.818804 0.9995738 
District of Columbia 1.384117647 -2.85539 5.623626 0.999999 
Florida -0.477058824 -4.8556 3.901486 1 
Georgia 0.699191176 -3.60605 5.004432 1 
Hawaii NA NA NA NA 
Idaho 4.242941176 -8.47558 16.96147 0.9999982 
Illinois 2.32627451 -2.33397 6.98652 0.9934362 
Indiana -2.507058824 -9.37585 4.361729 0.9999852 
Iowa NA NA NA NA 
Kansas NA NA NA NA 
Kentucky 0.242941176 -12.4756 12.96147 1 
Louisiana 1.367941176 -2.9373 5.673182 0.9999995 
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Maine -6.257058824 -18.9756 6.461465 0.9947997 
Maryland -0.257058824 -4.6356 4.121486 1 
Massachusetts -4.644558824 -9.94394 0.654826 0.2008211 
Michigan 3.27627451 -1.81898 8.371529 0.845374 
Minnesota NA NA NA NA 
Mississippi -0.450808824 -4.75605 3.854432 1 
Missouri -4.607058824 -13.8469 4.632735 0.9935526 
Montana NA NA NA NA 
Nebraska NA NA NA NA 
Nevada NA NA NA NA 
New Hampshire NA NA NA NA 
New Jersey -4.642773109 -10.1936 0.908046 0.2892878 
New Mexico -4.890392157 -12.6306 2.849855 0.8686923 
New York -1.707058824 -6.16791 2.753788 0.9999575 
North Carolina -2.934836601 -8.03009 2.160418 0.9516273 
North Dakota NA NA NA NA 
Ohio -0.345947712 -5.4412 4.749307 1 
Oklahoma -5.557058824 -18.2756 7.161465 0.9993584 
Oregon NA NA NA NA 
Pennsylvania -1.299915966 -5.76076 3.160931 0.9999999 
Rhode Island 0.242941176 -8.99685 9.482735 1 
South Carolina -0.980135747 -5.5341 3.573826 1 
South Dakota 3.942941176 -8.77558 16.66147 0.9999997 
Tennessee 1.528655462 -2.93219 5.989502 0.9999966 
Texas 3.015668449 -1.76714 7.798478 0.8712386 
Utah -3.557058824 -12.79685 5.68273 0.9999516 
Vermont NA NA NA NA 
Virginia -3.537058824 -9.825265 2.75115 0.9639274 
Washington NA NA NA NA 
West Virginia NA NA NA NA 
Wisconsin 1.342941176 -3.956444 6.64233 1 
Wyoming NA NA NA NA 
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Hispanic 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama -7.15705882 -19.12800847 4.81389082 0.9441056 
Alaska NA NA NA NA 
Arizona 3.34294118 -0.70924443 7.39512679 0.3355748 
Arkansas -1.79039216 -9.07568011 5.49489579 1 
California -0.48058824 -4.47090478 3.50972831 1 
Colorado -0.76882353 -4.75914008 3.22149302 1 
Connecticut -3.33563025 -7.53427549 0.86301498 0.4258889 
Delaware -2.87928105 -7.67504469 1.91648259 0.9411289 
District of Columbia -3.52372549 -7.91004968 0.8625987 0.3985932 
Florida -0.43205882 -4.48424443 3.62012679 1 
Georgia -3.98433155 -8.48601574 0.51735264 0.1924181 
Hawaii -3.57705882 -8.21338768 1.05927004 0.4990327 
Idaho -1.45705882 -10.15375212 7.23963447 1 
Illinois 0.74294118 -3.24737537 4.73325772 1 
Indiana -4.15705882 -12.85375212 4.53963447 0.998398 
Iowa NA NA NA NA 
Kansas -0.52372549 -6.0480686 5.00061762 1 
Kentucky NA NA NA NA 
Louisiana -2.15705882 -10.85375212 6.53963447 1 
Maine NA NA NA NA 
Maryland -3.66955882 -8.65745451 1.31833686 0.6166326 
Massachusetts -4.76705882 -9.40338768 -0.13073 0.0341729 
Michigan -2.95705882 -9.42211054 3.50799289 0.9993315 
Minnesota -2.35705882 -9.64234677 4.92822913 0.9999999 
Mississippi NA NA NA NA 
Missouri NA NA NA NA 
Montana NA NA NA NA 
Nebraska -3.18205882 -9.64711054 3.28299289 0.9972248 
Nevada 2.54919118 -1.50299443 6.60137679 0.8988443 
New Hampshire NA NA NA NA 
New Jersey -0.78782805 -5.0741156 3.49845949 1 
New Mexico 2.29588235 -1.6944342 6.2861989 0.9661125 
New York -2.14529412 -6.13561067 1.84502243 0.9874886 
North Carolina -4.10705882 -9.09495451 0.88083686 0.3399607 
North Dakota NA NA NA NA 
Ohio -5.33205882 -11.79711054 1.13299289 0.3361921 
Oklahoma -2.75705882 -7.55282246 2.03870482 0.9664875 
Oregon -2.32628959 -6.61257714 1.95999796 0.9855039 
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Pennsylvania -2.11261438 -6.90837802 2.68314926 0.9996958 
Rhode Island -3.64455882 -7.69674443 0.40762679 0.1658416 
South Carolina -3.65705882 -15.62800847 8.31389082 1 
South Dakota NA NA NA NA 
Tennessee -3.47372549 -8.9980686 2.05061762 0.8993449 
Texas 1.27235294 -2.71796361 5.26266949 0.9999999 
Utah -0.99705882 4.92153709 -6.91565473 1 
Vermont NA NA NA NA 
Virginia 0.24294118 8.93963447 -8.45375212 1 
Washington -1.59991597 2.59872927 -5.7985612 0.9999896 
West Virginia NA NA NA NA 
Wisconsin -2.25705882 2.73083686 -7.24495451 0.999464 
Wyoming -3.13705882 2.78153709 -9.05565473 0.9900268 
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American Indian or Alaska Native 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama NA NA NA NA 
Alaska -3.9570588 -6.134624 -1.7794932 0.0000558 
Arizona NA NA NA NA 
Arkansas NA NA NA NA 
California NA NA NA NA 
Colorado NA NA NA NA 
Connecticut NA NA NA NA 
Delaware NA NA NA NA 
District of Columbia NA NA NA NA 
Florida NA NA NA NA 
Georgia NA NA NA NA 
Hawaii NA NA NA NA 
Idaho NA NA NA NA 
Illinois NA NA NA NA 
Indiana NA NA NA NA 
Iowa NA NA NA NA 
Kansas NA NA NA NA 
Kentucky NA NA NA NA 
Louisiana NA NA NA NA 
Maine NA NA NA NA 
Maryland NA NA NA NA 
Massachusetts NA NA NA NA 
Michigan NA NA NA NA 
Minnesota NA NA NA NA 
Mississippi NA NA NA NA 
Missouri NA NA NA NA 
Montana -6.3570588 -10.867471 -1.8466467 0.0019938 
Nebraska NA NA NA NA 
Nevada NA NA NA NA 
New Hampshire NA NA NA NA 
New Jersey NA NA NA NA 
New Mexico NA NA NA NA 
New York -0.9570588 -5.467471 3.5533533 0.9870031 
North Carolina NA NA NA NA 
North Dakota -2.7070588 -6.060063 0.6459452 0.1723846 
Ohio NA NA NA NA 
Oklahoma -3.3570588 -9.565616 2.8514983 0.5839743 
Oregon NA NA NA NA 
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Pennsylvania NA NA NA NA 
Rhode Island NA NA NA NA 
South Carolina NA NA NA NA 
South Dakota NA NA NA NA 
Tennessee NA NA NA NA 
Texas NA NA NA NA 
Utah NA NA NA NA 
Vermont NA NA NA NA 
Virginia NA NA NA NA 
Washington NA NA NA NA 
West Virginia NA NA NA NA 
Wisconsin NA NA NA NA 
Wyoming NA NA NA NA 
 
Pacific Islander 
 
State Difference Lower CI Upper CI Adjusted P-Value 
Alabama NA NA NA NA 
Alaska NA NA NA NA 
Arizona NA NA NA NA 
Arkansas NA NA NA NA 
California NA NA NA NA 
Colorado NA NA NA NA 
Connecticut NA NA NA NA 
Delaware NA NA NA NA 
District of Columbia NA NA NA NA 
Florida NA NA NA NA 
Georgia NA NA NA NA 
Hawaii NA NA NA NA 
Idaho NA NA NA NA 
Illinois NA NA NA NA 
Indiana NA NA NA NA 
Iowa NA NA NA NA 
Kansas NA NA NA NA 
Kentucky NA NA NA NA 
Louisiana NA NA NA NA 
Maine NA NA NA NA 
Maryland NA NA NA NA 
Massachusetts NA NA NA NA 
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Michigan NA NA NA NA 
Minnesota NA NA NA NA 
Mississippi NA NA NA NA 
Missouri NA NA NA NA 
Montana NA NA NA NA 
Nebraska NA NA NA NA 
Nevada NA NA NA NA 
New Hampshire NA NA NA NA 
New Jersey NA NA NA NA 
New Mexico NA NA NA NA 
New York NA NA NA NA 
North Carolina NA NA NA NA 
North Dakota NA NA NA NA 
Ohio NA NA NA NA 
Oklahoma NA NA NA NA 
Oregon NA NA NA NA 
Pennsylvania NA NA NA NA 
Rhode Island NA NA NA NA 
South Carolina NA NA NA NA 
South Dakota NA NA NA NA 
Tennessee NA NA NA NA 
Texas NA NA NA NA 
Utah NA NA NA NA 
Vermont NA NA NA NA 
Virginia NA NA NA NA 
Washington NA NA NA NA 
West Virginia NA NA NA NA 
Wisconsin NA NA NA NA 
Wyoming NA NA NA NA 
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